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Progesterone is a steroid hormone in-
volved in female fertility, preparing the
uterus for implantation of fertilized
oocytes, and in the maintenance of preg-
nancy. Because of its contribution to re-
production it has been named the “steroid
hormone of reproduction” 1. Besides these
specific effects of progesterone on the
endometrium, it can also exert some
anti-estrogenic and thus antiproliferative
effects on tissues. Because of these effects
on proliferation it is not surprising that
progesterone, synthetic agonists, meso-
progestins (mixed agonists-antagonists)
or pure antagonists may be used in cancer
prevention and treatment. Progesterone
acts via the progesterone receptor (PR).
Knowledge of the function and regulation
of PRs is important to determine clinical
significance of involvement of PR in tumor
growth regulation.
This thesis focusses on the function
and regulation of PR in meningiomas, tu-
mors of the central nervous system (CNS),
that are partly under the influence of hor-
mones. To understand more about the PR,
the mechanism of its activation and func-
tion are described in this introduction.
Thereafter, a short overview is given of
apoptosis, particularly of the bcl-2 family
of proteins, some of which are regulated
by progesterone. The final part of this in-
troduction concerns the scope of this the-
sis.
Pathology and epidemiology of
human meningiomas
Meningiomas are the most common
tumors (up to 20%) of the CNS that are de-
rived from the arachnoidal cells of the
meninges, the membranes covering brain
and spinal-cord 2-4. Meningiomas occur at
9
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(Adapted from Steroids 2000, 65: 795-800)
a rate of about 2 in 100,000 subjects
per year 5. The development of menin-
giomas may be attributable to different
factors like head traumas, viruses, ioniz-
ing radiation, and neurofibromatosis 2
(NF-2). Meningiomas are benign neo-
plasms and are usually well demarcated
from the adjacent brain tissue. Therefore,
surgical resection is the primary treat-
ment and subsequently radiation therapy
may be used when necessary 6. Me-
ningiomas show a relatively high recur-
rence rate (20%) and are sometimes
unresectable. For this group of patients a
secondary adjuvant therapy would be
very helpful. However, such a treat-
ment is not readily available yet, since
meningiomas are relatively insensitive
to chemotherapy.
Meningiomas have attracted atten-
tion as possibly being hormone-sensitive
tumors due to (i) higher incidence rate in
women than in men (see Table 1-1; ra-
tio 2.5 : 1) 3, (ii) the epidemiological associ-
ation of meningiomas and breast cancer
7-11, and (iii) the reversible aggravation
of the symptoms during periods of rela-
tive progesterone excess, such as during
pregnancy and in the luteal phase of
the menstrual cycle 12. During pregnancy,
however, the increase in the size of the tu-
mor might be the result of cellular
edema 13.
10
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Males Females Sex unknown All
(n=104) (n=237) (n=63) (n=404)
Phenotype
ER– / PR– 32.7% 19.0% 23.8% 23.4%
ER– / PR+ 55.8% 67.5% 61.9% 63.4%
ER+/ PR– 3.8% 1.7% 3.2% 2.5%
ER+/ PR+ 7.7% 11.8% 11.1% 10.7%
Receptor levela
ER (mean) 4.5 4.6 3.3 4.4
S.E.M. 1.7 0.8 0.7 0.6
median 0 0 0 0
PR (mean) 118.8 172.9* 150.9 156
S.E.M. 18.5 19.6 63 13.2
median 57 70.5 25.3 66
age
mean 57 58 58
median 59 61 61
range 15-84 20-89 15-89
Table 1-1. Occurrence and concentration of ER and PR in human meningiomas as determined by
ligand-binding assay, update 2001 70. PR expression in meningiomas from female patients is statistically
higher than in those from male patients. afmol/mg;*P<0.02.
Occurrence of progesterone receptors
in meningiomas
Following the first report by Donnell
et al.,14 on the presence of ER in men-
ingioma tissue, a large number of papers
have appeared dealing with this subject.
Some authors reported the occurrence of
both ER and PR, whereas others estab-
lished an ER-negative (ER–) and PR-posi-
tive (PR+) phenotype. The differences
appeared to be caused by methodological
differences because large numbers of ap-
parently ER positive tumors were found to
be positive only by inadequate sin-
gle-point binding assays and not by more
reliable Scatchard plot analysis, enzyme
immuno-analysis, or immunohistochemis-
try. Although the discussion has settled in
favor of the ER–/PR+ phenotype, small
amounts of ER can be found using appro-
priate techniques in a number of
meningiomas.
The cumulative results of steroid re-
ceptor measurements performed by this
laboratory are shown in Table 1-1. These
results illustrate that the majority (87%) of
404 meningiomas was devoid of ER (<10
fmol/mg cytosol protein) and confirm the
predominant ER–/PR+ phenotype for
meningiomas. Figure 1-1 shows that in our
series of cytosols from meningiomas and
breast cancers, the predominant steroid
receptor phenotype for meningiomas is
ER–/PR+ and for breast cancer
ER+/PR+. Although the presence of ER in
meningiomas seems to be slightly in-
creased as compared to our previous up-
dates 15,16, it should be noted that even if
ER could be demonstrated in menin-
giomas, it is present at a very low level as
indicated in Table 1-1. With the extension
of our series, the difference in PR level be-
tween men and women has become more
pronounced, and this difference is statisti-
cally significant (P < 0.02). It remains to be
seen whether this difference has any bio-
logical significance.
Structure and mechanism of action of
the progesterone receptor
The genomic effects of progesterone
are mediated via the PR. The PR is a mem-
ber of a superfamily of transcription fac-
tors, which includes receptors for steroid
hormones, thyroid hormones, retinoic
acid, and orphan receptors. These pro-
teins are characterized by an organization
into specific functional domains that are
conserved between species and family
members (see Figure 1-2) 17. PR is local-
ized in the nucleus, most likely as a result
of a continuous active transport into the
nucleus, counter-balanced by diffusion
into the cytoplasm 18. This active transport
11
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Figure 1-1. Incidence of estrogen and
progesterone receptors in human meningiomas
and breast cancer cytosol. Update 1999 72.
Abbreviations: ER, estrogen receptor; PR,
progesteron receptor.
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Figure 1-2. Schematic illustration of the structure and function domains of the human progesterone
receptor (PR). The PR mRNA is depicted showing three different translation initiation start sites
(AUG). In the middle, the PR protein structure is illustrated. The three major PR isoforms are also
shown, PR-A, PR-B, and PR-C (adapted from references 21, 24, 37). Abbreviations: BUS, B Unique
Segment; IF, inhibitory function; AF, activation function; NLS, nuclear localization signal; DD,
dimerization domain; DBD, DNA binding domain; HBD, hormone binding domain.
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Figure 1-3. Model for activation mechanism of the human progesterone receptor (PR). Unliganded PR
is inactive and bound to heat shock proteins (HSP). Upon ligand binding, HSP dissociate and PR
dimerizes and is phosphorylated. By dimerization PR adopts a conformation capable of binding to a
member of the SRC-co-factor family. The complex is then capable of binding to progesterone
responsive elements (PRE), located in the promoter regions of PR target genes. Transcription initiation
can take place after binding of components of the general transcription complex (GTC) machinery and
additional co-factors (adapted from reference 71).
requires the so-called nuclear localization
signal (NLS) 19. The most highly conserved
region of the PR is the center of the protein
that corresponds to a two ‘zinc finger’
DNA binding motif (DBD). The
carboxy-terminal domain serves as the
ligand-binding domain (LBD) and is less
conserved compared to the DBD. This do-
main contains a region called the activa-
tion function 2 (AF-2), this AF-2 is ligand
dependent. The amino-terminal domain of
PR contains a ligand independent activa-
tion function (AF-1). Both AF-1 and AF-2
activate transcription in an unique pro-
moter- and celltype specific fashion 20;
they work in a synergistic manner and are
required for full receptor activity in most
cellular contexts. A third strong autono-
mous activation domain (AF-3) appears to
function only in a restricted cell and pro-
moter context 21.
The unliganded PR is in an inactive
conformation and bound to other proteins
like heat shock protein 90 22,23 (see
Figure 1-3). Binding of the ligand to the re-
ceptor elicits a series of events: dissocia-
tion from the heat shock proteins, change
of the tertiary structure of the protein, ac-
tivation of PR by phosphorylation,
dimerization, and high affinity binding to
Progesterone Responsive Elements (PRE)
in the DNA. The activated PR interacts in
a specific manner with the transcription
machinery complex, thereby initiating
transcription of progesterone responsive
genes. Apart from proteins from the basal
transcription complex, transcriptional ac-
tivation requires additional regulatory
proteins (co-factors) and will be discussed
in the next paragraph.
In human, two distinct promoters
have been identified that are regulated in-
dependently and give rise to different
PR-isoforms named PR-A and PR-B 24.
The PR-A and PR-B receptor isoforms are
almost identical, execept for an additional
stretch of 164 amino acids in the PR-B
isoform, called the B Unique/Upstream
Sequence/Segment (BUS), which is lo-
cated at the amino terminus of the recep-
tor. This BUS region encodes the AF-1
that is specific to the PR-B isoform and
plays an essential role in specifying target
genes that can be activated by the B but
not the A receptor isoform 21. When ex-
pressed in equimolar ratios in cells, PR-A
and PR-B can dimerize and bind to DNA
in three different ways: A:A or B:B
homodimers or A:B heterodimers. The
specific contribution of each of these
dimers to mediate the regulatory effects of
progesterone will depend on the differen-
tial transactivation properties contributed
to these complexes by the B-specific do-
main.
Both A and B isoforms of PR are capa-
ble of binding progesterone, dimerizing
and interacting with PRE, as well as acti-
vating the transcriptional machinery to
regulate PR-target gene expression. While
both PR-B and PR-A have similar ligand
and DNA binding affinities 25, in most cells
the homodimers of both isoforms appear
to exhibit different regulating proper-
ties 26. Thus, PR-A and PR-B with different
transactivation capacities may regulate
different physiological target genes in re-
sponse to progesterone. In certain cell and
promoter contexts, PR-A is capable of re-
pressing transactivation of PR-B and
of other steroid hormone receptors
13
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like ER 27,28. Thus, PR-A has the ability to
diminish overall progesterone responsive-
ness of specific target genes in specific tis-
sues. Therefore, differential expression of
the PR isoforms might be of clinical impor-
tance in the treatment of benign breast
disease with progestins. In breast tumors,
a higher expression of PR-A than PR-B
has been reported 29. Unfortunately, all
large clinical trials concerning breast can-
cer did only include total PR expression
and not the differential expression of PR
isoforms. Furthermore, PR-A and PR-B
respond differently to antiprogestins.
While antagonist bound PR-A is inactive,
antagonist bound PR-B can be converted
to a strong active transcription factor by
modulating intracellular phosphorylation
pathways in PR-B containing cells 30. In or-
der to understand the response of tumors
like meningiomas, to treatment with
antiprogestins, knowledge of the differen-
tial expression of PR isoforms might be
very helpful.
Similar to other steroid receptors, PR
is a phosphoprotein and its function
and role is still under intensive
study. Phosphorylation sites of steroid
receptors are generally mapped to serine
residues in the N-terminus upstream of
the DNA binding domain. There may
be as many as 14 phosphorylation
sites and phosphorylation is a highly
complex multistage process 31-34. The PR
exhibits basal phos- phorylation and
this phosphorylation is enhanced
in response to hormone treatment
suggesting that phosphorylation plays a
role in receptor activation, for instance by
increasing its DNA binding 35. A slower
round of phosphorylation that requires
DNA binding but does not contribute to
the net activation follows basal
phosphorylation. The BUS region of
PR-B, which contains the strong
autonomous activation function (AF-3), is
heavily phosphorylated 21,35. Mutations in
these phosphorylation sites which do not
result in the loss of PR function, however,
indicate that phosphorylation is not
required for transcription activation 35.
The differences in the specific
phosphorylation sites between PR-A and
PR-B may attribute to their differences
in biological behavior. For instance, a
strong preferential hormone-dependent
phosphorylation of Ser 294 on PR-B and
not on PR-A has been reported 36. The
flanking sequences on both proteins are
identical, indi- cating that conformational
differences between both proteins are
important for phosphorylation 36. In
summary, phosphorylation of the PR may
play a major role in the function of the
receptor, however, phosphorylation may
have subtle effects on transcription
activation and may also subserve other
functions.
Besides the two major PR isoforms,
additional PR like proteins have been de-
scribed. A PR-C isoform has been de-
scribed which was not able to bind DNA,
however, this isoform was still capable of
ligand binding and dimerization 37,38. PR-C
could interfere with the activation of pro-
gesterone responsive target genes 37-39. In
breast cancers, a smaller 78 kDa protein
was found capable of progesterone bind-
ing 29,40. The origin and biological signifi-
cance of this PR-78 are still not known.
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Progesterone receptor co-regulators
Nuclear receptor co-regulators con-
sist of two groups called co-activators and
co-repressors. Either a transcriptionally
permissive or non-permissive environ-
ment is created at the promoter site, due to
a combined effort of the receptor and
co-regulaters, which in turn communicate
with the general transcription complex
(GTC) and RNA polymerase II. The action
of most co-regulators is, by definition, rate
limiting for nuclear receptor activation
and repression, but does not significantly
alter basal transcription.
Numerous co-activators have been
identified that are recruited by the
liganded PR and enhance receptor de-
pendent transactivation. The best-known
co-activator family is the SCR family.
SCR-1 was the first co-activator identified
involved in PR activation, using a yeast
two-hybrid screen of a human lymphocyte
cDNA library with the hormone bound
PR-LBD as bait 41. Later, the homologous
proteins SRC-2 and SRC-3 were de-
scribed 42. SRC-1 was found to interact
with the PR in a ligand dependent manner
and antagonist RU-486 prevented this in-
teraction of SRC-1. Interaction of the PR
occurs through the AF-1 and AF-2 do-
mains of the PR 43. The activation domains
of SRC-1 are important for interaction
with other co-regulators or the basal tran-
scription machinery and SRC-1, has a role
in chromatin remodeling 43,44. After inter-
action between PR and SCR-1, this com-
plex is thought to recruit CREB Binding
Protein (CBP) and other co-factors 45.
Other factors that have been added to the
list of co-activators include (i) Ubiquitin
protein ligases, (ii) L7/SPA, (iii) HMG-1,
and (iv) SRA 42. This illustrates the
diversity of proteins recruited to the PR
promoter and eventually determines the
expression of PR target genes.
Besides these co-activators of nuclear
receptors, other families of proteins called
co-repressors are also known. Using a
yeast two-hybrid screen, Jackson et al.
have described that the nuclear
corepressor (NCoR) interacted with an-
tagonist-bound PR-Ligand Binding
Domain (PR-LBD) 46. In addition, overex
pression of NCoR and SMRT (Silencing
Mediator for Retinoid and Thyroid hor-
mone receptor) markedly suppressed
RU-486 partial agonist activity. This effect
was reversible in the case of PR by
overexpression of the PR-LBD 46. In addi-
tion, NCoR and SMRT preferentially asso-
ciate with antagonist-bound PR whereas
the partial agonist activity of RU-486
bound to PR is ablated by overexpression
of NCoR and SMRT 47. Other co-repres-
sors that have been identified are TRUP,
SUNCoR, and NURD 48.
Data of co-factor expression in human
meningioma is very limited. Carroll et al.
have reported expression of SRC-1, "Am-
plified In Breast cancer" protein (AIB-1),
and transcriptional intermediary factor 2
(TIF2) in respectively 81, 76, and 76% of
the meningiomas by immunoblot and
immunohistochemistry analysis. The ex-
pression of SRC-1 and TIF2 was signifi-
cantly related to the concentration of
progesterone receptors 49. Co-factors are
also involved in the differential trans-
activation capacity of the two major PR
isoforms, since PR-A and PR-B have been
15
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reported to have different binding affini-
ties to several co-factors 50.
Antiprogestins
Antiprogestins have a great therapeu-
tic potential, such as interruption of early
pregnancy, post-coital contraception, in-
duction of labor, and treatment of hor-
mone-dependent tumors. Studies in
animals have suggested that antipro-
gestins could be used in the treatment of
gliomas and ovarian, prostate, and
endometrial cancer 51. Because of the pres-
ence of PR in meningiomas and the epide-
miological data linking aggravation of
meningioma symptoms to periods of high
progesterone availability, the use of
antiprogestins for the treatment of
meningiomas has been suggested. Pilot
studies with limited numbers of pa-
tients 52-54 and case reports have fostered
the optimism with respect to the clinical
application of antiprogestins. A random-
ized double blind placebo controlled
phase 3 trial is currently underway to
study the activity of the antiprogestin
mifepristone in unresectable menin-
giomas 52.
The apoptotic protein family Bcl-2
Besides proliferative actions of ste-
roids in tissues of the reproductive organs,
estrogens and progesterone are consid-
ered to be involved in the control mecha-
nism of proteins involved in the regulation
of programmed cell death (or apoptosis).
In contrast to necrosis, apoptosis is regu-
lated by several sets of genes, the best
characterized of which are members of the
Bcl-2 family 55. The Bcl-2 family of proteins
comprises anti-apoptotic as well as
pro-apoptotic proteins and can be classi-
fied in the following subfamilies based on
bcl-2 homology and function of each pro-
tein 56 (see Fig. 1-4): (i) a subfamily includ-
ing bcl-2 itself, bcl-xl and bcl-w, all of
which exert anti-cell death activity and
share sequence homology particularly
within four bcl-2 homology (BH) regions,
BH-1 through BH-4; and (ii) a subfamily
represented by bax and bak that share se-
quence homology at BH-1,2 and 3 but not
at BH-4. All these proteins exert
pro-apoptotic activity; (iii) a subfamily of
pro-apoptotic proteins that share se-
quence homology only within BH-3 and
therefore are referred to as BH3-proteins.
The overall balance between cell death
agonists and antagonists in a cell deter-
mines the susceptibility to apoptosis.
One of the features of the Bcl-2 pro-
tein family is the ability of members to
form homo and heterodimers 57. Hetero-
dimerization between anti-apoptotic and
pro-apoptotic members of this family is
considered to inhibit the biological activ-
ity of each of the partners 57,58. This effect is
mediated by the insertion of the BH-3 re-
gion of a pro-apoptotic protein into a hy-
drophobic pocket composed of BH-1,
BH-2 and BH-3 of an anti-apoptotic pro-
tein 59.
Bcl-2 and bcl-x l were shown to pre-
vent apoptosis induced by various stimuli,
including serum deprivation, heat shock,
and chemotherapeutic agents, suggesting
the ability of both proteins to prevent
apoptosis down-stream of a common path-
way. Both proteins have been shown to
have a mitochondrial localization 60-62. The
16
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regulatory function of bcl-2 has been as-
cribed to: (i) its ability to interact with
other proteins that participate in
cell-death regulation; (ii) channel activity
that directly or indirectly influences mito-
chondrial permeability and prevents the
release of cytochrome c from the mito-
chondria and caspase activity 63. It is
known that the bcl-2 protein is phos-
phorylated in response to different stimuli
of cell death 64, however, phosphorylation
has been related to both inactivation and
activation of the anti-apoptotic function 65.
Besides a role for bcl-2 and bcl-xl in
apoptosis, studies have indicated that
Bcl-2 family members might also regulate
cell cycle progression 66-69.
Bax, bcl-2 associated protein x, was
isolated as the gene encoding a protein
that binds bcl-2 57. Bax acts in opposition to
bcl-2 and overexpression of bax allows
apoptosis to proceed, as for instance after
interleukin 3 (IL3) withdrawal from IL3
dependent cells, even in the presence of
upregulated expression of bcl-2 57. The tu-
mor suppressor p53, implicated in induc-
tion of both growth arrest and apoptosis
following DNA damage, is a positive regu-
lator of bax expression and a negative reg-
ulator of bcl-2 expression 73,74. Bax
expression is found diffusely distributed
throughout the cytosol, however, upon in-
duction of apoptosis, bax moves
intracellularly to a distribution co-local-
ized with the mitochondria 60. When bax
molecules have migrated to the mitochon-
drial membrane, bax is capable of
homodimerization and thereby channel-
ing the release of cytochrome C 75. After
cytochrome C release, caspases are
strongly activated that are capable of fur-
ther inducing apoptosis 76-78.
The human bak gene was isolated by
amplifying sequences similar to coding
17
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Figure 1-4. Structure of the Bcl-2 family proteins (adapted from reference 72). Abbreviations: BH,
Bcl-2 Homology domain; TM, trans membrane domain.
sequences for both BH-1 and BH-2 related
proteins. Bak is expressed in a wide range
of tissues among which several types of tu-
mors 79,80.
Since several apoptotic proteins have
been reported to be involved in tumor de-
velopment, and their expression is related
to tumor grade, recurrence and resistance
to chemotherapy, knowledge of the regu-
lation of these proteins in tumors might be
of clinical importance. The fact that some
of the proteins of the Bcl-2 family are un-
der control of steroid hormones suggests
that these steroids might be involved in
the homeostasis of these tumors. Not
much is known, however, about the ex-
pression or regulation of apoptotic pro-
teins in human meningiomas. Since
several of these proteins are regulated by
progesterone in other tissues, the expres-
sion of PR might be involved in the regula-
tion of these proteins in meningiomas as
well.
The aim of the thesis
The aim of this thesis is to obtain a better understanding of the effect of the presence
of progesterone receptors in human meningiomas. Special emphasis will be on the follow-
ing questions:
1. Which PR-forms are expressed in meningiomas and are the various PR
isoforms expressed equally in meningiomas?
2. Is PR related to the presence and occurrence of apoptotic proteins and there-
by to apoptotic processes?
3. Are ER and/or ER splice-variants involved in the regulation of PR expression
in meningiomas?
4. What is known about the growth hormone and insuline like growth factor axis
in human meningiomas?
18
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Summary
Meningiomas are benign intracranial tumors derived from the meninges. In general, these tumors
have a progesterone receptor (PR) positive phenotype. Meningiomas cultured as monolayer quickly
lose their ability to express PR. The loss of PR expression and a high proliferation rate in meningiomas
cultured as monolayer indicate that the cells might dedifferentiate when cultured. The aim of this study
was to develop a meningioma cell culture model with maintained PR expression high enough for quan-
titative analysis with a ligand binding assay (LBA). This model could then be used for investigation of
the role and regulation of PR in meningiomas.
In this study a monolayer, a spheroid and an ex vivo tissue culture method were tested. None of the
culture models tested was appropriate for meningioma cells to maintain their PR expression in vitro af-
ter prolonged periods of culturing. Both in monolayer and in spheroid cultures, after three days of cul-
ture, PR levels drop to below the lowest detection limit of the LBA. Spheroids obtained from breast
cancer cell lines, T47D and MCF-7, showed comparable amounts of PR expression as found for
monolayer cultures of these cell lines indicating that our experimental setup was valid. In the ex vivo
method, meningioma tissue fragments expressed only 28% of PR in the native tumor after three days of
culture. Still, this method is recommended since the tissue fragments maintain their organostructure
and stimulation of the cells shortly after excision, when most of the PR is still present, is possible. Be-
cause of the rapid decline in PR in cultured meningiomas, all data described in literature concerning
stimulation of cultured meningioma cells via the PR should be interpreted carefully.
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Introduction
Meningiomas are intracranial and
intraspinal tumors that arise from
arachnoidal cells in the meninges, espe-
cially in areas of the arachnoid villi. The
great majority of meningiomas are benign
neoplasias that can occur virtually any-
where in the central nervous system. At
the moment the main therapy is surgical
resection with a recurrence rate of 20% 1-3.
Adjuvant hormone therapy could be
very helpful in this group of unresectable
or recurred tumors. It is known that
meningiomas respond to changes in circu-
lating levels of progesterone. Patients suf-
fering from a meningioma show a re-
versible aggravation of symptoms during
periods of relative progesterone excess,
such as during pregnancy and the luteal
phase of the menstrual cycle 4. The inci-
dence of meningiomas in female patients
is more than twice as high as in males 5.
The incidence of meningiomas is also
higher in individuals with other hor-
mone-modulated tumors such as cancer of
the breast, ovary and endometrium 6.
This apparent sensitivity for proges-
terone could be explained by the pres-
ence of a functional progesterone receptor
(PR) expressed in meningioma cells.
Indeed, more than 75% of the me-
ningiomas express high levels of PR in
the virtual absence of the estrogen
receptor (ER) 7. Estrogen independent
expression of PR in meningiomas is in
contrast with PR regulation in
other endocrine regulated tumors, like
breast cancer.
In order to understand the regulation
and function of PR with respect to prolifer-
ation, differentiation and development
of meningiomas, many studies have
been done the last decades. The most
used in vitro model for stimulation
experiments with hormones or growth
factors is meningioma cells grown
as monolayer. Of these studies, the out-
come was contradictory and non-conclu-
sive 8,9. This discrepancy could be
explained by the fact that cultured
meningioma cells easily loose their ability
to express the progesterone receptor. In
cultured meningiomas, as soon as the sec-
ond day of monolayer culture, the PR lev-
els decrease to 20% of the native tissue 10.
We suggest that data derived from experi-
ments using meningiomas cultured as
monolayer need therefore to be inter-
preted with caution.
With the intention to develop a
meningioma cell culture model that main-
tained PR expression, a new meningioma
model was developed by Tonn et al. 11.
These authors described immunohisto-
chemical data of PR expression in menin-
giomas cultured as tri-dimensional
structures, so called spheroids, which
were obtained by preventing attachment
of the cells to the bottom surface of the cul-
ture flask, by using an agar coating 11-13.
Spheroids can be obtained from re-aggre-
gation of cells grown as monolayer (re-
ferred to as aggregated-spheroids) or by
immediately culturing tissue fragments
(referred to as fragment-spheroids).
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In addition, Camby et al. used an ex
vivo culture model in which tissue of
meningiomas was cut in small fragments
of approximately 2 mm3. This method may
be superior to others since the original
structure of the native tumor is secured 14.
Whether this method results in mainte-
nance of the progesterone receptor ex-
pression was not reported.
In order to develop a meningioma cell
culture model, appropriate for investment
of the role of PR in meningiomas, spher-
oid- and ex vivo- culture methods were op-
timized. One of the standards for success
was that PR levels have to be measurable
with a ligand binding assay (LBA) in order
to quantify PR expression levels.
Material and Methods
Tissues
Human meningioma tissue was
placed in ice-cold Medium (MEM
supplemented with 10% FCS, 10mM
essential amino acids, 2mM glutamine,
100U/mL penicilin, 100U/L strepto-
mycin, Gibco & Life Technology, Breda,
The Netherlands), immediately after
removal from the patient. Part of
the tumor was stored at –80°C until
further use for cytosol preparation.
Another part was used for the different
culture experiments.
Cytosol preparation
Before harvesting tissue fragments,
monolayer and spheroid cultures of
meningiomas were cultured in medium
containing 10% dextran coated charcoal
pretreated serum (DCC-FCS) for one day.
Meningioma tissue, culture specimen of
meningioma, MCF-7, and T47D cells were
chilled in liquid nitrogen, pulverized
with a micro- dismembrator (Braun,
Melsungen, FRG) and extracted with
10 mM phosphate buffer at pH 7.5
containing, 1.5 mM EDTA, 3 mM sodium
azide, 10 mM 1-mono- thioglycerol and
10% (v/v) glycerol. The resulting homo-
genate was centrifuged at 0-4°C for 30
minutes at 100,000 × g yielding a clear
cytosol.
Ligand binding assay
The PR levels of the tumors and
culture specimen were measured, as
described previously 7, by the ligand-
binding assay and scatchard plot analysis,
according to the guidelines of the EORTC,
Breast Cancer Cooperative Group 15. The
protein content of the cytosol was
estimated with the method of Bradford,
using reagents from Bio-Rad (Richmond,
CA, USA) and serum albumin (Kabi,
Diagnostica, Stockholm, Sweden) as
a standard 16. The lowest detection limit
for PR was 10 fmol/mg protein. The in-
between reproducibility for these assay
was; PR: 11.3% at 333 fmol/mg protein,
and protein: 5.8% at 3.4 mg/ml.
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Primary cultures of meningiomas
Ex vivo culture: tissue fragments
were rinsed with PBS, cut into pieces of
approximately 2 mm3, and seeded in cul-
ture flasks (T175) with a medium
overlayer. Tissue fragment were har-
vested after 3,4 or 6 days of culturing.
Monolayer culture: Tissue fragments
were rinsed in PBS and minced using scal-
pels. To further dissociate any remaining
fragments, the tissue was treated with
dispase (2.4 units/g tissue) at 37°C for one
hour. After centrifugation the pellet was
resuspended in medium and seeded in
flasks in 30 ml medium. Medium was re-
freshed the next day.
Monolayer spheroid culture: Spher-
oids were obtained from cells already cul-
tured as monolayer for one week. Cells
were harvested in 10 ml PBS by scraping
and centrifuged at 1500 rpm for 10 min-
utes. The pellet was resuspended in me-
dium and 5 µl was used for cell counting
with a Türker cell counting chamber, us-
ing tryphan blue for discriminating be-
tween intact and disrupted cells. Five
million cells were seeded in flasks (T175)
with an agar-coated bottom. Within one
day, beginning of spheroid aggregation
was seen.
In order to quantify growth of spher-
oids the diameter of several spheroids
were measured, using an inverted micro-
scope and a computer assisted measuring
program. To validate our experimental
culture conditions, spheroids were also
generated from two classical breast cancer
cell lines, MCF-7 and T47D, both express-
ing PR.
Results
Generation of monolayer and
spheroid cultures of meningiomas
Meningioma cells easily migrate from
dissociated meningioma fragments and
a confluent monolayer is achieved
within one week culturing (Figure 2-1A).
Meningiomas grown as monolayers,
in contrast to the in vivo situation,
showed a high proliferation rate. For
meningiomas cultured longer than 10
weeks, growth stops and tumor cells
were sometimes overgrown with
fibroblast like cells. Only meningioma
culures without fibroblast overgrowth
were used.
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A
B
Figure 2-1. Meningioma cells cultured as
confluent monolayer (A) and re-aggregated
spheroids (B). See text for details.
When a single cell suspension from
meningioma cells was seeded on agar,
cells attached and gave rise to spheroids
(Figure 2-1B). Growth was measured by
monitoring the diameter of the spheroid
(Figure 2-2). Spheroids continued to grow
for at least a period of 10 days.
Progesterone receptor expression in
primary cultures of meningiomas
Table 2-1 shows an overview
of PR expression in meningiomas cultured
as spheroids or as tissue fragment (ex vivo
culture). All, but two, native tumors were
PR positive. Meningioma cells, grown as
monolayer, lost the PR already before the
monolayer reached confluence. Spheroids
generated from monolayer cells did not
re-express the PR at measurable levels for
the LBA (>10 fmol/mg protein). Also in
spheroids directly derived of disaggre-
gated tissue fragments, no PR could be de-
tected one week after surgery.
Progesterone expression in
meningioma tissue fragments
To limit culturing time, meningiomas
were not dissociated but cultured as tissue
fragments referred to as ex vivo culturing.
An additional advantage of this method is
that the architecture of the original tumor
is preserved. PR expression was measured
in native tumor tissue and fragments after
3, 4 and 6 days of ex vivo culturing PR ex-
pression was measured. Figure 2-3 shows
the PR expression levels of 17 me-
ningiomas. Already after three days of ex
vivo culturing PR expression declines to
25 ± 28% (mean ± standard deviation) of
the levels in the native tissue.
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Figure 2-2. Growth kinetics of meningioma
cells, cultured as re-aggregated spheroids. See
text for details.
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Figure 2-3. Progesterone receptor (PR) content
in primary meningiomas. The left panel
illustrates the PR expression in fmol/mg protein
in the native tissue specimen. The right panel
shows the decline of PR expression during time
of culturing as ex vivo tissue fragments.
PR expression in spheroids from
MCF-7 and T47D breast cancer
cell lines
As a control for our experimental
setup, PR expression levels in monolayer
and spheroids obtained from two different
breast cancer cell lines, T47D and MCF-7,
were measured with a LBA. No significant
difference in PR expression in both cell
lines could be found between monolayer
and spheroid culturing (Table 2-2). For
these cells, culturing as tri-dimensional
spheroids is an appropriate culture model,
and gave sufficient protein amounts in or-
der to measure PR with a LBA.
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meningiomas PR
(fmol/mg protein)
Protein
(µg/µl)
nr. Culturea
method
sexb tissue monoc Ex
vivo d
Sphe-
roidse
tissue monoc Ex
vivod
sphe-
roidse
1 a f 26 <10 - <10 2.9 0.4 - 1.3
2 a m <10 <10 - <10 1.9 2.8 - 1.1
3 a f 421 <10 - <10 1.4 0.6 - 0.1
4 a f <10 <10 - <10 2.0 0.9 - 0.4
5 a m 23 <10 - <10 2.5 1.9 - 3.2
6 a f 160 <10 - <10 2.9 - - 1.9
7 a f 128 - - <10 2.1 - - 0.3
8 a f 15 - - <10 3.2 - - 0.8
9 a m 60 - - <10 2.2 - - 0.5
10 b f 144 - 15 - 3.1 - 2.2 -
11 b f 492 - 60 - 2.2 - 0.5 -
12 b f 392 - 27 - 1.8 - 0.7 -
13 b m 1436 - 223 - 4.4 - 6.3 -
14 b f 23 - <10 - 1.7 - 1.3 -
15 b m 29 - 21 - 2.1 - 1.0 -
16 b f 41 - <10 - 4.9 - 5.7 -
17 b f 168 - 66 - 1.7 - 2.2 -
18 b f 508 - 109 - 0.8 - 1.4 -
19 b m 177 - 103 - 2.1 - 0.6 -
Table 2-1. Overview of the progesterone receptor expression in meningioma tissues and cell cultures.
a Culture method: a, cells first cultured as monolayer and then spheroids were obtained by using an agar
coated culture flask; b, ex vivo method – meningioma tissue was cut in small pieces and immediately seeded
in agar coated flasks. b Patients' age at time of operation. c Cells harvested 1 week after excision. d cells
harvested 3 days after excision. e Cells harvested 2 weeks after excision.
monolayer spheroids
PR PR
(fmol/mg) n (fmol/mg) n P
MCF-7a 106 ± 61 5 163 ± 84 5 ns
T47Da 2258 ± 904 6 1866 ± 1284 3 ns
Table 2-2. Progesterone receptor expression in
MCF-7 and T47D cells cultured as monolayer
and as spheroids. Abbreviation: ns, not
significant; a mean ± S.D.
Discussion
It can be argued that progesterone,
via its receptor, is involved in the regula-
tion of growth and differentiation of
meningiomas. The proliferation rate of
meningioma increases when there are
high plasma progesterone levels as seen
during pregnancy and in the luteal phase
of the menstrual cycle 4. There is also a
predominance for female patients 5.
Grunberg et al. reviewed the responses
seen in several trials treating patients with
the progesterone receptor antagonist,
mifepristone (RU 486) or Medroxy Proges-
terone Acetate (MPA), a synthetic proges-
terone agonist 17.
Meningiomas show a typical sex ste-
roid hormone receptor phenotype. In con-
trast to breast cancer, which show a low
percentage of ER–/PR+ phenotype, more
than 75% of the meningiomas express PRs
in the virtual absence of the estrogen re-
ceptor 18. That the PR can be expressed
and be functional in the absence of ER is
demonstrated in the estrogen receptor
knock mouse (ERKO) 19. Regulation of PR
is tissue specific and may be regulated via
an estrogen independent pathway, how-
ever, exact regulation mechanisms of PR
synthesis are not known. Meningiomas are
an interesting cell model for investigation
of the estrogen independent regulation of
PR and its role in these tumors.
To investigate the function and the
ER unrelated regulation of expression of
the PR in meningiomas, there is a need for
a good cell culture model. The aim of this
study was to achieve a cell culture method,
in which meningioma cells, after pro-
longed culturing, still express the PR at
levels high enough for quantitative analy-
sis with a LBA. Three different culture
methods were tested, monolayer, spher-
oids, and ex vivo tissue culture. Progester-
one receptor expression was found in 24 of
the 26 meningiomas used for the experi-
ments (Table 2-1). The meningioma
monolayer cell model is a cell system in
which not only intracellular matrix com-
ponents are missing, but also the cell pro-
liferation is extremely high when
compared to the growth rate in vivo. We
and several other authors found that de-
spite the PR positive phenotype of the na-
tive tissue, meningiomas cultured as
monolayers very rapidly lose the ability to
synthesize PR 10,20,21 (table 2-1). The loss of
PR and the increased proliferation sug-
gest that meningioma cells dedifferentiate
when grown as monolayer cultures. Cul-
turing of meningiomas as monolayer is an
inappropriate cell culture model for PR re-
search and there is a need for other culture
models.
Another culture method, described
by Tonn et al., is meningioma cells cul-
tured in a three-dimensional conforma-
tion as re-aggregated or fragment
spheroids 13. Based on immunohisto-
chemistry data, cells located in the
non-proliferative regions may express
PRs 11-13. These authors, however, did not
find PR expression in all the spheroids, de-
spite the fact that they were obtained from
PR positive tumors. When PR expression
was found, it was in variable amounts 12. In
the present study, none of the spheroids
obtained from their native PR positive
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tumor tissue showed any PR expression
based on a LBA (Table 2-1). The amount of
PR expressed in a number of PR positive
cells, as reported by Tonn et al. based on
IHC-data, may be under the lowest detec-
tion limit of the LBA 12. The method of
spheroid generation and PR measurement
were proven valid by our results with the
T47D and MCF-7 cell lines, which showed
in both monolayer and spheroid cultures
equal amounts of PR expression (Ta-
ble 2-2).
Since prolonged culturing as
monolayer or as spheroids of meningioma
cells resulted in a decrease of PR expres-
sion, the ex vivo culture method was
tested. Freshly resected meningiomas
were cut into small tissue fragments and
cultured for not longer than a week. The
rationale of this method is that the
organotypical structure of the tissue is
maintained. A disadvantage, however,
might be that the inner cells may become
ischaemic. It is thought that dedif-
ferentiation could be the cause of the de-
cline of PR in meningioma cells cultured
as monolayer. Even in this ex vivo culture
model, in which dedifferentiation of cells
in such a short notice and without disturb-
ing the organo structure is not very likely,
PR expression could not be maintained.
Despite the efforts to maintain PR ex-
pression in these tissue fragments, the
conclusion is that after several days of cul-
turing the PR is declined (Figure 2-3). Tu-
mors that express high levels of PRs at the
moment of excision, expressed less than
25% of the PRs found in native tissue after
three days of culturing. The maintenance
of the infrastructure of the tissue, cell-cell
interactions and matrix components,
could not prevent a decline of PR expres-
sion. Apparently, components of blood,
which are missing in all the culture mod-
els, may be important in the fine regula-
tion of PR transcription in meningiomas.
When key factors responsible for the
activation of the PR gene are missing, a de-
cline in PR mRNA could be expected. In-
deed Tonn et al. showed that monolayer of
meningiomas cells expressed less mRNA
than their spheroid counterparts in which
they detected PR protein 12. The possibility
of an active degradation, however, could
not be ruled out. Leclercq et al. , described
the down-regulation of the estrogen recep-
tors by degradation of receptor proteins by
proteosomes 22. Whether this may be a
mechanism of PR degradation in cultured
meningiomas need to be sorted out.
Thus far, we do not known whether
the loss of PR in meningiomas cell cultures
is a tissue specific and/or a hormone recep-
tor specific process. It may be that not only
the PR, but also several other proteins are
limited in their expression under in vitro
conditions. Authors, who described stimu-
lation experiments with tumor cell mod-
els, rarely take the effort to establish the
level of the target protein expression after
the period of stimulation of the cells. Not
much is known about the presence of
other steroid hormone receptors as well at
the beginning of the experiments as after-
wards. Zava et al. described the presence
of glucocorticoid receptor (GR) and andro-
gen receptors (AR) in meningiomas cul-
tured for at least three passages. The
authors, however, did not describe the val-
ues of AR and GR in the native tissue 23.
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Gibelli determined the AR and GR in fresh
frozen tissue sections and in meningiomas
cultured as monolayer for approximately
five days 24. In their study, the receptor
concentration for frozen sections was ex-
pressed as fmol/mg protein and for the cell
culture specimen as fmol/mg DNA. Al-
though not directly comparable, the au-
thors evaluate that all the GR and AR
positive tumors also showed GR and AR
positive phenotype in the cell culture sub-
set 24. In conclusion, these data may sug-
gest that the decline of progesterone
receptors in cell culture models of
meningiomas may be a PR specific event.
Meningiomas transplanted into nude
mice may be the only model left which
maintains PR expression. Several authors
described a successful transplantation of
meningioma tissue or cultured cells into
the renal capsule, subcutaneously or
intracranially of athymic mice 25-28. None of
these studies concerned PR expression in
the meningioma transplant. Only Olson et
al. focused on the effects of PR antago-
nists. Meningioma implanted subcutane-
ously in athymic mice showed a growth
inhibition by RU-38486, an antipro-
gestational agent. PR expression levels in
the transplant after stimulation, however,
were not reported in the transplant 28. Be-
sides the xenograft model, two
meningioma cell lines were described,
IOMM-Lee and KT21-mg1, but there is no
report of PR expression in these cells 29.
In summary, monolayer, spheroids
and ex vivo tissue culture methods were
tested, in order to develop a culture
method in which meningiomas did not
lose the ability to express progesterone re-
ceptors. None of the tested culture models
were appropriate for meningioma cells to
maintain their PR expression in vitro. The
ex vivo method is recommended since the
tissue fragments hold their organo-
structure and stimulation of the cells
shortly after excision, when most of the PR
is still there, is possible. All data described
in literature concerning stimulation of cul-
tured meningioma cells via the PR should,
therefore, be interpreted carefully.
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Abstract
The majority of meningiomas expresses the progesterone receptor (PR), and show progesterone
responsiveness. In addition, an association has been reported between PR and prognosis. At least two
PR isoforms exist, PR-B (116-120 kDa) and PR-A (81 kDa), each of which are likely to have different bio-
logical functions. Knowledge of the differential expression of both isoforms is necessary to understand
the effects of progesterone on meningioma growth. Therefore, in this study, PR-A and PR-B expression
levels were determined in 61 human meningiomas by immunoblotting. Total PR expression levels were
determined with a ligand binding assay (total PRLBA).
Both PR isoforms and an additional PR 78kDa protein (PR-78) were expressed in the
meningiomas. Meningiomas expressing more PR-A than PR-B had significantly higher total PRLBA lev-
els (P<0.001). The PR-78 band intensity was negatively associated with that of PR-B (rs=-0.76,
P<0.0001). PR-78 may represent an endogenous degradation product, but a similar regulation pathway
in the biogenesis of both PR-B and PR-78 is not excluded.
Meningiomas contain both PR isoforms, but in highly variable ratios and this variability may have
some biological significance. Most meningiomas express more PR-A than PR-B. Therefore in
meningiomas, assuming that PR-B is more transcriptional active than PR-A, progesterone responsive-
ness could be based on transrepression rather than on transactivation of target genes.
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Introduction
Progesterone may play a role in the
development and proliferation of hormone
dependent tumors, like breast cancer and
meningiomas. Progesterone action is me-
diated via the progesterone receptor (PR),
which can be found in 75% of the human
meningiomas 1,2. Meningiomas expressing
high levels of the PR have a better progno-
sis and a higher survival rate 3-5. PR might
therefore serve as target for endocrine
therapy 6. To determine the biological sig-
nificance of PR expression in menin-
giomas, the regulation of PR in
meningiomas needs to be elucidated.
The progesterone receptor (PR) be-
longs to the family of ligand activated tran-
scription factors. The PR is expressed as at
least two isoforms, a full size protein
(PR-B) and a 164 amino acid N-terminally
truncated version of the B form, called
PR-A 7,8. The two isoforms are transcribed
from two different translation initiation
sites located on the same gene 9.
Besides PR-A and PR-B, an addi-
tional progesterone binding protein of 78
kDa (referred to as PR-78) was revealed by
immunoblot analysis of breast cancer
cytosols 10,11. Yeates et al. reported that
PR-78 is most likely not an artificial degra-
dation, nor a phosphorylation product of
PR-B or PR-A 11. The origin and biological
function of PR-78 remains to be eluci-
dated.
While both PR-A and PR-B have simi-
lar DNA and ligand binding affinities 12, in
most cell and promoter contexts both
isoforms appear to exhibit different
regulating properties. In vitro studies re-
veal that PR-B is a strong transactivator of
progesterone-responsive genes, whereas
PR-A is considered to be a dominant nega-
tive transrepressor of PR-B and other ste-
roid hormone receptors 13-15. The precise
mechanism underlying the differential ac-
tivities of PR-A and PR-B is not fully un-
derstood. PR-A, however, is missing the
N-terminally located ‘B Upstream Se-
quence’ (BUS), resulting in a possible
change in conformation and loss of
phosphorylation sites 16. The PR isoforms
may have different affinities for co-factors
and other proteins of the transcription ma-
chinery 17. Because of the differential ac-
tivities of PR-B and PR-A, the ratio of
expression of both isoforms determines
the final overall response of cells upon
progesterone stimulation, and may be im-
portant for the regulation of growth and
differentiation of endocrine related tu-
mors.
Meningiomas are tumors which are
thought to be hormonally regulated 18.
They are generally benign intracranial tu-
mors derived from arachnoidal cells in the
meninges, the membranes covering brain
and spinal cord. Meningiomas are the
most common intracranial tumors with a
20% recurrence rate following current
standard therapy, surgical resection with
subsequent radiation therapy when neces-
sary 19,20. Growth of meningiomas is in-
creased during periods with high
progesterone levels in the circulation 21.
Meningiomas express high levels of total
PR, as measured by a ligand binding assay
(LBA) 1. There is an association between
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total PR expression in the tumor and prog-
nosis for the patient 3-5. Several experi-
ments, in vitro and in vivo, have been
performed to inhibit cell growth using PR
antagonists 6,18,22,23. For development of en-
docrine therapy, however, the regulation
and function of PR expression in
meningiomas needs to be known.
In several previous publications, the
presence of PRs in meningioma, based on
a LBA, was reported 1,2. The expression
pattern of the PR isoforms in
meningiomas, however, is not known.
Both isoforms differentially mediate pro-
gesterone or PR antagonist signaling.
Therefore, the differential expression of
both PR isoforms in meningiomas is of
great interest. This study was conducted
to determine PR-A and PR-B expression
levels with an immunoblot analysis. Re-
sults were compared with total PR expres-
sion, determined with a LBA (referred to
as total PRLBA), and tumor grade.
Patients and Methods
Tissues
Sixty-one PR positive human
meningioma tissues were collected from
40 female and 21 male patients, the mean
age at the time of surgery was 57 years
(median: 60 years; range 45-81 years), op-
erated at the University Medical Center
Utrecht. The study was conducted in ac-
cordance with the guidelines of the local
ethical committee. Tissues specimens
were placed on ice immediately after re-
moval from the patient. Representative
specimens were frozen at -80°C until used
for cytosol preparation.
Cytosol preparation
The tissue (250-500 mg) was chilled in
liquid nitrogen, pulverised with a
microdismembrator (Braun, Melsungen,
FRG) and suspended in 2ml of 10 mM
phosphate buffer containing, 1.5 mM
EDTA, 3 mM sodium azide, 10 mM
1-monothioglycerol and 10% (v/v) glycerol,
at pH 7.5. The resulting homogenate was
centrifuged at 0-4°C for 30 min at
100,000 × g to yield a clear cytosol. Total
PR was measured by LBA immediately af-
ter cytosol preparation.
Receptor assay
Total tumor PR levels (total PRLBA)
were measured, as previously described,
by the LBA and scatchard plot analysis,
according to the guidelines of the Euro-
pean Organization for Research and treat-
ment of Cancer (EORTC), Breast Cancer
Cooperative Group 1,24. The protein con-
tent of the cytosol was estimated with the
method of Bradford, using reagents from
Bio-Rad (Richmond, CA, USA) and serum
albumin (Kabi, Diagnostica, Stockholm,
Sweden) as a standard 25. The lower cut-off
level for PR positivity was set to be 10
fmol/mg protein. The between-assay vari-
ability of these assays is PR (n=31): 11.3%
at 333 fmol/mg protein and for the protein
assay (n=31): 5.8% at 3.4 mg/ml.
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Protein electrophoresis and
immunoblot analysis
Sixty-one cytosols with PRLBA >10
fmol/mg protein were used for the
immunoblot analysis. PR isoforms were
separated by electrophoresis through
6.5% polyacrylamide (30% acrylamide/bis
solution, 37.5:1) resolving gel and a 2.6%
stacking gel both containing 0.10% So-
dium Docedyl Sulphate (SDS), using a
Mini Protean II apparatus (Bio-Rad, Rich-
mond, CA). The cytosol of each sample
loaded on gel contained 10 fmol PR, and
was diluted to 80µl with sample buffer. For
cytosol samples with very low PR levels
(<40 fmol/mg protein), the maximum
amount of cytosol possible was used. Sam-
ples were heated for 8 min at 99°C and then
loaded onto gel. After electrophoresis,
proteins were transferred to Immobilon-P
membrane (Millipore, Bedford, GB) at
125 V for 1.5h at 4°C in 25 mM tris, 192 mM
glycine, 20% (v/v) methanol as described
by Towbin et al. 26. The conditions used for
transfer were chosen after pilot experi-
ments which showed that shorter transfer
times significantly altered the ratio of
PR-A:PR-B in favour of PR-A (the lower
molecular weight form). Increasing the
transfer times beyond 1.5 h did not alter
the observed ratio indicating that transfer
was complete at this time.
After transfer, the membrane was
blocked with 1.5 mM phosphate-buffered
saline (PBS, pH 7.4) containing 5% low fat
milk powder (Protifar; N.V. Nutricia,
Zoetermeer, The Netherlands), and incu-
bated with a specific antibody (AB) against
human PR, monoclonal antibody Ab-4
(clone hPR a4, Neomarkers, Fremont,
USA) at a 1:1000 dilution 27. PR-A migrates
as a single band whereas PR-B migrates as
a triplet, for analysis the sum of the triplet
was used.
The specificity of hPR4a was verified
using other antibodies against both
isoforms (hPRa1, Neomarkers) and
against only PR-B (clone hPR a6,
Neomarkers). In order to establish the
inter-assay reproducibility of each experi-
ment, on each gel at least two identical
amounts of cytosol of human myometrium
were used as PR positive controls. The mo-
lecular weight of each PR isoform was es-
tablished with a molecular weight
standard (BioRad, Richmond, CA). After
incubation with the PR antibodies, blots
were incubated with horseradish
peroxidase-conjugated goat anti-mouse
antibody at a final dilution of 1:2500 (Dako
A/S, Denmark). Specific bands were visu-
alized by using enhanced chemi-
luminescence detection substrates (0.01%
(v/v) 250 mM luminol in DMSO, 0.004%
(v/v) 90 mM p-loumaric acid in DMSO,
0.002% (v/v) H2O2 in Tris 0.1 M, pH 8.5)
and blots were exposed to Kodak film
(Biomax-ML, Kodak, Rochester, NY,
USA). A control immunoblot, with and
without a specific hPR4a PR antibody, of
T47D (PR=1800 fmol/mg protein), LNCaP
(PR<10fmol/mg protein) and human
myometrium cytosol revealed that the
bands visualised were specific for PR.
Multiple exposures of each immuno-
blot were made, and results were used
only from those where PR-A and PR-78
bands could be analyzed separately, and
that fell within the linear range of the film.
Otherwise, a new assay was run using
more diluted samples. Band intensities
41
PR isoforms in meningiomas
were measured densitometrically (Sharp
JX330, Japan). The linear range of detec-
tion of PR on immunoblot was established
by a standard curve, made using increas-
ing concentrations of control cytosol, and
analysis by densitometry. A linear rela-
tionship between total PR concentration
(based on LBA) and densitometric detec-
tion by immunoblot analysis could be es-
tablished. The between-assay variability
of PR in cytosols of human myometrium
was 10.1% (n=31).
Statistical evaluation
For each sample the mean of the PR
isoform expression was calculated from at
least three independent immunoblot as-
says. Spearman rank sum tests (rs) were
used to compare total PRLBA, PR-A, PR-B
and 78-kDa band expression. Mann-Whit-
ney non-parametric tests were performed
to compare protein expression between
the subgroups. P values of <0.05 were con-
sidered statistically significant.
Results
Total progesterone receptor (PR)
expression in human meningiomas
based on ligand binding assay (LBA)
The PR concentration of 61 PR posi-
tive meningiomas is depicted in Table 3-1.
The average PR concentration of the
cytosols used was 181±24 fmol/mg protein
(mean ± s.e.m., n=61). The total PRLBA
concentration fell in the range 10-755
fmol/mg protein with the median at 98
fmol/mg protein. PR-A expression was
considered to be higher than PR-B expres-
sion when the total optical density of the
band was higher (Table 3-1, PR-A>PR-B)
and visa versa for PR-B>PR-A. No signifi-
cant differences could be found between
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Meningioma
subtype
n Total PRLBA a
(fmol/mg protein)
PR-A > PR-B b PR-B > PR-A b
- Syncitial 16 183 ± 49 9 7
- Transitional 4 82 ± 20 4 0
- Atypical 3 66 ± 11 2 1
- Malignant 1 23 1 0
- Unknown 37 221 ± 36 24 13
Total 61 181 ± 24 40 21
Table 3-1. Progesterone receptor (PR) isoform expression in human meningiomas. Abbreviations: Total
PRLBA , progesterone receptor determined with a LBA. a Data are presented as the mean ± standard error
of the mean (s.e.m.). bPR-A or PR-B is considered to be higher than PR-B or PR-A expression when the
optical density of the specific band was higher.
histological meningioma subgroups and
total PRLBA concentration.
PR isoforms
Figure 3-1 shows a representative
immunoblot of the two PR isoforms, PR-A
(81 kDa) and PR-B (116-120 kDa) and an
additional band PR-78. The PR-B isoform
migration pattern depends on the
phosphorylation status and can be seen as
multiple bands. Sixty-six per cent of the
tumors express more PR-A than PR-B (Ta-
ble 3-1). No significant differences in the
distribution of the two isoforms among the
histological subtypes of meningiomas
could be found. Figure 3-1 also shows that
there is a high variation (coefficient of
variation of 30%) between PR immunoblot
band density (PR-A + PR-B + PR-78) and
the calculated total PRLBA levels of
10 fmol/mg protein. This was unexpected
since the between-assay variability of the
immunoblot assay and of the LBA were
10.1% (at 79.5 % PR-A, n=31) and 11.3% (at
333 fmol/mg protein, n=31), respectively.
The PR-78 isoform
An additional 78 kDa band migrating
just below of PR-A was detected in all 61
meningiomas. To analyze whether this
78kDa band is associated with PR-A or
PR-B, Spearman rank correlation analysis
was performed for all the PR isoforms.
Figure 3-2 shows that PR-B and PR-78
are significantly negatively associated
(rs=-0.76, P<0.0001). No association was
found between PR-A and PR-78 (rs=-0.20,
P>0.5). Besides PR-A and PR-B, because
of its capability of ligand binding, PR-78
has also been included in the comparison
with the total PRLBA.
Association between PR isoforms and
total PR
Clinical studies that have compared
PR concentration in meningiomas with
prognosis or recurrence rate, have found
some relation between these factors and
total PR determined by a LBA (in this
study referred to as total PRLBA). The dif-
ferential expression of PR isoforms
may play an important role in these
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CM1 M2 M3 M4 M5CC
PR-A
PR-78
PR-B
Figure 3-1. Immunoblot analysis of the progesterone receptor (PR) isoforms in human meningioma
cytosols. For each of the vife samples depicted as M1 to M5, three control myometrium cytosols were
used (C). Each lane contains equal amounts (10 fmol) of PR established with a ligand binding assay
(LBA). PR-B (116-120 kDa) shows multiple bands depending on phosphorylation. Just below PR-A
(81 kDa) a 78 kDa band migrates.
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Figure 3-2.The PR-A to PR-B ratio and the total PR LBA expression in human meningiomas. The number
of tumors that express more PR-A than PR-B is higher in meningiomas expressing more than 200
fmol/mg protein. In the group with a low total PRLBA , both PR-A>PR-B and PR-B>PR-A expression
ratios are observed.
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Figure 3-3. The association between the band intensities of PR-B and PR-78. The densities of the PR-B
band and PR-78 band are strongly negatively-associated. No association was found between the density
of PR-A and PR-78 bands. Abbreviation: WB, Western immunoblot .
observations, therefore the association be-
tween total PRLBA and de differential ex-
pression of the PR isoforms expression
was determined.
PR-A and total PRLBA were found to
be significantly associated (rs=0.45;
P<0.001). Figure 3-3 shows the relation-
ship between the ratio PR-A:PR-B and the
total PRLBA. High expression levels of
PR-A with respect to PR-B were found in
all the tumors with a high total PRLBA ex-
pression (>200 fmol/mg protein). The
group of meningiomas expressing less
PR-A than PR-B, expressed significantly
lower amounts of total PRLBA than
the group with more PR-A than PR-B
(Figure 3-4; P<0.001). An association was
found between PR-78 and total PRLBA
of rs=0.3 (P=0.03). Meningiomas with a
high total PRLBA expression (>200 fmol/mg
protein) tended to express more PR-78
than PR-B.
Discussion
In this study, the distribution of pro-
gesterone receptor isoforms was deter-
mined in human meningioma cytosols and
compared with total PR levels determined
with a LBA (total PRLBA). The findings of
this study showed that more than 65% of
the tumors expressed more PR-A than
PR-B. In addition, PR-A was positively as-
sociated with total PRLBA levels. The dif-
ferential expression of PR isoforms in
meningiomas may have important
implications for the clinical aspects of the
disease.
Progesterone is thought to play a cru-
cial role in meningioma development and
proliferation. Follow up studies of patients
with meningioma disease showed that the
PR contents of meningiomas may have
clinical significance as a prognostic
45
PR isoforms in meningiomas
PR-A>PR-B PR-B>PR-A
**
Total PR (fmol/mg protein)LBA
300
400
200
100
0
Figure 3-4. Total PRLBA expression in
meningiomas with differing ratios of PR-A and
PR-B. The group of meningiomas with a higher
PR-A than PR-B band intensity (PR-A>PR-B,
n=39) expressed significantly more total PRLBA
than the group with a higher PR-B than
PR-A band intensity (PR-B>PR-A, n=22).
**(P<0.001).
parameter for survival and recurrence.
Hsu et al. and Brandis et al. , showed that
the presence of PR is a favourable prog-
nostic factor for meningiomas 3,4. In agree-
ment with Hsu, Fewings et al., in a study of
62 meningiomas, found that PR positive
benign meningiomas were less likely to re-
cur 5. Since PR isoforms exhibit differ-
ential transcriptional activity, the overall
response to progesterone or PR antago-
nists may depend on PR isoform distribu-
tion.
In all our meningioma samples and
the myometrium control, the presence of a
PR-78 band migrating just below the PR-A
isoform was detected. Graham et al. also
reported the presence of this PR-78 band
in a proportion of human breast cancer
cytosols 10. These authors found that the
PR-78 band accounted for up to 20% of the
total PR concentration. No association
was found between PR-78 and PR-A or
PR-B in these breast cancer cytosols. The
origin of the PR-78 band has been re-
ported not to be an artifact of the cytosol
preparation, since deliberate degradation
of the breast cancer cytosol samples did
not lead to more PR-78 10,11. Yeates et al.
performed additional experiments to
characterize the origin of the PR-78 band.
In breast cancer they ruled out the possi-
bility that PR-78 could be considered to be
a phosphorylated product of PR-A and
PR-B. They also showed that PR tran-
scripts, including splice variants, are un-
likely to be implicated in the formation of
PR-78 isoform. The PR-78 is, therefore,
most likely not a direct product of transla-
tion of the PR gene. Photo-affinity labeling
studies demonstrated specific binding of
ligand to PR-78 11.
In contrast to these findings, the re-
sults of our study showed a significant neg-
ative correlation between the expression
of PR-B and the PR-78 isoform in
meningiomas (Figure 3-2). The absence of
transcripts encoding for PR-78, and the
negative association with PR-B and not
PR-A, are consistent with the idea that
PR-B endogenously degraded into
PR-78 in meningiomas, but the data do
not exclude that there maybe a similar reg-
ulation pathway in the biogenesis of
PR-B and PR-78. In addition, most of
the antibodies used in literature were, ap-
parently, not able to detect PR-78 in vari-
ous other tissues. This may indicate that
although PR-78 is capable of progesterone
binding, PR-78 might miss some other
epitopes besides the B upstream se-
quence. Nevertheless, PR-78 protein is ca-
pable of ligand binding, therefore, it
may have a biological function in mediat-
ing progesterone signaling. Experiments
are underway to further address the origin
of PR-78.
Our immunoblot data, in which equal
amounts of PR based on ligand binding as-
say were used, showed a high within-assay
variability of PR-A and PR-B band intensi-
ties (see Figure 3-1). Several possible ex-
planations were ruled out by performing
the appropriate control experiments, such
as equalizing the total protein levels. The
amount of blood contamination also did
not alter these high differences. The pres-
ence of endogenous ligands in menin-
giomas might not be important since all
tumors were from post-menopausal
women, or from men. When the amount of
PR-78 band is taken into account, this dis-
crepancy decreases by 20%. Other PR
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proteins that bind ligand in the LBA, for
instance PR-C, which could not be de-
tected in our experimental subset, might
explain a part of the remaining discrep-
ancy.
The existence of PR-like proteins that
are capable of binding progesterone might
have important implications. If these
isoforms, PR-78 and possible others, do
not have a biological function the total PR
concentration used for clinical purposes is
overestimated. If the PR-78 isoform inter-
feres in the progesterone-signalling path-
way, for instance by binding to cofactors, it
might act as a transrepressor. In addition,
PR-like proteins may interfere with the
prognostic significance of steroid hor-
mones in hormone-responsive cancers. In
conclusion, PR-like proteins are present
in tumor cytosols and their precise func-
tion and role in progesterone signalling
needs to be ellucidated.
The PR is a phosphoprotein and con-
tains at least seven phosphorylation sites.
PR-B contains three more phos-
phorylation sites than PR-A located in the
PR-B upstream region 28-30. Slower electro-
phoretic mobility on SDS-gels has been re-
ported to be associated with increased
phosphorylation 28,31. In addition, in our
immunoblot analysis of meningioma
cytosol samples, variable differential ex-
pression of three closely migrating PR-B
bands was observed. The biological rele-
vance of this variability in PR-B sub-band
expression is not clear. Whether phos-
phorylation of PR has a functional role PR
remains poorly defined. Phosphorylation
may not alter transcriptional activity of
PR-B, but it could have other functions 29.
Growth of meningiomas seems to be
influenced by progesterone levels and a lot
of studies have achieved tumor growth re-
mission by using progesterone agonists,
progesterone depletion and, above all,
progesterone receptor blockade by pro-
gesterone antagonists. Olson et al., re-
ported inhibition of meningioma growth
in vitro of three meningiomas after treat-
ment with mifepristone (PR antagonist),
ranging from 18% to 36% after 28 days in
culture 32. We have shown that in menin-
giomas of 13 patients cultured for 8 days,
the thymidine-labelling index signifi-
cantly fell when increased concen-
trations of mifepristone were added18.
Other authors, however, could not confirm
these findings 33. In clinical studies re-
sponses were seen in patients with
unresectable meningiomas treated with
mifepristone 200 mg orally daily for 6-24
months. Grunberg et al. reported objective
responses seen in 8 out of 20 patients ac-
companied by subjective improvement in
5 patients 34. Lamberts et al. noted regres-
sion in 3 out of 10 patients while headaches
were improved in five patients 35. Haak et
al. also reported a case in which
mifepristone was used successfully 36.
Whereas elevated levels of progestin in
meningioma patients seems to stimulate
tumor growth, high dose of medroxy-pro-
gesterone acetate (MPA) resulted in a de-
crease of tumor size and PR expression in
a study reported by Markwalder et al. 23,37.
However, Jääskeläinen could not confirm
this in a study of 5 meningioma patients
using the same dose of MPA 38. Although
most studies that used anti-proges-
tins for treating meningioma have re-
ported some responses, more than half
of the treated patients did not show a
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response at all. Thus, data from both in
vivo and in vitro reports are not yet con-
clusive.
In gynecological cancers progestins
are used as therapeutic agents as reviewed
by Gadducci et al. 39. In metastatic
breast cancer, progestins are used as third
line therapy. Progestins are also used in
patients with advanced or recurrent
endometrial cancer and regression and
stabilisation of advanced recurrent
low-grade endometrial stromal carcino-
mas. The theory behind the success
is that progestins have anti-estrogenic ef-
fects like down regulation of the oestrogen
receptor (ER) and stimulation of the con-
version of oestradiol to the less oestro-
genic oestrone. In addition, progestins
seem to downregulate the anti-apoptotic
factor bcl-2, and to suppress estrogen in-
duced expression of vascular endothelial
growth factor (VEGF)-subtypes.
It has been reported that for breast
cancer PR-A expression is higher than
that of PR-B 10. In leiomyomas, both PR
forms are also expressed and there was a
predominance of PR-A over PR-B 40. For
endometrial cancers, 5 out of 11 cases
seemed to have a predominant expression
of PR-B mRNA. However, it is not yet
known whether this is translated to the
protein level 41. The different response of
meningiomas and gynaecological cancers
to progestin administration could up to
now not be clarified by PR isoform distri-
bution. Firstly, not much is known about
the ratio PR-A:B from clinical trials, and
secondly in most of the gynaecological tu-
mors PR-A expression also seems to be
higher. The anti-oestrogenic effect of
progestins, however, will not play a role in
meningioma since the majority of the tu-
mors do not express appreciable levels
of ER.
We suggest that progesterone block-
ade may only be effective in certain sub-
sets of meningiomas. Meningiomas with a
clear prevalence for PR-A or PR-B will re-
spond in a different way to endocrine
agents. If in meningioma PR-B is the more
transcriptionally active of the two
PR-forms, it could be anticipated that
meningiomas with a prevalence for
PR-A may be at least likely to respond
to endocrine agents. The prognostic
value of PR and the better outcome of
meningiomas that express high levels
of PR, may be due to transrepression activ-
ity of the prevalent PR-A isoform,
and thus via a transrepression instead
of a transactivation mechanism. Our ini-
tial idea: progesterone action via the
PR activates progesterone-respon-
sive genes in meningioma, needs to be
reconsidered. Since there is no
(pre-)clinical evidence that fully ad-
dresses the significance of PR isoform dis-
tribution and the response to endocrine
therapy, further clinical investigations
are needed.
In summary, meningiomas express
both PR-A and PR-B isoforms and an addi-
tional PR-78 product. The ratio of PR-A to
the PR-B protein expression levels is
highly variable and higher in the
meningiomas with a high total PRLBA ex-
pression. Perhaps this variability has
some clinical and biological significance in
meningioma disease.
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Abstract
Meningiomas are generally benign central nervous system neoplasms, which frequently express
progesterone receptor (PR) and only rarely express the estrogen receptor (ER). For breast cancer a re-
lation between steroid hormone receptors and proteins involved in the apoptotic process has been de-
scribed. For meningioma the exact relation between PR and these proteins is not known. In this study
ER, PR, bcl-2 and bax expression levels were determined in cytosol from meningiomas. As a reference
for our experimental conditions we also determined these proteins in cytosol from breast cancer. PR
and ER were determined with a ligand binding assay and scatchard-plot analysis. The expression levels
of the anti- and pro- apoptotic proteins, bcl-2 and bax respectively, were determined by
immunoblotting.
In 65% of the meningiomas bcl-2 expression was found in variable amounts. In contrast to breast
cancer, a significant negative association between PR and bcl-2 was found (P<0.01). Bax expression in
meningiomas appeared constitutive, not related to PR, and 2.6 times higher than in breast cancer. As
both PR and bcl-2 appear positively associated with prognosis, the negative relationship between bcl-2
and PR found in this study might have some biological and clinical significance.
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Introduction
Meningiomas are generally benign
intracranial tumors that arise from
meningothelial cells found in the
arachnoid villi of the meninges, the mem-
brane covering brain and spinal cord 1.
Meningiomas are one of the most common
brain tumors in adults. The standard
treatment is surgical resection and, when
necessary, additional radiation therapy
is used. Meningiomas recur in more
than 20% of the cases, and are some-
times inoperable due to their relatively in-
accessible locations. Standard therapy
alone is then insufficient and there is
a need for adjuvant therapy 1,2. There
are particular grounds for assuming
that meningiomas are depending on hor-
mones for their growth and differentia-
tion. Intervention of tumor growth via
steroid hormone receptors could be help-
ful for treatment of unresectable
meningiomas 3.
Hormone-dependent tissues, such as
uterus and breast cancer, express both es-
trogen receptors (ER) and progesterone
receptors (PR) to regulate their hormone
dependent proliferation. PR expression is,
at least partly, under estrogen control.
Meningiomas, which express relatively
high levels of PR, seldom express ER 4,5.
An extensive overview of literature from
the last two decades has showed that
PRs are expressed in almost 2/3 of the tu-
mors investigated (see also Chapter 1).
ER positive meningiomas are rela-
tively rare and have very low expression
levels of ER 4,5. In meningiomas, PRs are
most likely functional and progesterone
may play a role in the growth of the
tumor. The presence of PRs may also serve
as a favorable prognostic indicator of re-
currence 6,7.
In breast cancer a relation has been
described between PR and several
apoptotic proteins, like bcl-2 8. Bcl-2 seems
under progesterone and estrogen control
in in vitro experiments 9. Bcl-2 is a member
of the Bcl-2 proto-oncogene family. Bcl-2
protein itself (bcl-2) is an anti-apoptotic
protein and acts after a converging point
in the apoptotic cascade. Bcl-2 forms
heterodimers with bcl-2-associated X pro-
tein (bax), which is the pro-apoptotic
counterpart of the bcl-2 protein. The ratio
between bcl-2 and bax appears to deter-
mine the sensitivity of cells for apoptosis.
However exact working mechanisms are
still unclear.
In meningiomas bcl-2 expression has
been reported. Mosnier et al. showed that
bcl-2 expression in 82% (32/39) of the tu-
mors they investigated by immunoblot
analysis of meningioma cytosols 10. In ad-
dition, tumors with high bcl-2 expression
levels appeared to have a favorable prog-
nosis 11,12. Knowledge of the exact relation
of bcl-2 and PR in meningiomas is limited,
though may have some clinical signifi-
cance since both proteins have been de-
scribed to be prognostic markers.
In this study, both bcl-2 and bax pro-
tein levels were quantified in meningioma
cytosols, using immunoblot analysis.
ER and PR expression levels were quanti-
fied to establish the relationship between
bcl-2 and bax expression. For comparative
Bcl-2 and bax expression in meningiomas
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purposes the same experiments were done
with breast cancer specimens, of which
hormonal regulation of bcl-2 and bax
expression already has extensively been
studied.
Patients and Methods
Tissues
Human breast cancer or meningioma
tissue was placed on ice immediately after
removal from the patient. Representative
specimens were frozen at -80°C until they
were used for cytosol preparation.
Cytosol preparation from tissue
The tissue (250 mg) was chilled in liq-
uid nitrogen, pulverized with a
microdismembrator (Braun, Melsungen,
FRG) and extracted with 10 mM phos-
phate buffer containing, 1.5 mM EDTA,
3 mM sodium azide, 10 mM 1-mono-
thioglycerol and 10% (v/v) glycerol, at
pH 7.5. The resulting homogenate was
centrifuged at 0-4°C, at 100,000 × g for 20
min, to yield a clear cytosol. The ER
and PR were measured immediately after
cytosol preparation. Aliquots for assess-
ment of bcl-2 and bax were stored at -80°C.
Receptor assay
The ER and PR levels of the tumors
were measured, as described previously,
by the ligand-binding assay and scatchard
plot analysis, according to the guidelines
of the European Organization for Re-
search and Treatment of Cancer
(EORTC), Breast Cancer Cooperative
Group 13,14. The protein content of the
cytosol was estimated with the method of
Bradford, using reagents from Bio-Rad
(Richmond, CA, USA) and serum albumin
(Kabi, Diagnostica, Stockholm, Sweden)
was used as a standard 15. The lower cut-off
level for ER and PR positivity was set to be
10 fmol/mg cytosol protein. The be-
tween-assay reproducibility for the assays
were: ER(n=31): 10.6% at 58 fmol/mg pro-
tein, PR (n=31): 11.3% at 333 fmol/mg pro-
tein, and protein (n=31): 5.8% at 3.4
mg/ml.
Protein Electrophoresis and
Immunoblot analysis
Tumor cytosol proteins (40 µg/lane)
were separated by electrophoresis
through 12.5% polyacrylamide (30%
Acrylamide/Bis Solution, 37.5:1) resolving
gel and a 2.6% stacking gel both contain-
ing 0.10% SDS, using a Mini Protean II ap-
paratus (Bio-Rad, Richmond, CA, USA).
Proteins were transferred to Immobilon-P
membrane (Millipore,GB) (100V, 1hr, 4°C)
in 25 mM tris, 192 mM glycine, 20% (v/v)
methanol as described by Towbin et al. 16.
After transfer, unbound sites remaining in
the membrane were blocked in 5%
Protifar (Protifar; N.V.-Nutricia, The
Netherlands) in PBS buffer, (Phosphate
buffered saline, pH 7.4) and incubated
with specific antibodies (AB) against bcl-2
and Bax proteins. Bcl-2 was detected us-
ing specific anti-bcl-2 mouse AB at a final
dilution of 1:1000 (Clone 124, Dako A/S,
Denmark) and bax with anti-bax rabbit AB
at a final dilution of 1:10,000 (polyclonal
N-20, Santa Cruz Biotechnology, USA).
Blots were incubated with a horseradish
peroxidase-conjugated goat anti-mouse or
anti-rabbit secondary antibody at a final
dilution of 1:5000 (Dako A/S, Denmark).
For both bcl-2 and bax specificity of the
first antibody was confirmed with control
experiments, in which the first antibody
was left out of the assay. Specific bands
were visualized by using enhanced
chemiluminescence detection substrates
(200 µl 250 mM luminol in DMSO, 88µl 90
mM p-Loumaric acid in DMSO, 12 µl 30%
H2O 2 in 20 ml Tris 0.1 M, pH 8.5) and blots
were exposed to an auto-radiograph. Mo-
lecular weight was determined with
biotinylated SDS-PAGE standards broad
molecular weight marker and avidin HRP
(Bio-Rad, USA). Three controls of
myometrium tissue, positive for bcl-2 and
bax, were included on each gel containing
5 samples.
Band intensities were measured
densitometrically (Sharp JX330, Japan).
The linear range of detection of bcl-2 and
bax on immunoblot was established by a
standard curve made using increasing
concentrations of control cytosol. This was
analyzed by densitometry and established
the relationship between bcl-2 and bax
concentration and linearity of detection by
this method. Multiple exposures were al-
ways made from each immunoblot of tu-
mor cytosols, and results were used only
from those that fell within this linear
range. Densities of specimens were refer-
enced to those of the controls. The
interassay reproducibility for this assay
was 12.1%.
Statistical evaluation
All meningioma and breast cancer
cytotols were ordered by increasing levels
of PR or ER and divided in three equal
groups, resulting in tertiles 1 to 3 with low,
moderate, and high PR or ER expression,
respectively. Mann-Whitney non-parame-
tric tests were performed to compare pro-
tein expression between the tertiles.
Spearman rank sum tests (rs) were used to
compare bcl-2, bax expression results with
ER or PR expression. P values of less than
0.05 were considered statistically signifi-
cant.
Results
Steroid receptor expression and
apoptotic proteins in meningiomas
The results of steroid hormone recep-
tor analysis in meningioma cytosols are
shown in Table 4-1. In 15% of the
meningiomas ER expression was found
in a concentration of 14 ± 2 fmol/mg pro-
tein (mean ± s.e.m.). PR expression was
found in 86% of the meningiomas, and ex-
pression levels were 205 ± 31 fmol/mg pro-
tein. At least 75% of the meningiomas
expressed PR without the presence of ER,
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in agreement with previous results, indi-
cating the representativity of the speci-
mens. Examples of results of bcl-2 (Mr
26,000) and bax (Mr 21,000) immunoblots
are shown in Figure 4-1 (left panel). Ex-
pression of bcl-2 was found in 31/48 (65%)
meningiomas. Bax expression was found
in almost all meningioma specimens. Bax
protein expression levels were 2.6 times
(266% against 104%) higher in
meningiomas than in breast cancer tissue,
as shown in Figure 4-2 (P<0.0001). A sum-
mary of the statistical analysis of the rela-
tionship between steroid hormone
receptors and the apoptotic proteins bcl-2
and bax is given in Table 4-2. In
meningiomas, we found a significant nega-
tive association between PR and bcl-2
(P<0.01). Meningiomas with high levels of
PR showed a significant decrease in bcl-2
expression levels (Figure 4-3, black
bars). Bax appeared to be expressed con-
stitutively, and was not associated with
the PR in meningiomas (as shown in
Figure 4-2). Moreover, little biological
variation was found in bax expression be-
tween the tissues.
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Meningiomas Breast cancer
Bcl-2
Bax
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C
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Figure 4-1. Immunoblot analysis of bcl-2 and bax expression in breast cancer and meningioma cytosols.
Bcl-2 is variably expressed in meningioma as well as in breast cancer cytosols. Bax is constitutively
expressed in both tissues. Bax expression levels are higher in meningiomas than in breast cancer.
Meningioma samples are depicted as M1 to M10 and breast cancer samples as B1 to B10. Together with
5 samples, 3 control cytosols (C) were measured and used as an internal standard.
Receptor
phenotype
Meningiomas
(n=47)
Breast Cancer
(n=81)
ER PR
– – 11 % 9 %
+ + 11 % 81 %
– + 75 % 6 %
+ – 4 % 5 %
Receptor
expression
ER positivity 7 70
[ER] a , b 14 ± 2 c 130 ± 16 c
Median 11 81
PR positivity 40 69
[PR] a , b 205 ± 31 c 331 ± 50 c
Median 119 156
Table 4-1. Progesterone and estrogen recep-
tor expression in meningiomas and breast
cancer cytosols. a positive only; b fmol/mg
protein; c mean ± s.e.m.
Steroid receptor expression and
apoptotic proteins in breast cancer
cytosol
Since in breast cancer bcl-2 appeared
to be positively associated with PR and un-
der progesterone control, the negative as-
sociation found in meningioma was
unexpected. In order to verify our experi-
mental conditions, we performed the same
experiments with breast cancer cytosols.
In breast cancer cytosol ER expression
was found in 86% of the tumors and the av-
erage expression level was 130 ± 16
fmol/mg protein. PR expression was found
in 87%, 331 ± 50 fmol/mg protein. A pre-
dominance of the ER+/PR+ phenotype
with 81% was found (Table 4-1). The
Spearman correlation between the ER
and PR was rs=0.34, with a P < 0.01 (Ta-
ble 4-2). Examples of bcl-2 and bax
immunoblot assay are shown in Fig. 1
(right panel). Bcl-2 was expressed in 71/82
(87%) of the breast cancer cytosols. Bax
expression was found in almost all breast
cancers. Bcl-2 was significantly positively
associated with ER and PR. Higher levels
of steroid hormone receptors are associ-
ated with significantly higher levels of
bcl-2 expression, as represented in Fig-
ures 3 and 4 for PR and ER, respectively.
Bax was not associated with PR or ER.
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Bax protein expression (% of control)
Progesterone receptor (PR)  in tertiles
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Figure 4-2. Bax protein levels in meningioma
and breast cancer cytosols expressed as a
percentage of control, and divided in three
subgroups with low, moderate and high PR
expression. Bar and error bar represent mean 
sem, respectively. The mean of PR expression is
shown below each corresponding bar. Bax is
constitutively expressed in both meningioma
and breast cancer cytosols. Bax expression in
meningiomas is significantly higher than in
breast cancer. Neither in meningiomas nor in
breast cancer an association between bax and
PR was found. Abbreviations: PR progesterone
receptor; 1 mean (fmol/mg protein); *** P<0.0001
vs. Breast cancer.
Meningiomas
Breast cancer ER PR bcl-2 bax
ER - nd ns ns
PR 0.34* - -0.37* ns
bcl-2 0.41*** 0.50*** - ns
bax ns ns ns -
Table 4-2. Summary of the spearman rank correlation analysis in the comparison of bcl-2, bax and
steroid hormone receptor expression in meningiomas and breast cancer (rs). Abbreviations: ns not
significant, nd not determined. * P<0.01; *** P<0.0001.
Discussion
In this study, we found that most of
the meningiomas had an ER negative and
PR positive phenotype, this was a confir-
mation of our previous finding 4,14. In most
other hormonally regulated tissues, PR is
regulated via the ER pathway. Genes that
are under strict estrogen control may not
come to expression in the absence of ER.
Koehorst et al. described the absence of
pS2 and the low CatD expression, both es-
trogen inducible proteins, in 46 menin-
giomas 17. Other genes, like the PR gene,
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Figure 4-3.Bcl-2 expression in meningioma and
breast cancer cytosols expressed as a
percentage of control, and divided in three
subgroups with low, moderate and high PR
expression. Bar and error, bar represent mean
 sem, respectively. The mean of PR expression
is shown below each corresponding bar. The
group with high PR has a significantly lower
bcl-2 expression in meningiomas and a
significantly higher bcl-2 expression in breast
cancer versus their corresponding low PR
group. Abbreviations: 1 mean (fmol/mg protein);
*** P<0.0001 vs. corresponding low PR group;
** P<0.02 vs. corresponding low PR group;
* P<0.05 vs. corresponding high PR group; PR,
progesterone receptor.
**
*
100
Expression (% of respective control)
Bax
Bcl-2
Estrogen receptor (ER)  in tertiles
0
150
50
Low ER Mod ER High ER
N
ERa
SE
27
13
2
27
5
27
256
27
68
Figure 4-4. Bcl-2 and bax protein levels in
breast cancer expressed as a percentage of
control, and divided in three subgroups with
low, moderate and high ER expression. Bar and
error bar represent mean  sem, respectively.
The mean of ER expression is shown below each
corresponding bar. Bcl-2 but not bax expression
is significantly increased with higher ER
expression levels in breast cancer cytosols.
Abbreviations: 1 mean (fmol/mg protein); **
P<0.001 vs. corresponding low ER group; *
P<0.01 vs. corresponding low ER group; ER,
estrogen receptor.
appear to have at least a second transcrip-
tion initiation pathway. How transcription
of the PR gene is regulated in
meningiomas is still unknown.
There are some arguments for think-
ing that PRs play a role in meningioma
growth. For instance a predominance of
female patients was found 18. The size of
meningiomas increased when there are
high progesterone levels as seen during
pregnancy and in the luteal phase of the
menstrual cycle 19. Grunberg et al. re-
viewed responses seen in several trials
treating patients with the progesterone re-
ceptor antagonist, mifepristone (RU 486)
or Medroxy Progesterone Acetate (MPA),
a synthetic progesterone agonist 3.
Markwalder et al. described another argu-
ment, they treated patients with MPA
prior to surgical resection and found that
the treated group had a significantly
higher level of PR 20. Several in vitro ex-
periments have described hormone de-
pendence of meningiomas grown in cell
culture experiments 21.
PR expression in meningiomas might
have some clinical significance since
Brandis et al. found that PR was absent
more frequently from non-benign
meningiomas 22. Moreover, they have
found that the PR status in meningiomas
is related to tumor differentiation and thus
may be a prognostic factor 22. In addition,
Fewings et al. found that meningiomas
that are PR positive were less likely to re-
cur 6,7.
Bcl-2 immunostaining of meningio-
mas has been described by several authors
10-12,23,24. In addition, Mosnier et al. con-
firmed their own immunohistochemtry
(IHC) findings by immunoblotting and
found 32/39 tumors expressing measur-
able levels of bcl-2, however, in contrast to
own findings, they could not find a relation
with the PR based on IHC data 10. Since
our results differ from Mosnier et al. and
the positive relation that is found between
PR and bcl-2 in breast cancer, we vali-
dated our experimental conditions by
measuring these proteins in breast cancer
cytosols. Our findings confirmed the posi-
tive relation between PR, ER and bcl-2,
and therefore, validate our experiments.
The discrepancy with the findings of
Mosnier et al. may be caused by differ-
ences in technique.
Bcl-2 expression in meningiomas may
have clinical significance since Kara-
mitopoulou et al. found that bcl-2 protein
expression was associated with unfavour-
able prognosis of meningiomas 12. The neg-
ative association between PR and bcl-2
expression levels found in the present
study links the findings of these authors.
Hara et al. reported the only study of
bax expression in untreated meningio-
mas 11. They found very weak staining of
bax proteins in meningiomas using IHC.
This is in contrast to our own findings, in
which we observed constitutively high ex-
pression levels of bax in meningiomas
compared to breast cancer. High levels of
bax may indicate that meningiomas may
be sensitive for apoptosis induction. In-
deed, apoptosis is described in menin-
giomas, however, uncommonly for low
grade meningiomas 23,25.
In the present study, where we paid
particular attention to proper quantifica-
tion of the results by introducing a com-
mon specimen in all experiments (see
"patients and methods" section), neither in
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breast cancer nor in meningiomas an asso-
ciation was found between bax protein lev-
els and the steroid hormone receptors ER
and PR. Kandouz et al. found that bax
seems to be constitutively expressed in
breast cancer cell lines independent of
hormone stimulation 26. A direct associa-
tion between PR and bax in ovarian tissue
was reported 27. It seems that steroid hor-
mones, at least in meningioma and breast
cancer, may not regulate bax expression
levels. The hormonal regulation of bax is
most likely tissue-specific and remains to
be elucidated.
The ratio between pro- and
anti-apoptotic proteins determines the
overall sensitivity for cells to apoptosis. In
meningiomas that express high levels of
the pro-apoptotic bax in contrast to low
levels of the anti-apoptotic bcl-2, you
might expect the involvement of other
anti-apoptotic proteins to make tumor
growth possible. Work is currently under-
way to address the question whether the
anti-apoptotic protein Bcl-xl and/or insu-
lin like growth factor II are involved in
maintaining growth in meningiomas.
In summary, a significant negative re-
lation exists between PR and bcl-2 in
meningiomas. Bax expression was high in
meningiomas and might be constitutive.
Bcl-2, bax and PR may be valuable in pre-
dicting success of anti cancer endocrine
therapy and for other prognostic pur-
poses. The precise regulation of PR and
bcl-2 proteins, in an estrogen independent
pathway, remains to be elucidated.
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Abstract
Meningiomas are generally benign neoplasias that arise from the meninges and comprise 20% of
all intracranial tumors. These tumors frequently express the progesterone receptor (PR) and
meningioma growth is affected by treatment with antiprogestins as shown by in vitro and clinical stud-
ies. In addition, the PR is associated with recurrence and survival rate. Progesterone could also be im-
portant in the regulation of apoptosis since a negative correlation exists between PR and bcl-2. Bcl-2 is
an anti-apoptotic protein that is a prognostic factor in meningiomas. The PR exists in at least two
isoforms, PR-A and PR-B each of which are likely to have different biological functions depending on
cell and promoter context.
This study was conducted to investigate the expression of other apoptotic proteins than bcl-2, and
their relationship with the PR. Thus far, nothing is known about the expression of the anti-apoptotic
protein bcl-xl and the pro-apoptotic protein bak in human meningiomas and this issue was addressed in
the present study by using immunoblot analysis. Bcl-xl expression was found in 87/99 meningiomas and
PR negative meningiomas expressed significantly less bcl-xl protein. A positive correlation was found
between bcl-xl and PR-B protein expression (rs =0.34, P<0.02). Bak was expressed in 52/60
meningiomas and appeared to be unrelated to bak and PR expression levels. Bcl-xl and bak were signifi-
cantly associated (rs=0.42, P<0.001).
In conclusion, both bcl-xl and bak are variably expressed in human meningiomas. PR ex-
pression might be involved in regulating the apoptotic balance in meningioma, since bcl-xl was associ-
ated with PR-B, and this may have some biological and clinical significance.
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Introduction
Meningiomas arise from arachnoidal
cells present in the meninges, the mem-
branes covering brain and spinal cord, and
comprise as many as 20% of all intra-
cranial tumors 1. They are generally be-
nign neoplasms that frequently express
the progesterone receptor (PR), despite
the fact that estrogen receptor expression
is rarely found by ligand binding assay
(LBA) 2. The PR belongs to the super-
family of ligand activated transcription
factors. Clinical studies have shown that
PR expression might be clinically impor-
tant since the PR is a marker of recurrence
and survival rate of meningioma dis-
ease 3-5. The exact biological function of PR
expression in meningiomas is unknown.
The PR exists as at least two different
isoforms PR-A and PR-B. Both isoforms
have distinct transcriptional capacities
and may exert different biological func-
tions 6,7. Meningiomas express both PR
isoforms in variable amounts, however,
PR-A expression is higher in tumors with
high total PR expression 8. Since PR is
thought to be involved in the proliferation
of meningiomas, antiprogestins have been
tested for their anti-tumor activity in sev-
eral in vitro and clinical studies 9.
In breast cancer, steroid hormone re-
ceptors do not only play a role in prolifera-
tion but also in cell death or apoptosis. The
process of apoptosis is controlled by exter-
nal signals in combination with an autono-
mous genetic program. Hormone-de-
pendency has been described of members
of the Bcl-2 proto-oncogene family in-
volved in apoptosis 10. Expression of one of
these proteins, bcl-2 itself, is one of the ma-
jor anti-apoptotic proteins and regulated
by estrogen and progesterone 10. Through
the anti-apoptotic function of bcl-2, it is in-
volved in cancer chemotherapy-resistance
and associated with prognosis, recurrence
and sensitivity for adjuvant therapy of sev-
eral types of tumors 11.
In meningiomas, bcl-2 expression has
also been demonstrated. In contrast to
breast cancer, however, meningiomas
showed a negative association between
bcl-2 and total PR expression levels. The
pro-apoptotic counterpart of bcl-2, bax, is
also expressed in meningiomas. In gen-
eral, the ratio bcl-2 to bax expression lev-
els is thought to determine apoptotic
sensitivity of cells 12. Several meningiomas
show a high ratio bax to bcl-2, indicating
that at least other anti apoptotic proteins
are involved in maintaining meningioma
growth.
Knowledge of expression levels of
other members of the bcl-2 proto-onco-
gene family in meningiomas is limited. An-
other major anti-apoptotic protein besides
bcl-2 is bcl-xl. Bcl-xl prevents bax induced
apoptosis and is described in other hor-
mone dependent malignancies, like
glioma and neuroblastoma 13-15. Expres-
sion of bcl-xl seems to be hormonally regu-
lated by sex steroids, as was revealed by
breast cancer studies 16-19. The expression
of bcl-xl has been reported to be involved
in tumor progression. In addition, bcl-xl
might serve as therapeutic target in
antisense anticancer therapy. Therefore,
knowledge of the expression level of this
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protein in meningiomas is of clinical im-
portance.
Another protein from the bcl-2 family
is the pro-apoptotic protein bak. Bak ex-
pression has been reported in normal and
malignant breast tissue and other malig-
nancies 20,21, however, thus far, nothing is
known about the expression in menin-
giomas. The hormone dependency of bak
expression in breast cancer seems less
than was found for bcl-2 and bcl-xl. Al-
though one study reported that bak ex-
pression was decreased in ER-α negative
breast cancers 21.
Total PR expression in meningiomas
is associated with recurrence and survival
rate, but the exact function of this receptor
in these tumors is unknown. PR might be
involved in the regulation of the apoptotic
process, illustrated by the negative associ-
ation between total PR and bcl-2. This
study was conducted to determine the ex-
pression of other apoptotic proteins, bcl-xl
and bak, and their relation with PR in hu-
man meningiomas.
Patients and methods
Tissues
Human breast cancer or meningioma
tissue was placed on ice immediately after
removal from the patient. Representative
specimens were frozen at -80°C until they
were used for cytosol preparation.
Cytosol preparation
The tissue was chilled in liquid nitro-
gen, pulverized with a micro dismem-
brator (Braun, Melsungen, FRG) and
extracted with 10 mM phosphate buffer
containing 1.5 mM EDTA, 3 mM sodium
azide, 10 mM 1-monothioglycerol and 10%
(v/v) glycerol, at pH 7.5. The resulting ho-
mogenate was centrifuged at 0-4°C for 30
min at 100.000 × g to yield a clear cytosol.
The protein content of cytosols was esti-
mated with the method of Bradford using
reagents from BioRad (Richmond, CA,
USA) and human serum albumin (Kabi
Diagnostica, Stockholm, Sweden) as a
standard 22. The PR was measured imme-
diately after cytosol preparation. Aliquots
for assessment of bcl-xl and bak were
stored at -80°C.
Receptor assay
Meningiomas. PR levels were mea-
sured by a ligand-binding assay (LBA) and
scatchard plot analysis, according to the
guidelines of the European Organization
for Research and Treatment of Cancer
(EORTC), Breast Cancer Cooperative
Group as described previously 23,24. The
lower cut-off level for PR positivity was set
to be 10 fmol/mg cytosol protein. The be-
tween-assay variability for thess assays
was: PR (n=31): CV=11.3% at 333 fmol/mg
protein, and protein (n=31): 5.8% at
3.4 mg/ml.
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Breast cancer. For breast cancer
cytosol samples, total PR was assayed in
duplicate by enzyme immunoassay ac-
cording to the instructions of the manufac-
turer (Abbott Laboratories, Chicago, IL,
USA). Day-to-day performance of the kits
was monitored by assaying control sam-
ples provided with the kits and a
myometrium control cytosol prepared at
our laboratory. For the kit controls, the
found/target ratio for PR was 0.99  0.13
(n=8; CV=12.7%). The myometrium
in-house control specimen read 717  127
(n=8; CV=17.7%) fmol/ml in the PR assay.
Samples were considered to be receptor
positive when the assay result exceeded 20
fmol/mg protein.
Protein Electrophoresis and
Immunoblot analysis
Tumor cytosol proteins (50 µg/lane)
were separated by electrophoresis
through 12.5% polyacrylamide (30%
Acrylamide/Bis Solution, 37.5:1) resolving
gel and a 3.9% stacking gel both contain-
ing 0.10% SDS, using a Mini Protean II ap-
paratus (Bio-Rad, Richmond, CA, USA).
Proteins were transferred to Immobilon-P
membrane (Millipore, GB, 125V, 1hr, 4°C)
in 25 mM tris, 192 mM glycine, 20% (v/v)
methanol as described by Towbin et al. 25.
After transfer, unbound sites remaining in
the membrane were blocked with 10%
Protifar (Protifar; N.V.-Nutricia, The
Netherlands) in PBS buffer, (Phosphate
buffered saline, pH 7.4) and incubated
with specific antibodies (AB) against bcl-xl
proteins and bak. Bcl-xl was detected us-
ing specific anti-bcl-xl mouse AB at a final
dilution of 1:750 (Bcl-xl (Ab-2),
Calbiochem) and bak with anti-bak rabbit
Ab at a final dilution of 1:1000 (Bak, Santa
Cruz Biotechnology). Blots were incu-
bated with a horseradish peroxidase-con-
jugated goat anti-mouse (Dako A/S) or
donkey anti-rabbit (Amersham) second-
ary antibody at a final dilution of 1:2500 or
1:10000, respectively. Visualization using
ECL reagents (Amersham) was according
instructions of the manufacturer. Blots
were exposed to an autoradiograph. Mo-
lecular weight was determined with
biotinylated SDS-PAGE standards broad
molecular weight marker and avidin HRP
(Bio-Rad, USA). Three controls of
myometrium tissue, positive for bcl-xl and
bak, were included on each gel containing
5 samples.
Band intensities were measured
densitometrically (Sharp JX330, Japan).
The linear range of detection of bcl-xl on
immunoblot was established by a standard
curve made using increasing concentra-
tions of control cytosol and analyzed by
densitometry. A linear relationship be-
tween bcl-xl and bak concentrations and
densitometry could be established. Multi-
ple exposures were always made from
each immunoblot of cytosol samples, and
results were used only from those that fell
within the linear range. Densities of speci-
mens were referenced to those of the con-
trols. The between-assay variability of
bcl-xl and bak protein levels in cytosols of
human myometrium were 11.6 % (n=31)
and 14.2% (n=73), respectively.
Statistical evaluation:
Meningioma and breast cancer
cytosol samples were ordered by increas-
ing levels of PR and divided in four groups,
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resulting in quartiles, with total PR nega-
tive, low, moderate, and high total PR ex-
pression, respectively. Mann-Whitney
non-parametric tests were performed to
compare protein expression between the
subgroups. Spearman rank sum tests were
used to compare PR isoforms, bcl-2, bax,
bcl-xl and bak expression with each other,
and Spearman’s correlation coefficient (rs)
was used to evaluate the relationship be-
tween the expression levels of the various
proteins. P values of <0.05 were consid-
ered statistically significant.
Results
Progesterone receptor (PR)
expression in meningiomas
Expression levels of total PR in
meningiomas were determined with a
ligand-binding assay (LBA). In the total
PR positive tumors the PR isoforms, PR-A
and PR-B, were determined by immuno-
blotting (example is shown in Figure 5-1).
In 67% (66/99) of the meningiomas PR was
expressed with an average expression
level of 174±23 fmol/mg protein (median:
94 fmol/mg protein). In 66% of the total PR
positives overexpression of PR-A to PR-B
was found, median ratio of PR-A to PR-B
was 1,7. No differences in total PR and PR
isoform expression levels in meningiomas
could be found between genders.
Expression of apoptotic proteins in
meningioma
Up to now, nothing was known about
the expression levels of bcl-xl and bak pro-
teins in human meningiomas, both pro-
teins belong to the bcl-2 proto-oncogene
family. Therefore, immunoblot analysis
was performed to analyze expression of
these proteins in meningiomas. Represen-
tative immunoblots are shown in Figure
5-2. The bcl-xl immunoblot revealed a dou-
blet band at 32.5kDa and overall analysis
showed variable expression of bcl-xl in 87
out of 99 meningiomas. Bak immunoblot
analysis showed also variable expression
of bak in 52 out of 60 meningiomas. Some
cytosol samples showed an additional bak
band that turned out to be a degradation
product of bak full-length protein (data
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M1 M2
PR-A
PR-B
Figure 5-1. Example of immunoblot analysis of
the progesterone receptor isoform expression
in meningioma cytosol. PR-B (116-120 kDa)
appeared as multiple bands depending on
phosphorylation. PR-A shows a single band
(81 kDa) and just ahead of PR-A a 78 kDa PR like
protein migrated as described by Graham
et al.8,35 Both isoforms were expressed in me-
ningiomas at different levels.
not shown), therefore those samples were
not used for analysis. Bak expression was
significantly lower in meningiomas from
female than from male patients, as shown
in Figure 5-3 (P<0.01; 260% and 695%, re-
spectively).
Previous studies have shown that
bcl-2 expression was negatively associated
with total PR protein expression level,
therefore progesterone could play a role in
the regulation of apoptosis in menin-
gioma. In this study, therefore, the associ-
ation of total PR with other apoptotic
proteins was investigated. Figure 5-4
shows the bcl-xl and bak expression levels
in groups with different expression levels
of total PR; PR negative, low, moder-
ate and high. In total PR negative
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Figure 5-3. Bak expression in meningioma
cytosol samples from male (n=19) and female
(n=37) patients. Results are expressed as means
± sem. *P<0.01.
Meningiomas
Bcl-xl
Bak
C C C
C C C
M1 M2 M3 M4 M5
M6 M7 M8 M9 M10
Figure 5-2. Example of immunoblot analysis of bcl-xl and bak expression in meningioma cytosols. Both
bcl-xl and bak were variably expressed in meningioma cytosols. Meningioma samples were depicted as
M1 to M10. Together with 5 samples, 3 control cytosols (C) were measured, as an internal standard.
meningiomas, bcl-xl expression levels
were significantly lower (P<0.01). In all
other PR subgroups, bcl-xl and bak ex-
pression were not significantly different.
Spearman rank correlation analysis
revealed no significant association be-
tween total PR and both bcl-xl and bak.
This, however, could be masked by the dif-
ferential PR isoform expression. There-
fore, correlation analysis was performed
with PR-B and bcl-xl and bak expression
levels. Figure 5-5 shows that PR-B and
bcl-xl were positively associated, rs=0.34
and P<0.02. Bak expression was not sig-
nificantly associated with PR-A or PR-B.
Inter apoptotic protein analysis
For a large number of meningiomas
used in this study, bcl-2 and bax expres-
sion levels were determined in a previous
study, therefore, multiple correlation
analysis could be performed between the
different apoptotic proteins. A significant
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Figure 5-4. Means of bcl-xl and bak expression in meningioma cytosols expressed as a percentage of
control, and divided in three subgroups with low, moderate and high PR expression. Bars and error
bars represent mean ± s.e.m., respectively. The left panel shows that PR negative meningiomas express
significantly less bcl-xl (P<0.01). Abbreviations: PR, progesterone receptor; *P<0.01.
association was found between bcl-xl and
bak expression levels (rs=0.42; P<0.002).
Bcl-2 was not associated with bcl-xl or with
bak expression levels.
Breast cancer cytosols
In breast cancer, bcl-xl is known to
be positively associated with the expres-
sion of total PR. Since under our condi-
tions such a positive association could
not be found in meningioma cytosol,
breast cancer cytosols were analyzed as a
reference for our experimental conditions.
Indeed western immunoblot and Spear-
man rank correlation analysis revealed a
positive association between total PR and
bcl-xl of rs=0.54 and P<0.01.
Discussion
The aim of this study was to elucidate
the involvement of the PR in the regula-
tion of proteins from the apoptotic cascade
in human meningiomas. Expression levels
of the apoptotic proteins bcl-xl and bak
were determined in meningioma cytosols
samples by immunoblotting. These pro-
tein values were then compared with ex-
pression levels of total PR and PR
isoforms. This study showed that both
bcl-xl and bak were variably expressed in
meningioma cytosol samples. In addition,
bcl-xl was associated with PR-B and signif-
icantly lower in PR negative menin-
giomas. Bak expression seemed not to be
regulated by progesterone or to be associ-
ated with the PR.
The bcl-x gene is a bcl-2-related gene.
Due to alternative splicing, different
mRNA products are formed. A large bcl-x
form, bcl-xl, shows close similarity with
bcl-2. Bcl-xl has been reported as a potent
inhibitor of apoptotic cell death in various
cell types 26. It exhibits regulated expres-
sion during lymphoid development, and is
expressed in developing B cells as shown
by immunoblot analysis 27. Bcl-xl expres-
sion has also been reported in various
types of cancers; such as gynecological tu-
mors, like ovarian tumors, breast cancer
and in breast cancer cell lines 14 28,29; lym-
phomas 30; and in prostate cancer 31. Bcl-xl
expression levels have been reported to be
clinical important. Transfection of bcl-xl in
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Figure 5-5. Association between expression
levels of PR-B and bcl-xl in meningiomas. The
expression levels are positively associated
(rs=0.34, P<0.02).
human ovarian carcinoma cells resulted in
highly resistance of the cells to chemo-
therapeutic agents 29. In addition, promis-
ing results were obtained in studies in
which cell proliferation of breast cancer
cells was inhibited by bcl-xl-bispecific
antisense oligonucleotide treatment of
these cells 32,33.
The other protein invloved in
apoptosis and investigated in this study
was bak. Bak is a pro-apoptotic protein
and expressed in normal breast tissue, as
well as in breast cancer, malignant glioma
cells, gastric ad colorectal cancer 20,21. Reg-
ulation of bcl-xl and bak by sex steroids
has been described in several hormonally
regulated tissues. Marone et al. estab-
lished a negative correlation between PR
and bcl-xl in neoplastic ovarian tissue 14. In
addition, progestins increase the ratio of
bcl-xl to bcl-xs in a rat endometrial cell
line 17. Less is known about the hormone
sensitivity of bak expression. Gompel et al.
findings showed that estrogen and proges-
terone did not affect bak expression lev-
els 10. In contrast, Leung et al. reported in-
hibition of a time dependent increase
of bak mRNA in MCF-7 cell line 34. In addi-
tion, a decrease in bak expression has
been described in ER-α negative
breast cancers 21.
Previous investigations have showed
a negative association between Bcl-2 and
total PR expression levels in meningioma
cytosols. Treatment of meningioma tissue
fragments with the progesterone agonist
org2058 altered the bcl-2 expression levels
(data not shown) suggesting a direct effect
of progesterone on bcl-2 expression regu-
lation. This study showed that bak seems
not associated with PR. In contrast, bcl-xl
seems positively associated with PR-B.
These findings suggest that bcl-2 expres-
sion is most likely regulated differently
than bcl-xl or bak.
For comparative purposes, the rela-
tion between bcl-xl and total PR as ana-
lyzed in breast cancer cytosol samples. For
breast cancer, a positive correlation be-
tween PR and bcl-xl based on IHC data has
already been described in literature.
Breast cancer cytosol analysis revealed a
positive association between bcl-xl and PR
in PR positive tumors. This result further
validates our experimental method and
showed that the hormonal regulation of
bcl-x gene seems tissue specific.
For bcl-2, bax and bcl-xl no difference
between male and female patients could
be detected. Bak expression, however, was
significantly lower in meningiomas of fe-
male patients. Involvement of sex steroids
in the origin of this observation is not very
likely. First, this study showed that PR
was not involved in bak expression regula-
tion. Second, the group of meningioma pa-
tients in this study mainly consisted out of
man or post-menopausal woman, thus
with low estrogen levels. The biological
importance of lower bcl-xl levels in woman
is not known.
In summary, estrogen and progestin
dependency has been reported for bcl-2,
bcl-xl and bak in other tissues. Also, corre-
lation between ER, PR and these apoptotic
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proteins has been found. In meningioma,
only PR is abundantly expressed and only
negatively associated with bcl-2 expres-
sion levels. Bcl-xl was positively associ-
ated with PR-B and bak seemed not
regulated by progesterone in menin-
giomas. The hormone dependent regula-
tion of bcl-2 seems distinct from the
regulation of that of Bcl-xl and bak. This is
confirmed by the absence of a correlation
between bcl-2 with the latter two proteins.
In contrast is the association between
bcl-xl and bak, indicating that they may
share a common progesterone independ-
ent regulation pathway in meningioma.
In conclusion, the apoptotic proteins
bcl-xl and bak are expressed in menin-
giomas at variable amounts and this might
be clinically important. Our hypothesis is
that the PR may regulate the balance be-
tween pro- and anti-apoptotic proteins by
differentially regulating the anti-apoptotic
proteins bcl-2 and bcl-xl.
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Abstract
Overexpression of p53 has been reported to play a role in neoplasms of the central nervous system.
Meningiomas are generally benign intracranial tumors derived from the meninges. Overexpression of
the p53 protein in meningioma and a relation with histological type and recurrence has been reported.
Mutation of the p53 gene leads to a more stable p53 protein in quantities high enough for detection by
immunohistochemistry. In the search for these mutations the core domain of the p53 gene of
meningioma has been analyzed thus far. Only a very low incidence of mutations was reported. The ap-
parent discordance between overexpression of p53 protein and p53 gene mutations may be explained
by mutations located outside the core domain. This issue was addressed in the present study. All 11
exons of p52 of 17 meningiomas were analyzed for alterations of DNA by PCR single-strand conforma-
tion polymorphism (PCR-SSCP) analysis with subsequent sequencing.
PCR-SSCP analysis showed a various number of band shifts and nucleotide alterations, caused ei-
ther by alterations in the flanking introns or common polymorphism (codon 36 and 72). The allele fre-
quencies of the polymorphisms found in this small population of tumors resemble that of frequencies
found in literature. In addition, three nucleotide changes located in intron 2, 3 and 7 were found in 11, 3
and, 4 respectively out of 17 specimens. Based on this study and reports by others, we conclude that it is
not very likely that p53 mutations are involved in the etiology of meningiomas.
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Introduction
The p53 tumor suppressor
gene is located on the short arm of chro-
mosome 17 and encodes a 53 kDa nuclear
phosphoprotein involved in the regulation
of proliferation, DNA repair, and induc-
tion of apoptosis 1,2. Abnormalities of
the p53 gene have been reported to occur
frequently in a wide spectrum of hu-
man cancers 3. The wild type p53 product
suppresses transformation, whereas the
mutated p53 protein may inactivate the
wild type p53 function, allowing DNA rep-
lication on a damaged template and there-
fore resulting in cell transformation 4.
P53 has been reported to play a role in
neoplasms of the central nervous system
(CNS) 5. Meningiomas, generally benign
intracranial tumors derived from the
meninges, account for at least 15% of all
CNS tumors 6. Overexpression of the p53
protein in a substantial number of
meningiomas has been reported by sev-
eral authors and there may be a relation
between p53 expression and histological
subtype and recurrence 7-11. One of the
main causes of p53 overexpression is a mu-
tation in the p53 gene. In the search
for these mutations in meningiomas, re-
search has focused on the core domain
of the p53 gene and only a small percent-
age of mutations was found 12-14. This dis-
cordance may be explained by mutations
located outside the core domain, of which
is known that they also may contribute to
p53 protein over-expression 15. To
ellucidate a role of p53 gene mutations in
the etiology of meningiomas, knowl-
edge about the mutation frequency of
exons not included in the core domain
is required.
In this study we used single-strand
conformation polymorphism (SSCP) anal-
ysis of polymerase chain reaction (PCR)
products, with subsequent sequencing, to
analyze mutations in exon 1-11 of the p53
gene of 17 meningiomas of various
histological types (see Table 6-1).
Material and Methods
Tissues
Seventeen patients with meningeal
tumors diagnosed at the De Wever Hospi-
tal (Heerlen, The Netherlands) between
1997 and 2000 were included in our study.
The study was conducted in accordance
with the guidelines of the local ethical
committee. The characteristics of the tis-
sue are shown in Table 6-1.
DNA extraction and PCR analysis
Meningiomas were stored at
–80°C until used for DNA isolation. DNA
was isolated according to standard experi-
mental procedures using a DNA isolation
kit (Qiagen). The coding regions for p53
gene were amplified by Polymerase Chain
Reaction (PCR). The sequences of the
p53 primers, the predicted sizes of the
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amplified products and restriction en-
zymes used are depicted in Table 6-2. PCR
primers were adopted from Kropveld et al.
16. The PCR reaction was performed in a
50-µl reaction mixture containing 100 ng of
genomic DNA, 10 mM dNTP, 200 ng of
each of the primers, 1.0-2.5 mM MgCl2 (see
Table 2), Mg2+-free PCR buffer (10 mM
Tris and 50 mM KCl, pH 8.3) and 1.25 U
AmpliTaqGold (Roche Diagnostics). After
a first step of denaturation (10 min, 95°C),
35 cycles of PCR amplification 30s at 94°C,
30s at annealing temperature as shown in
table 1, 45 sec at 72°C, were carried out, fol-
lowed by 10 min at 72°C final extension in a
geneamp PCR system 2400 thermal cycler
(Perkin Elmer), Amplified fragments were
purified using a PCR purification spin kit
(JETQuick) PCR products were digested
with restriction enzymes according to
standard experimental procedures using
restriction enzymes and SuRE/Cut buffer
(Boehringer Mannheim) depicted in Ta-
ble 6-2.
Single Strand Conformational
Polymorphism (SSCP) Analysis and
Sequencing
Amplified and purified fragments
were analyzed with SSCP using a GeneGel
Excel 12.5/24 kit (Pharmacia Biotech) at 5,
15 and 30 °C. For most exons, excellent re-
sults were obtained at 15°C (600 V, 30W,
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nr. histological type agea sex exon 4
codon 36
exon
codon 72
exon 4
intron 3
exon 2-3
intron 2
exon 7
intron 7
1 fibroblastic 33 f x x x
2 meningothelial 34 f x x
3 maligne 38 m x x
4 syncytial 49 f x x
5 not specified
6 haemangio-peric
ytoom
25 m x x x
7 atypical 46 f x x x
8 meningothelial 74 f x x
9 atypical 69 m
10 syncytial 64 f
11 fibroblastic 41 m x
12 meningothelial 51 f
13 transitional 45 m x x x
14 unknown 29 m x x x
15 fibroblastic 44 m x x x
16 fibroblastic 48 f x x x
17 fibroblastic 70 f
Table 6-1. Patients characteristics and PCR-SSCP data of 17 human meningiomas. a age at operation.
30 mA) and a running time of 2-5.5 hours.
PCR products of each exon containing a
single mutation in the 5’ primer region
were made and used as a positive control
(see figure 6-1). Following SSCP analysis,
suspect PCR products were used for direct
sequencing. Double strand PCR products
were sequenced by dideoxy-chain-termi-
nation method 17 using the Dye Primer Cy-
cle Sequencing Ready Reaction Kit with
Taq FS (ABI). The PCR primers were used
as sequencing primers (3.2 pmol) for direct
sequencing of the amplified exon in both
orientations. After cycle sequencing, se-
quence products were separated on a 6%
denaturating polyacrylamide gel using an
automated DNA sequencer (373A, ABI).
Mutations were manually identified by
multi sequence analysis to validate the dis-
tinction between background and muta-
tions, by comparing sequence profiles of
many samples.
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Exon DNA-primer (DNA)
position
MgCl2
(mM)/
T(°C)
Restr.
enzyme
(Buffer)
Fragments
(bp)
Exon 1 5’ TTC TTC CTT CCA CCC TTC A 519-537 1.5/58 Cfo I (L) 300+342
3’ GTC CTA ACA TCC CCA TCA TCT 1140-1160
Exon 2-3 5’ GCT TGG GTT GTG GTG AAA CA 11506-11525 1.0/58 Hpa II (L) 200+252
3’ TCC AGG TCC CCA GCC CAA C 11940-11957
Exon 4 5’ GGG GCT GAG GAC CTG GT 11974-11990 1.5/58 Eco 57 (V) 114+264
3’ ATA CGG CCA GGC ATT GAA GT 12332-12351
Exon 5-6 5’ GCA GGA GGT GCT TAC ACA TG 12949-12968 1.0/56 Hpa II (L) 190+348
3’ CAC TGA CAA CCA CCC TTA AC 13467-13486
Exon 7 5’ CTC TTG GGC CTG TGT TA 13972-13991 2.5/55 nd 275
3’ ATT CCC GCC GGA AAT GTG AT 14227-14246
Exon 8-9 5’ GGG TGG TTG GGA GTA GAT 14355-14372 1.5/50 Cfo I (L) 163+298
3’ CGG CAT TTT GAG TGT TAG A 14797-14815
Exon 10 5’ TCC GTC ATA AAG TCA AAC AAT 17480-17500 2.0/51 Stu I (L) 138+250
3’ CGT GGA GGC AAG AAT G 17852-17867
Exon 11.1 5’ GAA AAG GGG CAC AGA CC 18533-18549 1.0/53 Hpa II (L) 289+247
3’ TAT GGG CCT TGA AGT TAG AGA A 19047-19068
Exon 11.4 5’ GTG AGG GAT GTT TGG GAG AT 18918-18937 2.0/57 Mva I (H) 103+333
3’ GGG GTG AGA TTT CCT TTT AGG T 19332-19353
Exon 11.3 5’ GCC AAA CCC TGT CTG ACA ACC T 19294-19315 1.0/55 Hae III (M) 316+318
Table 6-2. DNA primers and restriction enzymes used for SSCP based mutation analysis of the p53
gene. Primers were derived from Kropveld et al. with exeption of exon 11 16 . Abbreviation: nd, not
digested.
Results
The characteristics of the patients
and histological type of the meningiomas
and PCR-SSCP and sequence data are
shown in Table 6-1. All exons of the p53
gene were amplified with PCR using prim-
ers located in flanking introns (Table 6-2).
When the total PCR product length was
more than 300 base pairs, the products
were digested enzymatically to assure op-
timal mutation detection sensitivity
PCR-SSCP analysis
Of the seventeen meningiomas ana-
lyzed no band shifts were observed in
SSCP analysis of exon 1 and 8 to 11. Al-
though all positive controls of these exons
did show a mobility shift.
Of PCR products of exon 1-11, exon 2
to 7 showed multiple band mobility
changes. Of the 17 meningiomas examined
12 showed a band shift in SSCP analysis of
the PCR product of a combination of exon
2 and 3 (Table 6-1). From 17 meningiomas
10 showed three different migration pat-
terns of exon 4 PCR-SSCP products, possi-
bly indicating different nucleotide
84
Chapter 6
P53 exon 5-6
1
positive
control
negative
control
Figure 6-1. An example of PCR-SSCP
analysis of exon 5-6 showing one negative,
one positive control and one meningioma (1)
sample. All PCR controls were checked by
sequence analysis.
codon type Freq. (A) Freq. (a) description reference
Intron 2 38bp3’exon 2 point G>C (41)
Exon 4 36
72
point
point
94 CCG
71 CGC
6 CCA*
29CCC*
silent
Arg>Pro
(26,27,28)
Intron 3 65bp3'exon 3 point C>A (38)
Intron 7 72bp3'exon7
92bp3'exon7
point
point
C>T
T>G
Table 6-3. P53 nucleotide alterations found in 17 meningioma specimen. *17 individuals.
alterations. Four of the meningiomas
showed combinations of band shifts of
exon 4 (see #1-4 in Figure 6-1, left panel).
In 3 out of 17 meningiomas, SSCP analysis
revealed band shifts for the combination
of exon 5 and 6 PCR products. In 4/17
meningiomas also mobility changes were
found for the PCR products of exon 7. All
suspected PCR-products, the wild type
and the positive controls were directly an-
alyzed by sequencing and compared with
the p53 database sequences.
Direct DNA sequence
To characterize the nucleotide se-
quence alterations detected by mobility
shifts in PCR-SSCP analysis, the PCR
products were sequenced with the same
primers as were used for PCR-SSCP anal-
ysis. Overall results are shown in Table
6-3. An example of sequence analysis of
exon 4 is shown in Figur 6-2 (right panel).
The mobility shifts of exon 4 PCR products
appeared to be caused by two common
polymorphisms and an additional muta-
tion in intron 3 (Figure 6-2; specimen #2).
The first polymorphism is a point muta-
tion in codon 72, CGC to CCC resulting in
an amino acid change of ARG to PRO. The
allele frequencies found in 17 menin-
giomas were 0.71 for CGC and 0.29 for
CCC. The second polymorphism in exon 4
was a point mutation codon 36, CCG to
CCA and allele frequencies were 0.94 for
CCG and 0.06 for CCA. This nucleotide
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Meningioma nr.
P53 exon 4
A C G C G GA3’ C G C G G
Wt 5’ CGC 5’ CGC to 5’ CCC
Polymorphism codon 72
3’
Polymorphism codon 36
G G A N G G
5’ CCG TO CCA
G G A C G G
WT 5’ CCG
C 2 3 4 51
point mutation
intron 3
Figure 6-2. Example of PCR-SSCP analysis of exon 4 of the p53 gene in meningiomas is shown. Multiple
band shifts were observed. Lane 1 resembles the wild type phenotype. The right panel shows sequence
analysis of two polymorphisms at codon 36 and 72.
alteration does not lead to an amino acid
change. Besides two polymorphism
of exon 4, three meningiomas also showed
a point mutation in intron 3 (65bp
3’exon3). The mobility shift of exon 2-3
PCR products was explained by a point
mutation, 38 bp of the 3’ side of exon 2,
G>C with allele frequencies of 0.3 and 0.7
respectively. No further mutations were
found in the coding region. The mobility
shift of exon 7 PCR products was ex-
plained by two point mutations in intron 7
(72 and 97 bp 3’exon7, respectively). The
mobility shift of exon 5-6 PCR products
could not be explained by mutations
within the coding region.
Discussion
P53 gene alterations play a role in the
pathogenesis of many different types of tu-
mors. Wild type p53 induces cell cycle ar-
rest, preventing DNA replication errors
and allowing time for DNA repair. It has
also been linked to programmed cell death
or apoptosis of cell types containing criti-
cal levels of DNA damage 18. Dysfunction
of p53 caused either by mutation of the
gene or by inactivation of the wild type
protein, may therefore promote
neogenesis by perpetuating errors in
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author reference year p53 mutation remark
Nagashima et al. (22) 1999 0/7 High p53
expression
Janowska et al. (42) 1998 0/3 Angiomatous
meningiomas
Ohkoudo et al. (9) 1998 0/4 Recurrent
meningiomas, high
p53 PI
Tan et al. (43) 1997 1/13 From abstract, ar-
ticle in Chinese
Ono et al. (44) 1996 0/27
Chent et al. (12) 1995 0/22 (benign)
1/5 (malignant)
Wang et al. (13) 1995 1/5 IHC p53 positive
Ellison et al. (20) 1995 0/9 IHC p53 positive
Albrecht et al. (45) 1994 0/1 Malignant
Ohgaki et al. (14) 1993 0/22 Of which 7 atypical
Mashiyama et al. (25) 1991 1/8 Exon 2-11
Table 6-4. Summary of published data on p53 mutations in human meningiomas. Abbreviations: IHC
immunohistochemistry; PI, proliferation index.
DNA. 4,19. In normal cells, wild type p53 is
present only in minute quantities. Muta-
tions in the p53 gene may lead to a more
stable mutated p53 protein resulting in
quantities high enough for detection by
immunohistochemistry (IHC) 13,20.
Several authors have described p53
expression in several subtypes of
meningioma with IHC 8,9,20,21. Ohkouda et
al. and other authors reported clinical sig-
nificance for p53 expression in menin-
gioma since an association was found
between p53 immuno-reactivity and
histological type or recurrence 9-11,22. Wang
et al. found p53 expression in 4 out of 5
atypical meningiomas, but in non of the 19
benign meningiomas investigated. There-
fore they conclude that p53 could be con-
sidered as a marker for malignant trans-
formation 13. However, other authors
could not confirm these observations 20,23.
Although overexpression of p53 pro-
tein was found in approximately 36% of
the meningiomas, p53 gene alterations
were reported in only 4/126 specimens (see
Table 6-4). This suggests that p53 muta-
tions are not related to positive immuno-
histochemistry results and, are not likely
to play a major role in the etiology of
meningiomas. All reports, however, fo-
cused on just half of the p53 exons, i.e. 5-9.
This could have led to an underestimation
of the actual p53 mutation frequencies in
meningiomas. Kropveld et al. reported
mutations located outside the hotspot re-
gion that revealed 33% of the mutations
found in head and neck squamous cell car-
cinoma 15. This indicates that all the P53
exons should be analyzed before a role of
p53 mutations in meningioma could be ex-
cluded.
In the present study we have
used PCR-SSCP analysis for detecting
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1
1 43 100 300 324 355 363 393
2 4 5 6 7 8 9 10 11
TAD DBD TD CRD
Intron 2
+38bp
Intron 7
+72bp
+92bp
Intron 3
+65bp
Codon 36 Codon 249Codon 161
Codon 175Codon 72
Figure 6-3. Overview of point mutations of the p53 gene in human meningiomas derived from the
present study (black arrows) and from literature (gray arrows)12,13,25. All p53 exons are depicted with the
functional and structural domains of the p53 protein. Figure adapted from 40. Abbreviations: TAD,
transactivation domain; DBD, DNA binding domain; TD, tetradimerization domain; CRD, c-terminus
regulatory domain.
mutations in all the coding regions of the
human p53 gene in 17 meningiomas speci-
men. The effectiveness in detecting muta-
tions with SSCP-PCR is reportedly high
24,25. PCR products with a single mutation
were used as positive controls. Several
exons showed differential band migration
by SSCP analysis and direct sequencing of
the suspected PCR products revealed sev-
eral nucleotide alterations. In exon 4 of the
p53 gene two types of polymorphism were
present. A polymorphism at codon 72 re-
sults in a translation to either Arginine or
Proline. The allelic frequencies,
0.71p53Arg and 0.29p53Pro, found in the
tissues of our meningioma patients corre-
sponded with those described for other tis-
sues 26-28. This polymorphism has been
reported to be associated with the suscep-
tibility to several types of cancer. The
Arginine phenotype may confer protec-
tion against development of human
papillomavirus- associated vulval neopla-
sia as shown in a UK woman population 29.
Codon 72 polymorphism also seems to af-
fect the risk of lung cancer related or unre-
lated to smoking 30-33. Several other
population studies done among patients
with cervical cancer in UK and Taiwan, in
smoking related non-small cell lung can-
cer patients, a Chinese population suffer-
ing from several types of cancer, however,
revealed no association with codon 72
polymorphism 33-37. Although no healthy
subjects were included, the allele frequen-
cies found in the present study, which are
comparable to those in published control
populations 26-28, do not point to a major
role for codon 72 polymorphism in etiology
of meningiomas.
The second polymorphism observed
was a nucleotide change in codon 36 which
does not lead to an amino acid change
but eliminate a FinI restriction site and
creates a BccI site. The allelic frequencies
found in meningiomas also corresponded
with those found for other populations 38.
To our knowledge, the allele frequen-
cies of these two polymorphisms of exon 4
were not described previously for
meningiomas.
No nucleotide alterations could be de-
tected in eleven exons of the p53 gene that
could reveal a role for p53 mutations in the
etiology of meningiomas. Other possibili-
ties, like mdm-2 expression, may contrib-
ute more to the p53 overexpression found
in meningiomas. Mdm-2 is involved in the
stabilization of p53 resulting in a possible
accumulation of the wild type protein 39.
Mdm-2 expression has been reported in
meningiomas with p53 expression 9.
In summary, then, in the pres-
ent study we analyzed DNA of 17
meningiomas for possible mutations lo-
cated in exon 1 to exon 11. Although SSCP
analysis showed a various number of band
shifts in several exons, only nucleotide al-
terations could be found that were caused
by alterations in the flanking introns or
caused by known polymorphisms. Based
on this study and reports by others, the
conclusion is that p53 mutations are not
very likely to be involved in the develop-
ment of meningiomas.
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Abstract
The abundant expression of progesterone receptors (PR) in human meningiomas is well estab-
lished. It is unknown, however, how PR expression is regulated, especially since the estrogen receptors
(ER) are seldom found and only very low concentrations in these tumors. At the mRNA level, ER-α
splice variants occurring in meningioma have been described, however, these variants appear not to be
involved in the apparently autonomous PR expression. Wild type ER-β mRNA has already been demon-
strated in meningiomas, but was not correlated with PR expression. However, ER-β splice variants
could still play a role in PR regulation in meningiomas. In normal breast tissue, breast cancer and other
tissues these ER-β variants have already been demonstrated. This study was conducted to reveal a pos-
sible role for ER-β in the regulation of PR expression in meningiomas. At mRNA level, the presence of
wild type (wt) and splice variants of ER-β were analyzed with rt-PCR and southern blot analysis, the to-
tal PR protein expression levels were determined with a ligand binding assay. Meningiomas contained
wt, ∆2 in 11 out of 14, ∆4 in 1 of 10, and ∆5 ER-β mRNA in 5 out of 8 tumors. However, a relationship with
PR expression could not be found, both PR negative and PR positive meningiomas contained wt and
splice variants of ER-β mRNA. Based on previous findings concerning ER-α, and this study, we con-
clude that ER is not likely involved in the apparently autonomous regulation of PR expression in
meningiomas.
93
Chapter 7
Alternatively spliced estrogen receptor beta mRNA
expression in human meningiomas
F.M. Verheijen, H.M. Jacobs, N. Hermans, M. Sprong, J.H.H. Thijssen,
M.A. Blankenstein.
Department of Endocrinology, University Medical Center Utrecht, The Netherlands
Submitted for publication
94
Chapter 7
Introduction
The autonomous expression of pro-
gesterone receptors (PR) in human
meningiomas has been established for
more than two decades now. The parallel
observation that, in spite of PR expres-
sion, meningiomas essentially lack estro-
gen receptors (ER) has presented a
challenge for the same period of time. The
ER and PR are members of the ste-
roid/thyroid/retinoid receptor gene super-
family 1. Meningiomas are regularly be-
nign lesions and one of the most common
tumors of the central nervous system.
Standard therapy is surgical resection
with subsequent radiation therapy when
necessary 2,3. Meningiomas have attracted
attention as being possible hormone sensi-
tive tumors due to their higher incidence
in woman than in men 4; the epi-
demiological association of meningiomas
and breast cancer 5; and the reversible ag-
gravation of the symptoms during preg-
nancy and in the luteal phase of the
menstrual cycle 6.
The estrogen independent expression
of PR has led to the hypothesis that in
meningiomas, ER forms may prevail
which do not bind the ligand, and hence
are not detected with a Ligand Binding As-
say (LBA) and immunoassays employing
antibodies that recognize the hormone
binding domain of the ER. These
ER-splice variants could be capable, how-
ever, of binding to an estrogen responsive
element (ERE) and triggering PR expres-
sion. The ER-α splice variants have been
demonstrated in meningiomas, however,
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ER-α variant
mRNA
tissue / cell line
ER-β variant
mRNA
tissue / cell line
∆2 HPA,, T47D, PRL, GPH,
HOSE 9,15,16,26,27
∆ 2 HPA 15
∆3 HPA, T47D, RP 9,26,28 ∆ 3 RO, RP 16
∆4 HPA, RB, M, RP, HOSE,
VSMC, BT, MCF7 8,15,16,26,27
∆ 4 BGC 31
∆5 HPA, M, BT, PRL, GPH,
HOSE 8,15,16,26,27
∆ 5 MDA-MB-231, MCF7, BT,
OT, NHB 13,14,32,33
∆6 BT 34 ∆ 6 OT, BT 14,32
∆7 HPA, M, T47D,
HOSE 8,9,15,26,27
∆ 7
∆3/4 RP, VSMC 28,30 ∆ 5/6 OT, BT 14,32
Table 7-1. ER mRNA variants identified in tissues and cell lines. Abbreviations: HPA, human pituitary
adenoma; representative, rat pituitary; RB, rat brain; T47D/ MDA-MB-231/ MCF7, breast cancer cell line;
HT, human testis; PRL, prolactinomas; GPH, gonadotroph tumors; BT, breast tumor; OT, ovarian tumor;
M, meningiomas; MB, mouse breast; MO, mouse ovary; MU, mouse uterus; RO, rat ovary; BGC, bovine
granulosa cells; NHB, normal human breast; HOSE, human ovarian surface epithelial cells; VSMC,
vascular smooth muscle cells.
they are most likely not responsible for the
initiation of PR expression. ER-α/∆4 was
unable to bind ligand as well as an ERE
and is not transcriptionally active 7.
ER-α/∆5 is present in both PR positive and
negative meningiomas 8. ER-α/∆7, finally,
is a dominant negative repressor 9. Ten
years after the cloning of ER-α, a second
ER-form was cloned known as ER-β, ini-
tially from rodent and later from human
tissue 10-12. Of the ER-β also several splice
variants have been reported. Table 7-1
gives an overview of the expression of
splice variants in several types of tissues.
For these splice variants a biological sig-
nificance has been reported by several
authors 13-16. In a significant proportion of
meningiomas, wild type ER-ß mRNA has
been demonstrated by Carroll et al. 17. Al-
though ER-α splice variants are not in-
volved in PR regulation in meningiomas,
splice variants of the novel ER-β have not
yet been studied in meningiomas. This
study was conducted to reveal the pres-
ence of ER-β splice variants and to com-
pare the outcome with the PR phenotype
of meningiomas. ER-β splice variants were
determined with a sensitive PCR-South-
ern blot analysis and PR expression levels
were measured with an LBA.
Materials and methods
Tissues
Human meningioma tissues were
placed on ice immediately after removal
from the patients. Specimens were frozen
at –80°C until they were used for RNA ex-
traction. For southern blot analysis, 17 hu-
man meningioma tissues were collected
from 9 female and 8 male patients, the
mean age at the time of surgery was 62
years (median: 67 years; range 25-75), op-
erated at the University Medical Center
Utrecht, The Netherlands. The study was
conducted in accordance with the guide-
lines of the local ethical committee.
RNA Isolation
Total RNA was prepared from 100 mg
of frozen meningioma tissue sections, a
testis sample and a myoma, using Trizol
(GibcoBRL) reagent according to the
manufacturer’s instructions and quanti-
fied spectrophotometrically. Its integrity
was assessed by gel electrophoresis.
cDNA synthesis
Total RNA (1.5 µg) and 100 ng random
hexamers were denatured at 70°C for 10
minutes. cDNA synthesis was carried out
in 20 µl 50 mM Tris-HCl (pH 8.3) contain-
ing 75 mM KCl, 8 mM MgCl2 , 10 mM
dNTP, 20 U RNAse inhibitor (Boehringer,
Mannheim, Germany) and 200 U of
M-MLV Reverse Transcriptase (Promega
madison, WI, USA). After denaturation of
the RNA the reverse transcription was
performed in one cycle: 50 minutes of in-
cubation at 42°C and 15 minutes enzyme
inactivation at 70°C. Reactions without
M-MLV RT were also carried out as a
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negative control during cDNA synthesis,
and also amplified with PCR
PCR amplification
In the PCR reactions, 5  l of cDNA
product was used. PCR amplification was
carried out in 50 l 15 mM Tris-HCl pH 8.3
containing 57.5 mM KCl, 1.8 mM MgCl2,
250 ng primers, 0.5 mM dNTP and
1 U Ampli Taq Gold™. The nucleotide se-
quences of primers and probes used are
presented in Table 7-2. Primers 1 to 10
were used during the 35 cycles of amplifi-
cation. Each cycle consisted of a denatur-
ation step at 94C for 1 min, annealing step
at 60C for 1 min, and 2 minutes of exten-
sion at 72C. To control for extraneous
contamination of genomic DNA or cDNA,
PCR mixture with no template was in-
cluded.
Southern hybridization
PCR products (18 µl) were ap-
plied to a 2% agarose gel and electro-
phoresed for 1.5 hours at 100 V. After dena-
turation in 0.5 M NaOH for 30 minutes, the
gel was neutralized in 0.5 M Tris-HCl (pH
7.2) containing 1.5 M NaCl and 0.001 M
EDTA (pH 8.0) for 30 minutes. PCR prod-
ucts were transferred under vacuum to a
HybondTM-N membrane (Amersham, Lit-
tle Chalfont, UK). The membrane was
prehybridized for 2 hours at 55°C in 5x
SSPE, 5x Dennhardt’s solution, 0.5 % SDS
and 50 µg/ml of sheared salmon sperm
DNA. The probes were end-labeled in 10
mM Tris-HCl pH 7.6 containing 10 mM
MgCl2, 5 mM DTT and 100 ng probe (Ta-
ble 7-2) using T4 Polynucleotide kinase
and [-32P]ATP. After purification of the
32P end labeled probes using Probe-
Quant™ G-50 Micro columns according to
the manufacturer’s instructions, hybrid-
ization was performed overnight at 50C.
After hybridization the membrane was
washed in SSPE 2x, 0.1% SDS at 60C and
exposed to X-ray films. Meningioma sam-
ples not containing a wild-type ER-ß sig-
nal were not taken into account since this
was most likely due to a PCR failure.
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Exon Primers Nucleotide Probe Nucleotide
2-3 5’ ggtccatcgccagttatcac 3’
5’ gccacatcagccccatcatt 3’
368- 387
779- 800
ex2 S 5’ caggttcaaagagggatgctc 3’
ex3 AS 5’ accattcccacttcgtaacacttc 3’
517- 537
719- 742
4 5’ tgccaggcctgccgacttc 3’
5’ gccacatcagccccatcatt 3’
699- 717
112-1134
ex3 AS 5’ caggttcaaagagggatgctc 3’
ex2 S 5’ accattcccacttcgtaacacttc 3’
719- 742
996-1019
5 5’ ggccaagagaagtggcggccacg 3’
5’ aaaccttgaagtagttgccaggagc 3’
830- 852
1235-1259
ex4 S 5’ aagttggccgacaaggagttggta 3’
ex5 AS 5’ gccacatcagccccatcatt3’
996-1019
1115-1134
6 5’ accaagtgcggctctt 3’
5’ ggtcacggcgttcagcaag 3’
1075-1090
1382-1400
ex5 AS 5’ gccacatcagccccatcatt 3’
ex6 S 5’ gctcctggcaactacttcaaggtt 3’
1115-1134
1235-1258
7 5’ gctcctggcaactacttcaaggtt 3’
5’ gatcatggccttgacacaga 3’
1235-1258
1644-1667
ex6 AS 5’ gatcatggccttgacacaga 3’ 1291-1310
Table 7-2. Primer and probe sequences used for southern blot analysis of ER-β.
Sequence analysis
PCR products were purified with A
JETQuick PCR purification spin kit. The
PCR primers were used as sequencing
primers (3.2 pmol) for direct sequencing of
the amplified exon in both orientations.
After cycle sequencing, sequence prod-
ucts were separated on a 6% denaturating
polyacrylamide gel using an automated
DNA sequencer (373A, ABI).
Results
Southern blot analysis of ER-
In order to reveal the presence of
ER-β splice variants in meningiomas, we
performed PCR and southern blot analysis
of exons 2-7 of the ER-β gene in human
meningiomas. Full length mRNA of the
ER-β wild type was detected in all
meningiomas as well as in myoma and tes-
tis controls. To detect ER-β splice variants,
PCR was performed with exon flanking
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PR(fmol/mg P.)
569 0 0064 T M 281 123 907
Exon 1-4
A Primers:Exon 1><Exon 4
Probe in Exon 2Probe in Exon 3
∆ β2ER-
PR(fmol/mg P.)
433
260
64569 0 0 0 0 0 0? M
Exon 3-5
B Primers:Exon 3><Exon 5
Probe in Exon 4Probe in Exon 3
∆ β4ER-
436
136
2980 ? 0 0 0 64 TM
Exon 4-6
C Primers:Exon 4><Exon 6
Probe in Exon 5Probe in Exon 4
∆ β5ER-
PR(fmol/mg P.)
430
291
Figure 7-1. Example of southern blot hybridization of PCR products revealed ER-β deletion variants
(see Table 7-2 for primers and probes). A. Hybridization was performed with a probe in exon 1 and 4 (left
panel) and revealed two bands, the wild type product and an additional ER-β/∆2 splice variant as
confirmed by hybridization with a probe in exon 2 (right panel). B. Hybridization was performed with a
probe in exon 3 and 5 (left panel) and revealed two bands in one meningioma and myoma control, the
wild-type product and an additional ER-β/∆4 splice-variant, as was confirmed by hybridization with a
probe in exon 4 (right panel). C. Hybridization was performed with a probe in exon 4 and 6 (left panel)
and revealed two bands, the wild type product and an additional ER-β /∆5 splice variant was confirmed
by hybridization with a probe in exon 5 (right panel).
primers and southernblot was performed
with radio labeled probes in and outside
the specific exons (see Table 7-2).
Besides the wild type ER-β mRNA,
several additional bands with a different
mobility were detected. To establish the
exact character of the bands, southern blot
analyses was performed with probes lo-
cated in the specific exon. In those blots
only wild type ER-β mRNA remained visi-
ble (Figure 7-1). In addition, the extra
bands were isolated and analyzed by di-
rect sequencing (an example is given in
Figure 7-2). Direct sequencing proved that
indeed these extra bands were ∆2, ∆4 and
∆5 splice variants of the ER-β gene.
ER-β/∆2 mRNA was detected in 11 out
of 14 meningiomas analyzed and no corre-
lation could be found with ER or PR.
ER-β/∆4 mRNA could only be detected in
the myoma control and in one out of 10
meningiomas. The steroid receptor phe-
notype of this meningioma was ER nega-
tive/PR positive. ER-β/∆5 mRNA was
found in 5 out of 8 meningiomas analyzed
of which both PR positive and PR negative
phenotypes were present.
An ER-β variant with a 54 nucleotide
insertion at the exon 5-6 junction found in
other tissues, could not be found in 13
meningiomas. The ∆6 and ∆7 splice vari-
ants were also not present in 11 and 14
meningiomas, respectively.
Discussion
Generally, meningiomas have a pro-
gesterone receptor (PR) positive and es-
trogen receptor (ER) negative phenotype
based on a LBA 18. Even when ER is pres-
ent it is only expressed at low quantities.
In most other hormone sensitive tissues,
PR expression is under estrogen control,
and hence PR and ER are positively
ER-ß splice variants in meningiomas
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Figure 7-2. Sequence analysis of the wild type
ER-β and ER-β /∆2 amplified with primers in
exon 1 and 4. Exon 1-2 transition and exon 2-3
transition are shown in the upper two panels,
whereas the junction between exon 1 and exon 3
mRNA is demon- strated in the lower panel.
associated. Clinical studies showed that
PR expression in meningiomas might have
significance as prognostic marker for sur-
vival or recurrence 19-21. How the PR ex-
pression is regulated in meningiomas is
still unknown, and knowledge of this regu-
lation could be helpful for understanding
the biological role of PR in these tumors.
Although ER protein levels are not
detectable with a LBA, mRNA expression
of both ER-α and ER-β has been demon-
strated by PCR and southernblot analy-
sis 8,17, but no relationship could be found
between ER mRNA, neither for αnor for β,
and PR expression levels. Besides the wild
type ER forms, ER splice-variants of both
ER genes have been described in litera-
ture. On basis of detailed studies, the ER-α
splice-variants were not likely involved in
the regulation of PR expression in
meningiomas 8. ER-α splice-variants of the
ER-α in meningiomas has not been
studied, therefore this study was con-
ducted to reveal whether splice-variants of
the ER-β could be involved in PR regula-
tion. The presence of ER-β splice variants
in meningiomas was analyzed with
PCR-southernblot analysis and the rela-
tionship between the presence of ER-β
splice variants and PR expression levels
was investigated.
In this study besides wild type ER-β
mRNA, multiple forms of the ER-β splice
variants were detected. The functional
consequences of these ER-β forms in
meningiomas are unknown. Full length
ER-β is comprised of several functional do-
mains important for DNA binding, hor-
mone binding, and maximal transcription
activation (see Figure 7-3). Deletion of a
specific domain due to alternative mRNA
splicing may give rise to a variant receptor
with altered ER activity. ER variants may
exert different biological effects; first by
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Figure 7-3. Schematic representation of the human ER-β protein. The common and functional domains
of the ER-β are indicated. Above the A-F domains the corresponding exons of the ER-β gene are
depicted (adapted from reference 25).
competing with the ability of wild type
ER-β to bind with high affinity to estrogen;
second by affecting the formation of stable
ER homodimers after ligand binding;
third by altering the transactivation of
ER-βat estrogen responsive elements; and
fourth by scavenging of co-activators or
co-repressors. Therefore, alternatively
spliced ER-β variants may give rise to a va-
riety of receptor isoforms that may poten-
tiate diverse actions of estrogen via ERs.
We found that the ER-β/∆2 mRNA is
frequently co-expressed with wild type
ER-β in human meningiomas. Shupnik
et al. observed ER-β/∆2 in human pitu-
itary tumors 15. The protein encoded by
ER-β/∆2 mRNA will be severely truncated
due to the introduction of a stop codon in
exon 3 and misses the ligand binding do-
main. ER-α/∆2 has been shown to be
highly effective in repressing Fos-medi-
ated transcription in Hela cells 15,16. The bi-
ological significance of ER-β/∆2, however,
is not known. In meningioma no relation-
ship was found between the presence of
this splice variant mRNA expression and
the PR protein expression levels.
The ER-β/∆4 mRNA could only be
found in one meningioma which was posi-
tive for PR expression. The ER-α variant
lacking exon 4 is known to be a silent vari-
ant not capable of binding estradiol or
binding to an estrogen responsive element
(ERE) 7. Walther et al. found ER-β/∆4 in
several types of tissues, but the function of
this splice variant could not be clarified 22.
The deletion of exon 4 would induce a
frame shift, though exon 5-8 would not be
affected. We consider it unlikely that
ER-β/∆4 is responsible for PR expression
in meningiomas, since both PR negative
and positive meningiomas were ER-β/∆4
negative.
Jacobs et al. recently revealed that
ER-β/∆5 could not be responsible for PR
synthesis in meningioma 8. The ER-β/∆5 is
found in several meningiomas in this
study. This splice variant should be ex-
pected to encode a c-terminally truncated
ER-β protein that is capable of binding
ligand. As the DNA binding domain and
hinge region remain intact, this splice
variant may also be capable of
dimerisation and may have some
transcriptional activity. Vladusic et al. re-
ported co-expression of wild type ER-β
and the ∆5 splice-variant in an estrogen
unresponsive breast cancer cell line and in
malignant breast tumors. Also, a hormone
dependent breast cancer cell line ex-
pressed both wild type and ER-β/∆5 23.
Since ER-β/∆5 was found in ER negative
and PR negative meningiomas, it could
not be responsible for PR expression in
these tumors.
An ER-β variant with a 54 nucleotide
insertion at the exon 5-6 junction has been
described in mouse uteri, ovaries and
mammary tissue by Lu et al. 14, and in nor-
mal rat ovary and pituitary tissue by
Petersen et al. 24 In ER-β positive breast
cancer, however, this variant could not be
detected. This ER-β variant is able to
ligand binding and ERE binding, but it re-
quires 1000 fold higher concentrations of
estradiol compared to the wild type ER-β.
This variant is also able to suppress wild
type ER-α and ER-β mediated transcrip-
tion 24. In our subset of meningiomas
this insertion, however, could not be
101
ER-ß splice variants in meningiomas
detected. No ER-β mRNA missing exon 7
has been described up to now. Though
the ER-α/∆7 has been reported to be a
dominant negative repressor of transcrip-
tion activation 9. The ER-β/∆7 could not be
found in meningiomas.
In conclusion, although several splice
variants of the ER-β gene could be detec-
ted in human meningioma specimens, not
one of the found splice variants is likely to
be responsible for PR expression in
meningiomas. A role for both ER-α/β wild
type and splice variants based on mRNA
data in meningiomas is not very likely.
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Abstract
The predominance of meningiomas in women, the association between meningiomas and breast
cancer, and their accelerated growth during periods of high progesterone levels in the circulation, have
led to a number of studies examining a possible role for the progesterone (PR) and estrogen receptors
(ER) in these tumors. Data from previous studies based on reliable ligand binding assays (LBA) shows
that meningiomas are rich in PR, whereas ER is seldom found and only in very low concentrations. Be-
cause of the discrepancy in literature about the presence of ER in meningiomas and the abundant ex-
pression of PR, which is considered to be an estrogen target gene, a sensitive immunoblot assay for
further exploring ER protein expression in these tumors was developed.
Despite the initially assumed ER negative and PR positive phenotype of meningiomas,
ER- expression was detected in all 22 meningiomas investigated by immunoblotting. A relation, how-
ever, with the level of PR could not be established, since PR negative meningiomas also expressed ER-α.
Therefore, it remains to be elucidated whether these minute quantities of ER-αhave any transcriptional
activity and hence biological significance. This is doubtful since other estrogen target genes, like pS2,
appeared also to be downregulated in meningiomas.
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Introduction
The aberrant expression of progester-
one receptors (PR) in human menin-
giomas has been established for more than
two decades now. The observation that, in
spite of PR expression, meningiomas es-
sentially lack estrogen receptors (ER) has
presented a challenge for the same period
of time. Meningiomas are regularly benign
lesions and one of the most common tu-
mors of the central nervous system. Stan-
dard therapy is surgical resection with
subsequent radiation therapy when neces-
sary 1,2. Meningiomas have attracted atten-
tion as being possible hormonally
sensitive tumors due to their higher inci-
dence in woman than in men 3; the epide-
miological association of meningiomas
and breast cancer 4,5; and the reversible ag-
gravation of the symptoms during preg-
nancy and in the luteal phase of the
menstrual cycle 6. Following the first re-
port in 1979 by Donnell et al. on the pres-
ence of ER in meningioma tissue, a large
number of papers have been published
dealing with this subject. Some authors re-
ported the occurrence of both ER and PR,
whereas others established an ER nega-
tive and PR positive phenotype.
The discrepancy could be explained
by the use of different techniques with dif-
ferential sensitivity, like single point
ligand binding assay (LBA), multiple point
LBA with scatchard plot analysis, enzyme
immunoassay, or immunohistochemistry.
An overview of LBA data of 400 menin-
giomas has been reported 7. These results
illustrate that, using the well established
cut-off of 10 fmol/mg protein, ER in the
majority of the meningiomas were below
this level confirming the predominant
ER-/PR+ phenotype of meningioma.
Our previous findings of PCR-south-
ern blot analysis of ER-α and ER-α mRNA
in meningioma tissue that were negative
by the cut-off used for LBA 8, have led to
the hypothesis that meningiomas may ex-
press ER in minute quantities that are not
high enough for detection by a LBA. At
least in theory, these low ER levels might
be biological active and could be involved
in the up-regulation of PR. To evaluate
this hypothesis, a sensitive immunoblot
assay for detecting ER-α in meningiomas
was developed.
Material and methods
Tissues
Human meningioma tissues were
placed on ice immediately after removal
from the patients. Specimens were frozen
at -80 C until they were used for cytosol
preparation. For immunoblot analysis, 18
human meningiomas were collected from
11 female and 7 male patients, the mean
age at the time of surgery was 68 years
(median: 67 years; range 52-95) operated
at the University Medical Center Utrecht.
The study was conducted in accordance
with the guidelines of the local ethical
committee.
107
ER protein expression in meningiomas
Cytosol preparation
The tissue (500 mg) was chilled in liq-
uid nitrogen, pulverized with a
microdismembrator (Braun, Melsungen,
FRG) and suspended in 2 ml of 10 mM
phosphate buffer containing, 1.5 mM
EDTA, 3 mM sodium azide, 10 mM
1-monothioglycerol and 10% (v/v) glycerol,
at pH 7.5. The resulting homogenate was
centrifuged at 0-4°C for 30 min at
100,000 × g to yield a clear cytosol. Total
ER and PR were measured by LBA imme-
diately after cytosol preparation, as previ-
ously described 7 and aliquots for protein
electrophoresis were stored at –80°C.
Protein electrophoresis and
immunoblot analysis
Meningioma cytosol samples (2 to 3
times concentrated as compared to control
cytosol from breast cancer and myo-
metrium) were used for immunoblot anal-
ysis under denaturating conditions. Total
proteins were separated by electrophore-
sis through a 7.5% polyacrylamide (30%
acrylamide/bis solution, 37.5:1) resolving
gel and a 2.6% stacking gel both contain-
ing 0.10% sodium dodecyl sulphate (SDS),
using a Mini Protean II apparatus
(Bio-Rad, Richmond, CA). Maximal
amounts of cytosol (62.5 µl) were diluted
with 12.5 µl Sample buffer. Samples were
heated for 8 min at 99°C and then loaded
onto the gel. After electrophoresis, pro-
teins were transferred to Immobilon-P
membrane (Millipore, Bedford, GB) at 125
V for 2 h at 4 °C in 25 mM tris, 192 mM
glycine, 20% (v/v) methanol containing
0.01 % sodium docedyl sulphate (SDS), as
described by Towbin et al. 9. After transfer,
the membrane was blocked with 1.5 mM
phosphate buffered saline (PBS, pH 7.4)
containing 5% low fat milk powder
(Protifar; N.V. Nutricia) and incubated
with a specific antibody (AB) against hu-
man ER- (ER Ab-15 (clone AER611)),
mouse monoclonal at a 1:1000 dilution 10.
The molecular weight of each ER
form was established with a molecular
weight standard (BioRad). As control sam-
ples ER- human recombinant (Panvera)
and positive control lysate for ER- Ab-10
(Neomarkers) were used. After incubation
with the ER antibodies, blots were incu-
bated with horseradish peroxidase-conju-
gated goat anti-mouse antibody at a final
dilution of 1:2500 (Dako A/S). Dilutions of
cytosol containing less than 0.5 fmol/mg
protein (based on LBA) could easily be de-
tected with this immunoblot assay. Spe-
cific bands were visualized by using
enhanced chemiluminescence detection
substrate (Westpico ECL, Amersham) and
blots were exposed to Kodak film
(Biomax-ML, Kodak). Quantification of
these immunoblots is not appropriate and
result were only used for establishing the
presence of ER-α.
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Figure 8-1. Immunoblot analysis of ER-α
positive cytosol sample. A) Increasing amounts
of cytosol protein resulted in a shift of the ER-α
immunoblot signal. B) Addition of albumin to a
positive ER-α construct sample resulted in a
band shift of the signal.
Results
The concentrated cytosols of
meningiomas as used, contained large
amounts of albumin that interfered with
the migration pattern of the ER protein
band. Figure 8-1 shows that increasing
amounts of cytosol resulted in a lower mi-
gration of the ER-α band. By adding
meningioma cytosol to an ER-α positive
control the effect of albumin on the migra-
tion of ER-α was demonstrated. Although
the ER-α band of the positive construct
and the ER bands found in the
meningioma cytosol samples migrated dif-
ferently, they are actually of the same size.
The use of ER positive breast cancer
cytosols, an ER positive cell lysate, and an
ER-α construct, showed the specificity of
the ER antibodies used. The size of the
ER-α was between 60-65 kDa. In addition,
experiments (data not shown) were per-
formed to determine that cross-reactivity
between both ER forms did not take place.
Figure 8-2 shows a representative
immunoblot of ER-α expression in con-
centrated meningioma cytosol samples
and unconcentrated breast cancer
cytosols. The results are summarized in
Table 8-1. The LBA revealed that 13/22
meningiomas showed no ligand binding,
indicating that ER protein levels were be-
low 10 fmol/mg protein. Immunoblot anal-
ysis, however, revealed that all
meningioma cytosol samples showed ER-α
expression in variable amounts. Groups of
meningiomas with low and high expres-
sion of PR expressed ER-α.
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Meningioma LBA Imblot
nr. PRa ERa ER-α
1 382 <10 +
2 19 <10 +
3 15 <10 +
4 107 <10 +
5 137 <10 +
6 114 <10 +
7 74 50 +
8 105 39 +
9 <10 <10 +
10 123 <10 +
11 97 <10 +
12 13 <10 +
13 236 <10 +
14 34 23 +
15 250 11 +
16 340 <10 +
17 215 35 +
18 48 <10 +
19 <10 <10 +
20 <10 <10 +
21 <10 <10 +
22 <10 <10 +
Table 8-1.Estrogen receptor (ER) expression in
human meningiomas by ligand binding assay
(LBA) and immunoblotting (Imblot).
ER-α
ERa
PRa
00
0
0 24 490
13 19 40
concentrated
Meningioma cytosols breast cancer
115114
Figure 8-2. Immunoblot analysis of ER-α
expression in human meningioma and breast
cancer cytosol samples. ER-α expression was
found in both meningiomas and breast cancer
cytosols. a fmol/mg cytosol protein – Band
intensities can not be compared since different
amounts of cytosol protein were loaded onto the
gel.
Discussion
Meningiomas are generally benign le-
sions of the meninges and show a high re-
currence rate of more than 20% 1,3. For
unresectable and recurrent meningiomas
adjuvant endocrine therapy could be very
helpful. The progesterone receptor has
been considered to be a potential target
for endocrine therapy using anti-
progestins 11. The PR has also been de-
scribed as a prognostic factor for
recurrence and survival rate for
meningioma patients 12-14. In most other
hormone sensitive tissues, PR expression
is under estrogen control and the PR is as-
sociated with the ER 15. To unravel the reg-
ulation and function of the PR in
meningiomas a lot of research has been
performed in the last three decades to in-
vestigate the presence of ER in these tu-
mors.
There are numerous discrepancies in
the literature among the results for ER ex-
pression in human meningiomas. Most
can be explained by the use of different
techniques. Studies done with 16[18F]-
fluoro-17-β-oestradiol ([18F]FES) using pos-
itron emission tomography (PET) demon-
strated a marked uptake of [18F]FES by the
tumor in four of the six patients 16. In addi-
tion, addition of 17-β-estradiol to
meningioma cell cultures showed that 2
out of 4 cultures responded to this steroid
17. Kumar et al. used estrogen bound to flu-
orescent-iso-thiocyanate (FITC) to dem-
onstrate the presence of ER in 33% of 46
meningiomas, although receptor concen-
trations in these tumors were not known 18.
In contrast to these findings are the find-
ings of Bozzetti et al., who investigated the
occurence of ER in patients with primary
untreated meningiomas with a dextran
coated charcoal (DCC) method and the re-
sults were compared with those of an
immunocytochemical assay (ICA). Low
concentrations of ER were found in 8 out
of 44 samples assayed by DCC, specific
staining was never observed in any of the
samples tested by ICA 19. In agreement
with this observation, our own data show
ER expression could not be found in the
vast majority of the meningiomas, based
on our own LBA data 20,21.
The specificity of the antibodies used
in the immunoblot analysis of the current
study were confirmed by the estimated
molecular weight of the ER-α band and by
positive controls of ER-α positive cell
lysate and an ER-α construct. The migra-
tion of the ER protein bands was depend-
ent on the amount of albumin in the
cytosol samples. Cross reactivity of the
ER-α antibody with ER-β was excluded.
Thus, a sensitive immunoblot assay was
developed for the detection of ER-α pro-
tein levels, which could be helpful for in-
vestigation of the ratio of ER isoform
expression and their role in tumor devel-
opment.
ER-α mRNA levels were found in
most of the meningiomas based on PCR-
southernblot analysis, indicating that ER
mRNA was present in meningioma cells.
Due to amplification by the PCR method,
the exact concentration of ER mRNA
could not be determined. Our novel hy-
pothesis was that low concentrations of
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ER mRNA are present in meningiomas
and that these transcripts are translated in
to minute ER protein levels. This is in con-
trast with our initial idea that
meningiomas contained appreciable
amounts of ER mRNA and that the ab-
sence of ER protein levels indicated a
post-translation inhibition of ER mRNA.
This study showed that, at least by
immunoblotting, ER-α was expressed in
meningiomas in low quantities. When
presence of a receptor and not its biologi-
cal activity is the criteria for ER positivity,
meningiomas should be considered to
have an ER positive and PR positive phe-
notype. The regulation of PR expression in
meningiomas is still not clarified by the
presence of the minute ER protein expres-
sion levels and remains unknown.
The biological function of these low
levels of ER expression in meningiomas is
not known. PR expression is considered a
marker of ER activity in other hormonally
regulated tissues. The correlation be-
tween ER and PR expression is tissue spe-
cific and in myometrium cytosol samples
we found a positive correlation of rs =
0.80 22. Most of the meningiomas in this
study expressed both ER and PR. How-
ever, ER expression was also found in
meningiomas with no or low PR expres-
sion. Expression of other ER regulated
proteins in meningiomas seems also to be
affected. Koehorst et al., have compared
expression of the estrogen–modulated
proteins Cathepsin-D and pS2 in breast
cancer to that of meningiomas 23,24. By con-
trast, however, pS2 was not expressed at
all in meningiomas and Cathepsin-D
protein was found at only half the concen-
tration seen in breast cancer 24. According
to international guidelines for cytosol
based assays, ER>10 fmol/mg cytosol pro-
tein usually indicates ER activity; ER>100
fmol/mg cytosol protein is considered
strongly positive. The expression levels
found in meningiomas were far below 10
fmol/mg cytosol protein. This indicates
that involvement of ER-related pathways
in gene expression in meningiomas is not
likely.
In contrast, as long as the agonist-oc-
cupied ER has the ability to bind an ERE
(or, alternatively, bind to AP-1 or Sp-1
transcription factors), there is no reason
why the target gene would not be up-regu-
lated, providing the appropriate
coactivators and RNA Polymerase II
transcriptional components are available
in the nucleus. Although meningiomas
should from now on be considered as ER
and PR positive tumors, the biological ac-
tivity of ER in these tumors remains un-
known.
In conclusion, a specific and sensitive
immunoblot assay was developed, which
revealed that, in contrast to the previously
existing thoughts, meningiomas are ER-α
positive. The minute ER expression levels,
however, could not clarify the expression
of PR, a marker for recurrence and sur-
vival of meningioma patients and a possi-
ble target for endocrine adjuvant therapy,
since ER-α expression was also found in
PR negative meningiomas.
111
ER protein expression in meningiomas
Reference List
1 Smith DA and Cahill DW. The biology of meningiomas. Neurosurg.clin.N.Am. 1994, 5:
201-215
2 McDermott MW. Current treatment of meningiomas. Curr.Opin.Neurol. 1996, 9: 409-413
3 Kepes JJ. Meningiomas; Biology, Pathology and differential diagnosis. Masson Publishing
U.S.A.New York. 1982, 17-19
4 Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary ma-
lignancies of other sites.The unique association between meningiomas and breast cancer.
Neurology. 1975, 25: 705-712
5 Jacobs DH, McFarlane MJ, Holmes FF. Female patients with meningioma of the sphenoid
ridge and additional primary neoplasms of the breast and genital tract. Cancer. 1987,
60: 3080-3082
6 Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in rela-
tion to pregnancy and menstruation. J.Neurol.Neurosurg.Psychat. 1958, 21: 89-91
7 Blankenstein MA, Verheijen FM, Jacobs HM and others. Occurrence, regulation, and sig-
nificance of progesterone receptors in human meningioma. Steroids. 2000, 65: 795-800
8 Jacobs HM, van Spriel AB, Koehorst SG and others. The truncated estrogen receptor alpha
variant lacking exon 5 is not involved in progesterone receptor expression in meningiomas.
J.Steroid Biochem.Mol Biol. 1999, 71: 167-172
9 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide
gels to nitrocellulose sheets:procedure and some applications. 1979. Biotechnology . 1992,
24: 145-149
10 Clarke CL, Zaino RJ, Feil PD and others. Monoclonal antibodies to human progesterone re-
ceptor:characterization by biochemical and immunohistochemical techniques. Endocrinol-
ogy. 1987, 121: 1123-1132
11 Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum.Reprod. 1994,
9 Suppl 1: 202-207
12 Brandis A, Mirzai S, Tatagiba M and others. Immunohistochemical detection of female sex
hormone receptors in meningiomas: correlation with clinical and histological features.
Neurosurg. 1993, 33: 212-217
13 Fewings PE, Battersby RD, Timperley WR. Long-term follow up of progesterone receptor
status in benign meningioma: a prognostic indicator of recurrence? J.Neurosurg. 2000,
92: 401-405
14 Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in
meningiomas: prognostic considerations. J.Neurosurg. 1997, 86: 113-120
15 Vegeto E, Cocciolo MG, Raspagliesi F and others. Regulation of progesterone receptor gene
expression. Cancer Research . 1990, 50: 5291-5295
16 Moresco RM, Scheithauer BW, Lucignani G and others. Oestrogen receptors in
meningiomas: a correlative PET and immunohistochemical study. Nucl.Med.Commun.
1997, 18: 606-615
17 Speirs V, Boyle-Walsh E, Fraser WD. Constitutive co-expression of estrogen and progester-
one receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cul-
tures to steroid hormones. Int J Cancer. 1997, 72: 714-719
112
Chapter 8
18 Kumar S, Mandal AK, Mandal A and others. Study of oestrogen and progesterone receptors
in meningiomas by a technique utilizing the binding hormones in a polymerized state. In-
dian J Pathol.Microbiol. 1995, 38: 189-192
19 Bozzetti C, Camisa R, Nizzoli R and others. Estrogen and progesterone receptors in human
meningiomas: biochemical and immunocytochemical evaluation. Surg.Neurol. 1995,
43: 230-233
20 Blankenstein MA, Van der Meulen-Dijk C, Thijssen JH. Assay of oestrogen and progestin
receptors in human meningioma cytosols using immunological methods. Clinica Chimica
Acta. 1987, 165: 189-195
21 Clarke CL, Roman SD, Graham J, Koga M, Sutherland RL. Progesterone receptor regula-
tion by retinoic acid in the human breast cancer cell line T-47D. The Journal of Biological
Chemistry. 1990, 265: 12694-12700
22 Ven vd J, Sprong M, Donker GH, Thijssen JHH, Mak-Kregar S, Blankenstein MA. Levels of
oestrogen and progesterone receptors in myometrium and leiomyoma tissue after suppres-
sion of oestrogens with GNRH analogues. Gynecol. Endocrinology. 2001 In press
23 Assimakopoulou M. Human meningiomas: immunohistochemical localization of progester-
one receptor and heat shock protein 27 and absence of estrogen receptor and PS2. Cancer
Detect Prev. 2000, 24: 163-168
24 Koehorst SG, Spapens ME, van der Kallen CJ and others. Progesterone receptor synthesis
in human meningiomas: relation to the estrogen-induced proteins pS2 and cathepsin-D and
influence of epidermal growth factor, Forskolin and phorbol ester in vitro. Int.J.Biol
Markers. 1998, 13: 16-23
113
ER protein expression in meningiomas
114
Introduction
Several decades of research
have demonstrated that there is an associ-
ation between the insulin growth factors
(IGFs) and tumor growth. IGFs and their
receptors are expressed in human tumors
of the central nervous system (CNS) such
as meningiomas. Meningiomas are benign
neoplasias derived from the meninges.
Treatment of these tumors consists out of
surgical resection, however, these tumors
have a high recurrence rate (20%) and are
sometimes unresectable, indicating that
there is a need for adjuvant therapies. As
meningiomas are relative insensitive to
chemotherapy adjuvant therapies have to
be searched in hormonal treatments.
Large clinical trials using progesterone re-
ceptor (PR) antagonist are underway to
address this anti-tumor endocrine ap-
proach. Quite recently, tumor growth re-
mission was reported by using a growth
hormone (GH) receptor antagonist, indi-
cating the possibilities of endocrine ther-
apy in the treatment of tumors. Not much
is known about the functional significance
of the GH-IGF axis in meningiomas, which
could be a target for endocrine therapy. In
this manuscript, we review the expression
of the GH-IGF axis in meningiomas and
the possibility to use the GH-IGF-axis in
endocrine therapy.
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The IGF axis in meningiomas
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The IGF-axis components
The IGFs, IGF-I and IGF-II, are po-
tent mitogenic and differentiation-pro-
moting growth factors. They can inhibit
apoptosis and also induce differentiation 1.
the IGFs are produced in multiple tissues
and can act both in an endocrine and
autocrine/paracrine fashion. They both
exert their intracellular effects predomi-
nantly via the type 1 IGF-R. The type 2
IGF-R is believed to be involved in clear-
ing of the IGFs from the circulation 2. In
the circulation, IGFs are bound to mem-
bers of high affinity IGF binding proteins
(IGFBPs). The six known IGFBPs modu-
late IGF activity by providing tissue and
cell-type specific localization of the IGFs
and by directly modulating the interaction
of the IGFs with their receptors. They
mainly act as autocrine / paracrine factors
at or close to their sites of synthesis and
may either inhibit or potentiate IGF activ-
ity. Furthermore, they differ in their
IGF-binding capacity 1.
IGF-I
IGF-I is mainly produced in the liver,
where its transcription in controlled by
GH. IGF-I mediates many of the growth
promoting effects of GH and has a long
term impact on cell cycle progression,
which is regulated by the type 1 IGF-R 1.
IGF-I stimulates the expression of cyclin
D1, which accelerates progression of the
cell from G1 to S phase 3,4, resulting in in-
creased DNA synthesis. A cellular action
of the IGF-I complementary to its stimula-
tion of cell proliferation is its capacity to
inhibit cell death in certain cell contexts 5.
IGF-I is able to stimulate the expression of
Bcl-2 proteins (anti-apoptotic) and to
suppress the expression of bax (pro-
apoptotic). This results in an increase in
the relative amount of bcl-2/bax hetero-
dimer, thereby blocking initiation of the
apoptotic pathway 5-7. IGF-I is thought to
be primarily involved in postnatal growth
and less inprenatal development. The ex-
pression of the igf-1 gene is developmen-
tally regulated, with levels of IGF-I mRNA
in most tissues increasing 10- to 100-fold
between birth and adulthood 8 and then
serum IGF-I gradually declines 9.
IGF-II
In contrast to IGF-I, IGF-II synthesis
appears to be relatively independent of
GH 10. IGF-II mRNA levels in all tissues
are high during late fetal and perinatal pe-
riods and decline thereafter 11. After birth,
human IGF-II levels remain constant
throughout adulthood. IGF-II is suggested
to play an essential role in embryonic
and fetal growth 12,13, whereas IGF-I is sug-
gested to be mainly involved in postnatal
growth. The igf-2 gene contains four sepa-
rate promoter sites 14 and differential pro-
moter usage regulates the tissue and
developmental stage expression of IGF-II
15. The use of specific promoters has been
reported to be upregulated in various
types of tumors 15-21. Besides regulation by
different promoters, the igf2 gene has also
parental allele specific expression. In nor-
mal cells, IGF-II is maternally imprinted
in that it is expressed only from the pater-
nal copy of the gene 22. Loss of imprinting
results in biallelic expression of IGF-II
leading to overexpression of this growth
factor. Loss of IGF-II imprinting has been
reported in a variety of tumors 23-26. The
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above described data indicate that dis-
turbed igf gene regulation may result in
tumor growth.
The IGF receptors
Type 1 IGF-R protein is a tetramer of
two identical α-subunits and two identical
β-subunits 27,28. The actions, mitogenic and
anti-apoptotic, of both IGF-I and IGF-II
are mediated through the type 1 IGF-R
27,29. However, IGF-I has a 2-15 fold higher
binding affinity than IGF-II 30,31. IGF-I
downregulates its own receptor resulting
in a negative feedback mechanism 28,32-34.
Highest levels of type 1 IGF-R mRNA oc-
cur during fetal development and in the
early postnatal period. Although type 1
IGF-R expression is significantly down-
regulated in the adult, it is present in most
types of tissue 10.
In contrast to type 1 IGF-R, type 2
IGF-R is a single peptide chain and has no
tyrosine kinase activity 35. The type 2
IGF-R is also known as the mannose-6-
phosphate receptor. The binding affinity
of IGF-II for the type 2 IGF-R is 500 fold
higher than that of IGF-I. Binding of
IGF-II to the type 2 IGF-R results in degra-
dation of IGF-II and thereby antagonizing
its biologic activity 2. Besides the scaven-
ger function, it is less clear whether any of
the biological actions of IGF-II are
mediated by this receptor. There is some
evidence that the type 2 IGF-R mediates
migration stimulation of cells 36. This ca-
pacity to induce motility response in cells
has important implications in the invasive
and metastatic potential in tumor cells.
IGFBPs
IGFBPs are able to inhibit or enhance
the action of IGFs, resulting in either sup-
pression or stimulation of cell prolifera-
tion 37,38. When binding to IGFs, IGFBPs
play three major roles: 1) transporting
IGFs; 2) protecting IGFs from degrada-
tion; and 3) regulating the interaction be-
tween IGFs and type 1 IGF-R. Normally,
IGFBPs have higher binding affinity for
the IGFs than does the type 1 IGF-R,
thereby blocking the interaction of the
IGFs with the type 1 IGF-R. However,
binding of the IGFs by the IGFBPs also
protects IGFs from proteolytic degrada-
tion, which enhance the action of IGFs by
increasing their bio-availability at the lo-
cal level. The actual impact of IGFBPs on
IGFs depends largely on posttranslational
modification of IGFBPs by phosphory-
lation and proteolysis 1,37,38. Besides IGF
dependent functions, IGFBPs also have
IGF independent effects. For example,
IGFBP-3 has inhibitory effects that are in-
dependent of IGF binding, which is proba-
bly mediated by cell surface receptors 1.
The IGF-axis in meningiomas
IGF-receptors
First evidence for the presence of IGF
binding sites in meningiomas came from
Glick et al. 39. They reported a high affinity
125I-IGF-I binding in all 5 meningiomas as
measured by competition binding assay.
Similar results were obtained by Kurihara
et al. 40, after Scatchard plot analysis these
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authors suggested the presence of a single
high class affinity binding site for IGF-I in
all eight examined meningiomas. IGF-I
binding sites were localized homoge-
neously in tissue sections derived from fi-
brous and meningothelial types of
meningiomas 40. Tsutsumi et al. 41 also lo-
calized 125I-IGF-I binding sites in tissue
sections of meningiomas. Binding sites
were localized in all eight (2
meningotheliomatous, 4 transitional, 1
angioblastic and 1 malignant) menin-
giomas. In situ hybridization of 3
meningiomas (2 transitional and 1
syncytial) showed strong type IGF-R ex-
pression in all 3 meningiomas 42. Lichtor et
al. explored the expression of type 1 IGF-R
in 12 meningotheliomatous meningiomas
by immunohistochemistry. Four of the 12
tumors showed type 1 IGF-R immuno-
reactivity. However, none of the type 1
IGF-R positive tumors showed IGF-I
immunoreactivity 43. The staining pattern
was very regional and only tumor cells
showed immunofluorescence. No im-
munoreactivity was found in tumor ves-
sels, fibrous components or tumor capsule
43. In angioblastic types of meningiomas,
relatively large numbers of IGF-I binding
sites were located in the intratumoral
vasculature and the number of binding
sites in the stromal component was lower
40. 125I-IGF-I binding was found in tissue
with cell rich components rather than in fi-
brous components. However, identifica-
tion of precise cell types expressing these
binding sites in meningioma tissue was
not feasible with the used quantitative
autoradiographic system, because of limi-
tations in resolution of the technique 41.
There are conflicting results whether
IGF-I binding sites are also present in
normal brain tissue. Three out of four
studies could not find expression of the
type 1 IGF-R in control tissue 40-43.
Much less is known about the expres-
sion of the type 2 IGF-R in meningiomas.
Strong type 2 IGF-R mRNA levels were
found in meningiomas using in situ hy-
bridisation (ISH) in one study and no sig-
nificant levels could be found in the
control pachymeninges 42.
In conclusion, it appears that
meningiomas express elevated levels of
the type 1 IGF-R predominantly located in
the tumor cells of various histological sub-
types. Whether there are protein levels of
type 2 IGF-R present in meningiomas is
not clear, however, mRNA levels of this re-
ceptor have been demonstrated. The high
expression of the type 1 IGF-R, mediating
mitogenic and apoptotic signals, might
have biological significance in the devel-
opment of meningiomas.
IGF-I
IGF-I was shown to stimulate DNA
synthesis in a dose-dependent manner of
cultured meningothelial cells, cultured
angioblastic meningioma 41, primary me-
ningioma subcultures, as shown by
3H-thymidine incorporation and cell
counting 40. It was shown that suramin, an-
tagonist of IGF action via type 1 IGF-R, in-
hibits 125I-IGF-I binding to meningiomas
in a dose dependent manner, indicating
that the mitogenic action of IGF-I was me-
diated via the type 1 IGF-R 41. Quantitative
receptor autoradiography showed that ad-
dition of suramin dissociated 125I-IGF-I
previously bound to meningioma tissue as
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a function of time. Suramin potently inhib-
ited or even blocked the IGF-I induced cell
proliferation Presence of IGF-I in
meningiomas was shown by immuno-
histochemistry. Only tumor cells were
fairly intense and uniform stained. No
staining was found in tumor vessels, fi-
brous components or tumor capsule. As
mentioned before, none of these IGF-I
positive tumors was type 1 IGF-R positive
43. There was no significant IGF-I staining
in control pachymeninges.
ISH studies showed the presence of
IGF-I mRNA in the tumor cells of
meningiomas, indicating local production
of IGF-I by meningiomas. IGF-I mRNA ex-
pression in non-malignant control pachy-
meninges was significant lower 42.
However, Detta et al. concluded that IGF-I
expression was lower as compared to
other proto-oncogene expression mea-
sured in the same study 44. In contrast,
Glick et al. failed to detect IGF-I tran-
scripts in 5 human meningiomas of the
same pathological grade using Northern
blot analysis 45. This difference might be
due to a difference in sensitivity of the
techniques used. Autocrine secretion of
IGF-I in situ, in tumor cyst fluid, was stud-
ied using a specific radioimmunoassay 46.
This assay could measure IGF-I and
IGF-II separately, after removal of
IGFBPs, measurable levels of IGF-I were
detected in the cyst of both meningiomas
tested 46. Autocrine secretion of IGFs by
meningiomas in vitro was also studied us-
ing medium of primary meningioma tu-
mor cultures 47.
In summary, IGF-I mRNA is demon-
strated in meningioma cells indicating
that these tumors are capable of express-
ing IGF-I. Furthermore, it appears that
IGF-I is secreted into the intratumoral
fluid and exerts an auto and/or paracrine
activity.
IGF-II
Expression of IGF-II meningioma
cells was also shown using ISH 42-44and
northern blot analysis 44,45. However, not
all analyzed meningiomas showed IGF-II
expression, and Detta et al. concluded that
IGF-II expression was lower than other
proto-oncogene levels measured in the
same study 45. Several studies have been
performed to study IGF-II protein levels
in human meningiomas. Immunohisto-
chemistry using immunofluorescence
showed IGF-II protein in 8 out of 12
meningiomas analyzed. Another study
showed strong staining of IGF-II protein
in 2 transitional and 1 syncytial
meningiomas 42.
IGF-II expression appeared elevated
in meningiomas since there was no signifi-
cant IGF-II mRNA expression in the con-
trol pachymeninges 42. In addition, no
immunoreactive staining was found in
normal brain tissue 42,43. IGF-II expression
appeared to be restricted to solely tumor
cells. No immunoreactivity was found in
tumor vessels, fibrous components or tu-
mor capsules, and endothelial cells lining
the blood vessels in the meningioma also
were negative for IGF-II.
Glick et al. investigated the capability
of meningiomas to produce and excrete
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IGF-II in vitro. All studies were performed
either with cells in primary culture or after
a single passage, IGF-II was excreted by 6
of 11 meningiomas 47.
In conclusion, meningiomas
express elevated levels of IGF-II mRNA
and IGF-II protein solely in tumor cells.
Since secretion of IGF-II by meningioma
cells has been demonstrated in vitro,
IGF-II might exert an autocrine or
paracrine function in the development of
meningiomas.
IGFBPs
Although IGFBPs have been reported
to play a role in oncogenesis, not much re-
search has been performed on IGFBP ex-
pression in meningiomas. Unterman et al.
48 demonstrated and characterized
IGFBPs in meningioma tissue, primary
cultures or after a single passage. Binding
activity of IGF-I was detected in condi-
tioned medium from 6 out of 7
meningiomas, even very high levels of
binding activity was present in condi-
tioned medium of four meningiomas. The
IGFBPs from the media from these
meningiomas were further characterized
by different techniques. Western ligand
blotting using 25I-labled IGF probes re-
vealed the presence of different IGFBPs.
Immunoblotting and immunoprecipitatio
n revealed the presence of IGFBP-1, 3 and
most likely -4. In addition, immuno-
histochemical studies were performed
with several specific mouse monoclonal
antibodies against IGFBP-1. Of seven
meningiomas that were examined, three
stained intensely with each of the
monoclonal antibodies against IGFBP-1
tested, while three were weakly positive.
Positive staining was primarily present
within cells and in the extracellular ma-
trix, although little immunoreactivity was
detected in fibrous stroma present in some
of the meningiomas 48.
Nordqvist et al. 49 studied the relation
between IGFBP-2 and IGF-II. In 68
meningiomas IGF-II and IGFBP-2 expres-
sion was determined by northern analysis.
Variable levels of expression of both
IGF-II and IGFBP-2 mRNA levels were
observed. In many tumors an inverse cor-
relation between the levels of IGF-II and
IGFBP-2 mRNA existed so that high levels
IGF-II mRNA were accompanied by very
low levels of IGFBP-2 mRNA or vice versa.
Screening for a high ratio IGF-II to
IGFBP-2 could identify all (8 out of 68)
anaplasia and/or atypical meningiomas.
The remaining cases were meningiomas
with a lower malignancy grade. Fourteen
of these tumors showed high IGF-II and
high IGFBP-2 mRNA levels without any
sign of anaplasia. The 8 meningiomas
showing high IGF-II/IGFBP-2 mRNA ra-
tios and 8 with low IGF-II-IGFBP-2 mRNA
ratios were subjected to ISH. In particu-
larly, the IGF-II mRNA distribution varied
considerably from sample to sample.
Some tumors showed quite uniform label-
ing all through the tissue, whereas others
had distinct foci with strong labeling sur-
rounded by areas with no or very low
levels of expression. In contrast the pat-
tern of IGFBP-2 expression was more uni-
form. In tumors with regions that labeled
intensely with the IGF-II probe, IGFBP-2
labeling was non-overlapping, with most
abundant labeling surrounding the IGF-II
foci 49.
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Growth hormone receptors (GH-Rs)
Little is known about GH-R
and GH in meningiomas. The presence of
GH-R mRNA was shown in 14
meningiomas investigated. Blockade of
the GH-R with a GH-R antagonist (B2036)
reduced serum-induced DNA synthesis in
20% of the meningioma cultures. In addi-
tion, increased thymidine incorporation
was found in a dose dependent manner af-
ter IGF-I stimulation 50.
In follow up experiments, 15
meningioma cultures were xenografted
into athymic mice to further explore the
modulation of the GH/IGF-I axis. Again
they observed significant growth retarda-
tion of the tumor in mice treated with a
GH-antagonist. Since intratumoral IGF
levels were not altered, the authors sug-
gest a direct blockade of the GH-R in the
tumors or decreased IGF levels in the cir-
culation causing the tumor size reduc-
tion 51. Since the characteristics of mening
iomas grown in culture very rapidly alter,
we still have our reservation about these
findings.
Apoptosis and the IGF axis
Meningiomas show a relative low
apoptotic index in combination with a low
proliferation rate, resulting in a low
growth rate of these tumors. Meningiomas
express relative high levels of the
pro-apoptotic proteins bax and bak com-
pared to breast cancer. The anti-apoptotic
proteins from the same Bcl-2 proto-onco-
gene family, bcl-2 and bcl-xl, are variably
expressed in meningiomas. A relation be-
tween members of the Bcl-2 family and the
type 1 IGF-R has been described for
several cell types. IGF-I appeared to be a
strong inhibitor of apoptosis induction.
The fact that meningiomas express ele-
vated levels of the type 1 IGF-R and show
low levels of apoptosis have led to the hy-
pothesis that the type 1 IGF-R might be in-
volved in the regulation of apoptosis in
meningiomas.
Singleton et al. described a relation
between activation of the type 1 IGF-R and
apoptotic proteins in neurons. Short-term
activation of the type 1 IGF-R by both
IGF-I and IGF-II blocked hyperosmotic-
coupled apoptosis and inhibited apop-
tosis-associated changes in bcl-2 cellular
concentration 52. Later these findings were
confirmed by several others. Wang et al .
defined the effect of IGF-I on bcl-2, bax,
caspase 3 expression in H9C2 cells. IGF-I
partially inhibited bax induction, caspase
3 activation and DNA fragmentation and
enhanced cell survival. IGF-I stimulation
also resulted in decreased induction of
bcl-2 53. Baker et al. performed studies
done with two transgenic mice models
overexpressing either bcl-2 or IGF-I pro-
teins in olfactory bulb or cerebellar neu-
rons, respectively. These studies indicated
that in the developing brain, IGF-I modu-
lates expression of IGFBP-2 as well as the
bcl-2 protein 54. Leri et al. reported a mark-
edly down regulation of bax by IGF-I via
the induction of mdm2 and the formation
of mdm2/p53 complexes in isolated rat
myocytes. The complex formation re-
sulted in a downregulation of p53 function
55. Not only bcl-2 and bax appeared to be
affected by the type 1 IGF-R but also other
members of the Bcl-2 protein family, like
bcl-xl and bad. Parrizas et al .
reported a relation between IGF-I and
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bcl-xl in differentiated PC12 cells. Incuba-
tion with IGF-I resulted in a significant in-
crease of bcl-x mRNA after 3-6 h
incubation and a doubling of bcl-xl protein
levels by 24h incubation 56.
The main signalling pathway for
type 1 IGF-R mediated protection against
apoptosis has been recently ellucidated.
First, IGF-I induces “a cAMP-response el-
ement (CRE) site containing” bcl-2
promoter through a phosphatidylinositol-
3-kinase pathway (PI-3) 57. The type 1
IGF-R mediated rescue from apoptosis is
blocked by PI-3 kinase inhibitors 58. Sec-
ond, the serine threonine kinase AKT/pro-
tein kinase B is a target of IGF-I
signalling and has been shown to activate
CRE-binding protein (CREB). Enhanced
CREB activity by AKT signalling leads to
increased bcl-2 promoter activity in a rat
PC12 cell line 59. Third, IGF-I prevents po-
tassium deprivation induced bad dephos-
phorylation in a wortmannin sensitive
manner of cerebellar granule neurons 60.
In addition, Type 1 IGF-R activates alter-
native pathways for protecting against
apoptosis induced by withdrawal of
interleukin 3 in a murine hemopoeitic cell
line devoid of insulin receptor substrate 1.
All these pathways, however, appeared to
result in bad phosphorylation 61.
The direct involvement of the IGF
system in the regulation of expression of
bcl-2 protein members and hence sensitiv-
ity for apoptosis justifies investigation of
anti-tumor endocrine therapeutic ap-
proaches interfering with the IGF-axis
components. Both IGFs, IGF receptors
and bcl-2 protein families are expressed in
meningiomas, however, of the relation
between the IGF system and bcl-2 familie
members nothing is known thus far.
Knowledge of this interaction will be of
major clinical and biological importance.
Therapeutic approaches using the IGF
system
The IGF-system has an important
mitogenic and anti-apoptotic function in
cell growth and development. For that rea-
son the IGF system could be used as a po-
tential therapeutic target to suppress
cellular proliferation. Different ap-
proaches are employed to target this sys-
tem, including antisense strategies,
monoclonal antibody technology, peptide
analogs, chimeric toxic proteins, domi-
nant negative mutants and suramin.
Antisense strategies for tumor growth
remission involve the inhibition of growth
factor or growth factor receptor gene ex-
pression by introducing a source of nucle-
otide sequences complementary to a given
endogenous mRNA species resulting in
translational shutdown of protein synthe-
sis. Insertion of an antisense IGF-I into
IGF-I producing glial tumor cells substan-
tially inhibits IGF-I production. The injec-
tion of these genetically altered cells into
animals results in regression of both al-
tered and wild type tumor cells. Although
the mechanism of the regression is un-
clear, antisense blocking of IGF-I expres-
sion may reverse a phenotype that allows
the glial tumor cells to evade the immune
system 61,62. The type 1 IGF-R has also been
target of antisense gene technology in
brain tumors. Antisense type 1 IGF-R
RNA inhibited IGF-I mediated growth in
monolayers and clonogenicity in soft agar.
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When wild type cells were injected in ani-
mals, tumors developed, whereas type 1
IGF-R antisense RNA transfected cells
were non-tumorigenic. Moreover, trans-
fected cells prevented wild type glial tu-
mor cells completely from tumor
formation. Furthermore the transfected
cells caused complete regression of estab-
lished glial tumors 63. One of the mecha-
nisms by which type 1 IGF-R antisense
strategies has been postulated to cause its
anti-tumor effects is via the induction of
apoptosis. A decrease in the level of type 1
IGF-R may cause massive apoptosis in tu-
mor cells. On normal cells, this decrease
has much less effect, while they can take
refuge in the Go (resting) state of the cell
cycle 64. A second mechanism of antisense
strategy might be an immune response,
since at the place of tumor regression a
lymphocytic infiltration occured. The
antisense therapy for IGF-II has not yet
been tested on brain tumor tissue yet.
However, on other cultured tumor cells
(pancreatic cancer TC3 and ovarian can-
cer AO cells) IGF-II antisense strategies
inhibited cell proliferation and induced
apoptosis 65,66.
The development of monoclonal anti-
body technology has led to a number of ap-
plications for targeted therapy. The use of
specific antibodies to inhibit cellular pro-
liferation by blocking the type 1 IGF-R, us-
ing αIR3, has been described in a number
of malignancies, both in vivo and in vi-
tro 67. This antibody binds to the ligand
binding domain of the IGF-I receptor and
inhibits IGF-I mediated effects 10. How-
ever, the use of this antibody technology in
humans will be limited because of
anti-idiotype antibodies being rapidly pro-
duced. IGF-I peptide analogs that inhibit
type 1 IGF-R receptor autophos-
phorylation have been developed 68. The
growth of three tumor cell lines was inhib-
ited by these peptide analogs of IGF-I 69.
A new class of selective cytotoxic
agents has been constructed using
gene-splicing techniques in which growth
factors, functioning as target agent, are
fused to a toxic protein toxin. These IGF-I
recombinant constructs 70 were shown to
be effective in the specific killing of human
glioblastoma cell lines by binding to the
type 1 IGF-R and subsequently delivering
of the toxin to tumor cells 71. Although chi-
meric toxins composed of IGF-I and have
extraordinary cell-killing activity, their
use in vivo may be limited since the type 1
IGF-R is expressed in many major tissues.
Systemic administration of IGF-I-toxin fu-
sion proteins may therefore lead to organ
toxicity before any therapeutic effect can
be achieved. Direct infusion of these tox-
ins in the tumor could be an alternative ap-
proach.
Several dominant negative mutant
type 1 IGF-R derived from human type 1
IGF-R cDNA have been developed 72.
These dominant negative receptors were
transfected into rat glioblastoma cells and
they all reduced cell growth, although the
levels of inhibition varied. They competed
for the ligand with the endogenous recep-
tor, resulting in decreased cell growth 73.
One dominant negative receptor,
truncated at residue 952, forms chimerae
with wild type endogenous receptors.
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Tumor cells expressing this receptor
do not form tumors in nude mice,
the dominant negative receptor interferes
with the endogenous receptor inducing
apoptosis 74.
Suramin inhibits the binding of IGFs
to the type 1 IGF-R and thereby inhibiting
mitogenic signaling of the IGFs via the
type 1 IGF-R, resulting in a decrease of
growth rate 41,75. The drug does not affect
the receptor itself, but binds directly to the
peptide. No in vivo studies using suramin
on meningiomas have been performed,
however the effect of suramin on a human
glioma xenografted in a nude mouse con-
siderably reduced tumor growth 76.
In conclusion, targeting the IGF sys-
tem by a variety of strategies has been
shown effective in in vitro systems. Before
these kind of therapies will be clinical use-
ful multiple difficulties have to be sorted
out, like delivery, immune response and
specificity.
Conclusion
As a group of essential growth modu-
lators, IGFs play a critical role in regulat-
ing cell growth and apoptosis. This
important function has led to the specula-
tion concerning their possible role in
meningioma development and growth.
Several experiments demonstrated bio-
logical mitogenic effects of IGF-I via the
type 1 IGF-R in meningiomas. IGF-I and
IGF-II, type 1 IGF-R and type 2 IGF-R, and
several IGFBPs are present in at least a
subset of human meningiomas. The IGF
components were present in various
histological subtypes of meningiomas and
mainly localized in the tumor cells. Espe-
cially the elevated levels of the type 1
IGF-R compared to normal meninges have
attracted our attention since this receptor
is directly involved in the regulation of ex-
pression of Bcl-2 protein family members.
Meningiomas show a high recurrence rate
and at the moment no adjuvant therapy is
available since these tumors are relatively
insensitive to chemotherapeutic agents.
We hypothesize that the type 1 IGF-R by
regulating bcl-2 and bcl-xl protein levels
might be involved in this
chemotherapeutic resistance. The great-
est benefit of tumor growth intervention of
meningiomas might be expected from
upregulation of apoptosis since these tu-
mors have a low proliferation and low
apoptotic index. The suspected involve-
ment of IGF components in meningiomas
justify investigation of the expression of
these components (especially IGFBPs)
and the relation between IGFs, IGFBPs,
IGF-Rs and members of the bcl-2
proto-oncogene family. The expression of
all these proteins has already been de-
scribed for meningiomas, however, noth-
ing is known about the interaction
between these proteins and the possibility
to aim at these proteins for adjuvant
therapy.
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The present thesis was initiated to im-
prove our understanding of the high con-
centration of PR in human meningiomas,
with a special emphasis on the relation of
the PR with proteins involved in
apoptosis. This chapter will discuss the
outcome of several studies presented in
this thesis in conjunction with additional
preliminary data.
First, because no cell culture model of
meningiomas that actively expresses PR is
available or could be developed (chapter
2), our research has mainly been restricted
to inventory studies. This general discus-
sion starts with a paragraph about the dif-
ficulty of PR investigation in menin-
giomas. Furthermore, the differential ex-
pression of PR isoforms is discussed with
special emphasis on the newly discovered
PR-78 variant. This is followed by a short
discussion on the role for ER in PR synthe-
sis in meningiomas. This paragraph will
end with a summary about the use of
progestins and antiprogestins in clinical
practice.
Second, the present thesis reports
about a relation between PR and proteins
involved in apoptosis, like bcl-2. To inves-
tigate direct effects of progesterone on
bcl-2 expression, stimulation experiments
were performed usingex vivo meningioma
tissue fragments. The outcome of these
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General discussion
experiments will be discussed. Further-
more, to demonstrate a direct relation be-
tween PR or proteins of the Bcl-2 family
with apoptosis in meningiomas, knowl-
edge of actual levels of apoptosis in these
tumors is required. Preliminary data from
experiments assessing apoptosis by the
TUNEL-assay will be presented and dis-
cussed.
Third, as shown in chapter 9, knowl-
edge of the GH-IGF axis in meningiomas
could be a source for development of novel
therapeutic strategies. Our laboratory has
started inventory studies to some of these
GH-IGF components and preliminary data
are shown in this section.
This general discussion will end with
our general thoughts and remarks about
the significance of PR in meningiomas.
PR expression in cultured
meningiomas
The present thesis has focused on the
biological role of PR in meningiomas.
Studies directly investigating this subject
are severely complicated by two compo-
nents:
First, the PR is very rapidly degraded
when meningiomas are cultured, inde-
pendently of serum, growth factors, hor-
mones or different kinds of culture
conditions (chapter 2). Therefore, investi-
gations on the biological role of PR in
meningiomas is restricted, unfortunately,
to inventory studies. In addition, interpre-
tation of studies in which meningioma
cells have been stimulated with progestins
or antiprogestins is very difficult.
Surprisingly, most studies described in lit-
erature ignored this PR degradation in
their meningioma cell culture studies,
since presence of PR protein levels after
stimulation has very rarely been mea-
sured. The results obtained from our stud-
ies, at least partially, clarify the
discrepancy found in literature concern-
ing the response of meningiomas to
progestins.
Second, the total PR receptor status
of meningiomas, as seen in studies done
thus far, over-simplifies the complex
mechanism of regulation of PR target
genes because of the different PR isoforms
with their distinct biological functions.
The results described in chapter 3 show
that meningiomas express multiple PR
isoforms that might have biologically dif-
ferent functions. This indicates that over-
all, progesterone response of menin-
giomas to progesterone might be depend-
ent on the differential expression of the PR
isoforms.
Progesterone receptor
It is generally accepted that relatively
high concentrations of PRs prevail in hu-
man meningiomas (chapter 1). The PR ex-
ists as multiple isoforms with distinct
biological functions, dependent on the cell
and promoter context 1. PR expression in
meningiomas has been reported to be as-
sociated with clinical parameters as recur-
rence, histological type and survival
rate 2-4. The exact regulation of transcrip-
tion of the PR gene in meningiomas is still
not known. Normal meningothelial tissue
also expresses PRs, although, in low
amounts 5. Thus, PR levels appear to be
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increased in meningiomas compared to
the meninges, however, a role for PR in
the etiology of meningiomas remains to be
elucidated.
The proliferation rate of
meningiomas is low, but tumor size in-
creases during periods of high levels of
progesterone in the circulation (chap-
ter 1). In the present thesis, we have shown
that both PR-A and PR-B were variably
expressed in meningiomas (chapter 3),
and that the ratio PR-A to PR-B might
have biological significance. Meningiomas
that expressed high total PR levels all ex-
pressed more PR-A than PR-B. When it is
assumed that PR-A is capable of repress-
ing progesterone action via PR-B, as was
shown in several in vitro experiments in
literature (chapter 3), the ratio PR-A to
PR-B might determine the response to
progestins or antiprogestins.
Meningioma growth is increased dur-
ing periods with high levels of progester-
one in the circulation. To simplify the
complex mechanism of PR action a work-
ing model was made as is shown in Figure
10-1. Since the transcription activation ca-
pacities of PR isoforms is target gene pro-
moter and cell type dependent, several
options for PR signaling are shown in Ta-
ble 10-1. The major PR isoforms are capa-
ble of transcription activation, although
PR-B is the most potent activator. PR-A,
and other PR forms, are capable of repres-
sion of the transcriptional activity of PR-B
and other steroid hormone receptors
(SHR), most likely at the protein level 6.
We hypothesize that the growth
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1) PR-A activated 1.1) Growth promoting PR-target genes are upregulated
1.2) PR-B and other SH-R are suppressed and thereby growth inhibiting
PR-target genes are downregulated
1.3) PR-A is not suppressing PR-B and PR-B upregulates growth
promoting target genes
2) PR-B is activated 2.1) Growth inhibiting PR target genes are upregulated
2.2) see 1.3
Antiprogestins
3) PR-A is blocked 3.1) Transactivation of PR target genes is blocked
3.2) Transactivation function of PR-B and other SH-R is no longer
repressed
4) PR-B is:
4.1) Blocked 4.1.1) Growth stimulating target genes are blocked
4.1.2) Growth inhibiting PR target genes are no longer suppressed by PR-A
4.2) Activated 4.2.1) Growth inhibiting PR target genes are upregulated
Table 10-1. Working model of the activation mechansim of PR isoforms in human meningiomas.
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PR-A
PR-B
SHR
PR-A
target-genes
Other PR forms
like PR-78 and PR-C
PR-B
target-genes
SHR
target-genes
overall
response
to progesterone
tumor growth
Progesterone
PR-A
PR-B
SHR
PR-A
target-genes
PR-B
target-genes
SHR
target-genes
overall
response
to progesterone
tumor size
Progesterone
antagonist
?
PR-A
PR-B
SHR
PR-A
target-genes
PR-B
target-genes
SHR
target-genes
overall
response
to progesterone
tumor growth
not affected
Progesterone
antagonist
?
A
B
C
Figure 10-1. a) A schematic hypothetical illustration of the working mechanism of PR action in human
meningiomas. Progesterone binds to PR-A, PR-B and other PR forms. The overall progesterone action
will be determined by the differential expression of the PR forms in the cells. PR-A is described as a
suppressor of PR-B and other steroid receptor action. Progesterone antagonists will block the
repression of PR-A and this might result in the (up)regulation of other PR target genes. The overall
response will be dependent on the ratio of different PR isoforms (1b, 1c). Meningiomas that express
more PR-A than PR-B might already show a repression of progesterone action and these tumors are not
likely to benefit from progesterone antagonist treatment (1c).
stimulation by progesteron of meningio-
mas is caused by the transrepression of
growth inhibiting target genes of PR-B or
SHR. Antiprogestin treatment will release
the repression by antagonist bound PR-A
and thereby at least the SHR target genes
will be upregulated. The transcriptional
activity of PR-B upon antagonist binding
is cell type specific and might either be re-
pressed or PR-B target genes might be
stimulated, upregulating growth inhibit-
ing genes. We hypothesize that, assuming
PR-A is the potent trans-repressor of most
PR-target genes, progesterone action in
most of the meningiomas is mediated via
trans-inhibition of target genes.
A novel PR isoform (PR-78)
Besides the two best known PR
isoforms, PR-A and PR-B, other PR like
proteins have been described. For in-
stance, Wei et al. described an N-termi-
nally truncated PR form referred to as
PR-C 7,8. PR-C is most likely capable of
trans-inhibition of the other PR isoforms
by competition for co-factors. Graham et
al. described the existence of a fourth
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PR-B
PR-78
PR-A
42kDa
hPR4ahPR6a
Figure 10-2. Immunoblot example of
PR-isoform expression in human meningioma
cytosol samples. Two different PR specific
antibodies were used to demonstrate a 42 kDa
protein that could be arise from the degradation
of PR-B in PR-78 and 42kDa residual product. A
PR antibody with an N terminal located epitope
demonstrates a 42kDa protein band. Because a
42kDa degradation product only contain B
unique sequence it should not be recognized by
an antibody directed against a c-terminal
epitope (hPR4a).
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Figure 10-3. Bcl-2 protein levels in tissue
fragments of 3 meningioma patients. All three
tumors specimens showed different PR isoform
expression. Tissue fragments of these tumors
were treated with Org 2058, progesterone
agonist, for 24h. After stimulation the PR
expression was decreased but still present. No
differences in bcl-2 expression could be found
in treated or not treated tissue fragment.
Further experiments are needed to further
explore a direct effect of progesterone on the
expression of bcl-2.
PR-form capable of ligand binding in
breast cancer further referred to as PR-78
9,10. We could confirm the presence of such
an isoform in meningiomas. The origin of
this PR-78, however, is still not known.
Our data indicate that PR-78 might be a
degradation product of PR-B since there
was a negative association found between
these two proteins (chapter 3). When it is
assumed that PR-B gives rise to two prod-
ucts, PR-78 and a smaller product of 42
kDa, the latter should also be detectable
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Figure 10-4. A, B, C. In situ hybridization (anti-sense probe in A, B; sense probe in C) analysis clearly
demonstrate IGF-II mRNA in nucleus and cytoplasm (to a lesser extend) of most of the meningiomas
(19/24). Vascular endothelial cells did not show IGF-II mRNA pointing out that IGF-II transcription is
restricted to tumor cells (B). D, E, F. Immunohistochemistry study using a specific antibody directed
against human IGF-II. Pro-IGF-II protein was found in 12/22 meningiomas. G, H, I. TUNEL assay
analysis demonstrating apoptotic cells in meningioma tissue samples. Apoptotic cells were found in 9/18
meningiomas. The example shown was a meningioma with a high number of apoptotic cells. A color
version of this figure is depicted on the cover. FOR IGF-II IN SITU HYBRIDISATION AND TUNEL ASSAY, E.
VAN DEN BORN IS GRATEFULLY ACKNOWLEDGED; FOR IGF-II IHC, N. ROFFERS IS GRATEFULLY
ACKNOWLEDGED.
by specific antibodies directed against the
N-terminus of PR-B. Therefore, immuno-
blots were performed to detect a possible
residual N-terminal product. Indeed
Figure 10-2 shows that cytosols of
meningiomas contained a specific band of
the expected 42kDa. In addition, a PR anti-
body directed against the C-terminal part
of PR failed to detect this protein. Correla-
tion analysis, however, did not reveal that
PR-B and PR-42 are negatively associated.
Therefore the hypothesis that PR-B give
rise to PR-78 could not be confirmed in
this way, and other regulatory pathways
behind the origin of PR-78 may not be
ruled out at the present.
Since both PR-78 and PR-C are capa-
ble of binding progesterone it is obvious
that these PR isoforms will be important
for understanding the response of
meningioma cells to progesterone and
antiprogestin stimulation. Because of the
existence of several PR-forms, with most
likely distinct biological functions and all
capable of ligand binding, the use of a LBA
in clinical studies should be reconsidered.
Estrogen receptor (ER)
In other hormonally responsive tis-
sues, like breast cancer, PR is under estro-
gen control. For myometrium cytosol
samples a spearman rank correlation be-
tween ER and PR of r s=0.90 was found
(unpublished data). Meningiomas contain
wild type and splice variants mRNA levels
of both ER forms as was demonstrated by
rt-PCR and southernblot analysis (chap-
ter 7). The ER splicevariants are not likely
to have a regulating role in growth of
meningiomas. First, it is most doubtful
whether the mRNA of ER splicevariants
will be translated into protein in
meningiomas. Second, PR is a marker for
ER activity in other tissues, however, no
relation between ER splice variants
mRNA and PR expression could be estab-
lished in meningiomas (chapter 7).
In literature, by the use of other tech-
niques like immunohistochemistry, ER ex-
pression has been reported. The receptor
phenotype of meningiomas was consid-
ered to be ER negative and PR positive
based on ligand binding data (chapter 1).
Based on the controversy of apparent ab-
sent ER binding activity and high amounts
of ER mRNA found in meningiomas, sensi-
tive immunoblot assays have been per-
formed. These experiments revealed that
although no ligand binding to ER could be
found, these meningiomas expressed min-
ute quantities of ER-α (chapter 8). With
this technique ER-α expression was de-
tected in concentrated meningioma
cytosol samples that were lower than the
cut-off value of the LBA (10 fmol/mg pro-
tein) (chapter 8). Immunoblot studies to
detect ER-β protein levels are currently
underway.
In retrospect, the presence of ER was
observed already by Koehorst et al. at our
laboratory in 1994 11. They showed that in
bandshift analysis with a synthetic estro-
gen binding element (ERE) a shift was
seen, indicating a protein capable of bind-
ing ERE. Further analysis with ER specific
antibodies revealed indeed that this pro-
tein could be one of the ER forms. Since
meningiomas, at that time, were consid-
ered ER negative, this ERE binding pro-
tein was referred to as ER-like protein.
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We conclude that the receptor pheno-
type of meningiomas is ER and PR posi-
tive. Whether these minute ER protein
levels found in meningiomas are biologi-
cally important remains to be seen. In both
PR positive and PR negative menin-
giomas, ER- protein was found, this indi-
cates that ER is not likely to play a role in
the synthesis of PR in meningiomas.
Progestins and antiprogestins
Progestins have been used for many
years as one of the elements in the endo-
crine therapy of breast cancer. The two
main progestins used in clinical practice
are medroxy progesterone acetate (MPA)
and megestrol acetate (MA). Progestins
may decrease the amount of estrogens
available to tumor cells, during progestin
treatment estradiol (E2), estrone and an-
drogen levels are decreased. Progestins
also have the ability to decrease the
amount of estrone sulfate (E1S) in breast
tissue 12. In addition, progestins can block
the conversion of E1S to E2 in hormone-de-
pendent breast cells and decrease ER ex-
pression levels. In conclusion, the
anti-estrogenic action of progestins is im-
portant in anti-tumor endocrine therapeu-
tic approaches.
Estrogenic or antiestrogenic actions
do not appear to be involved in the devel-
opment of meningiomas, based on stimu-
lation experiments and the low ER
expression levels of far less than 10
fmol/mg protein (see chapter 1 and 8). In
other hormonally regulated tissues, like
myometrium and breast cancer, ER target
genes, i.e. PR, CatD, pS2, c-myc, are
upregulated after activation of the ER by
estrogens. In meningiomas some, but not
all, of these ER target genes are repressed
13,14. Studies using an estrogen hyper-sen-
sitive cell line have shown that the number
of occupied ERs necessary for transcrip-
tion activation was cell and promoter de-
pendent 15,16. This may be caused by the
number of ERE and AP-1 binding sites on
the promoter regions of these target
genes. In the case of PR, however, no com-
plete estrogen responsive elements (ERE)
in the promoter region of both PR-A and
PR-B could be found 17. When assuming
that intra-tumor estrogen levels and ER
levels of meningiomas are too low for acti-
vating most of the ER-target genes, like
PR, the anti-estrogenic effects of
progestins, as seen in other types of can-
cer, will not take place in meningiomas.
That means that progestins might only ex-
ert their proliferative actions via the rela-
tively high expression of PR. Therefore,
several studies have been done to investi-
gate the therapeutic possibilities of
anti-progestins. These anti-progestins
have been shown to inhibit growth of
meningioma cells in culture 18,19 and re-
duce the size of meningiomas implanted
into nude mice 20,21. In addition, clinical tri-
als in which meningioma patients were
treated with anti-progestins found objec-
tive responses as shown by reduced tumor
size 18. Overall results, however, are still
controversial and non-conclusive and,
therefore, the result of large clinical trials
is awaited. To further explore and under-
stand the response of meningiomas to
progestins and anti-progestins further
knowledge of the function and regulation
of PR in meningiomas is required.
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PR and apoptotic proteins
This present thesis was also focused
on the role of PR in the regulation of pro-
teins involved in apoptosis, since mem-
bers of the Bcl-2 family have been
described as being hormonally regulated
in breast cancer (chapter 4 and 5). In
meningiomas, PR was negatively associ-
ated with bcl-2 and positively with bcl-xl
and bak. To find out whether there is a di-
rect effect of progesterone on the regula-
tion of apoptotic proteins stimulation
experiments were carefully performed, of
course taking notice of the previously de-
scribed limitations. Meningioma tissue
fragments (see ex vivo culture in chap-
ter 2) were cultured for 24 hours and stim-
ulated with the progesterone agonist Org
2058 (10E-07 M). The PR isoform expres-
sion was determined by immunoblotting
at the beginning and at the end of the ex-
periments. Figure 10-3 shows the prelimi-
nary results, indicating no difference in
bcl-2 levels although no definite conclu-
sion could be drawn of these preliminary
data.
It is clear that the differential expres-
sion of the PR isoforms will determine the
final response of Org-2058 on bcl-2 expres-
sion levels, assuming that bcl-2 is under
progesterone control in meningiomas. To
clarify the association that was found be-
tween apoptotic proteins and PR (chapter
4 and 5), the working model (Figure 10-1)
might also be helpful. Bcl-2 is negatively
associated with total PR. The fact that
meningiomas that express high total PR
express relatively more PR-A than PR-B
this indicates that the transcription of
bcl-2 might be repressed by PR-A (Table 1,
option 1.2). A second observation was that
bcl-xl was associated with PR-B but not
with total PR or PR-A. This indicated that
PR-A only interferes in the comparison
study with total PR, however, PR-A is not
involved in the regulation of bcl-xl. In the
working model this option is represented
by option 1.3.
It is concluded that, PR forms are as-
sociated with proteins from the Bcl-2
family. The role of the different isoforms in
the regulation mechanism, however, is
complex and protein dependent. The pos-
sible regulation of apoptotic proteins by
progesterone needs further elucidation
and is clinically important.
Apoptosis in meningioma
Because PR expression levels might
be involved in the regulation of apoptotic
proteins it might also influence the sensi-
tivity of cells for going into apoptosis. To
investigate this, comparative studies were
performed in which actual levels of
apoptosis in meningiomas were deter-
mined by a TUNEL assay and members of
the Bcl-2 family by immunoblotting. Of
data obtained thus far, correlation analy-
sis were performed to reveal any relation
of PR, members of the Bcl-2 family and the
presence of apoptotic cells. Figure 10-4G-I
shows a representative picture of a
meningioma containing apoptotic cells.
Thus far, no direct association between
PR and apoptosis could be revealed. Inter-
esting was that only a low number of
meningiomas were found positive for
apoptosis. Apparently, the proteins in-
volved in apoptosis are regulated in such a
way that the tumors have a low level of
apoptosis. Whether PR isoforms play a
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significant role in keeping this balance
might be clinically significant and needs to
be investigated.
Other endocrine therapeutic
approach; the IGF system in
meningiomas
The use of anti-progestins as a novel
adjuvant therapeutic agent to slow down
meningioma growth is not as easily
achieved as initially was thought. It is
therefore wise to consider other endocrine
therapeutic approaches. Two recent pub-
lications have reported that the GH-IGF
axis is involved in the regulation of prolif-
eration of meningiomas 22,23. In addition,
these authors showed the use of GH-R an-
tagonists could inhibit meningioma cell
proliferation. Both IGF-I and II have been
reported to have anti-apoptotic functions
in tumors. As a basis for further studies
chapter nine of this thesis contains a re-
view of IGF components in meningiomas.
Meningiomas express relative high levels
of type 1 IGF receptors compared to nor-
mal meninges. Expression of both IGFs is
also demonstrated in meningiomas.
Type 1 IGF receptors might be involved in
proliverative and apoptotic processes in
meningiomas. About the expression of
pro-IGF levels in these tumors, described
to be involved in some neoplasms, nothing
is known up to now. Therefore, our labora-
tory started pilot experiments to investi-
gate IGF-II and pro-IGF-II. Preliminary
results are shown in Figure 10-4. In
55% of the meningiomas demonstrable
pro-IGF-II protein levels were found
(10-4D-F). IGF-II mRNA was detected in
19/24 meningiomas as shown in Figure
10-4A-C. Correlation studies, however,
could this far not reveal a relation between
pro-IGF-II or PR and apoptosis. Further
investigations of the GH-IGF components
are necessary to explore adjuvant thera-
peutic possibilities in the near future.
Conclusive remarks
The aim of the present thesis was to
obtain a better understanding of the pres-
ence of PR in human meningiomas. We
conclude that meningiomas express multi-
ple forms of the PR. The PR forms were
found differentially associated with
apoptotic proteins like bcl-2. We hypothe-
size that PR might be important for the
regulation of the sensitivity for apoptosis.
In addition, relatively high expression lev-
els of type IGF receptors may contribute to
this as well. Both PR and bcl-2 are de-
scribed as markers for tumor grade, sur-
vival and recurrence. The prognostic
significance of PR, however, might be due
to low expression of bcl-2 levels found in
meningiomas with high PR expression lev-
els. The role that PR plays in retaining the
balance between pro and anti-apoptotic
proteins is clinically important.
Our insight in the expression of estro-
gen receptors in meningiomas has
changed drastically. Initially we thought
that meningiomas did not express the ER,
however, it turned out that these tumors
all contain minute quantities of ER-. The
hypothesis that the expression of PR is es-
trogen independent, however, still stands.
The initial idea that ER splice variants
could be responsible for PR regulation has
become most unlikely.
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Our mechanistic insights in the suc-
cess change of anti-tumor endocrine ap-
proaches are paradoxical. The negative
association between PR (therapeutic tar-
get) and bcl-2 (involved in therapy resis-
tance) makes that meningiomas
expressing high levels of PR should bene-
fit the most of a PR antagonist treatment.
In contrast, meningiomas with high PR
levels express relatively more PR-A pro-
tein. In these tumors PR action might be
repressed and PR antagonist treatment
will then most likely not be successful. In
this case meningiomas with relative more
PR-B than PR-A expression will benefit
the most of such a treatment.
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Progesterone is a steroid hormone involved in female fertility, preparing the uterus for
implantation of fertilized oocytes, and in the maintenance of pregnancy. Progesterone can
also exert some anti-estrogenic and anti-proliferative effects on neoplastic tissues. Proges-
terone acts via its receptor (PR) and knowledge of the function and regulation of PRs is im-
portant to determine clinical significance of involvement of PR in tumor growth regulation.
Meningiomas have attracted attention as being progesterone sensitive central nervous
system tumors. The aim of this thesis was to obtain a better understanding of the role PR
plays in these tumors.
The development of a meningioma cell culture model is discussed in chapter 1.
Meningiomas cells cultured as monolayer quickly lose their ability to express PR. The loss of
PR expression and a high proliferation rate in meningiomas indicate that the cells might
dedifferentiate when cultured. In this chapter a spheroid and an ex-vivo culture method
were tested, however, both methods failed to maintain PR expression in meningioma cells.
Investigation of PR in meningiomas is therefore mainly restricted to inventory studies.
In meningiomas at least two PR isoforms exist, PR-B and PR-A, each of which are likely
to have different biological functions. Chapter 3 shows that meningiomas express both PR-A
and PR-B, and an additional PR-78 product. The ratio of PR-A to PR-B protein levels is
highly variable and higher in the meningiomas with high total PR expression based on a
ligand binding assay (LBA). This variability might have some clinical and biological signifi-
cance in meningioma disease.
Chapters 4 and 5 illustrate that PR expression in meningiomas is related to proteins in-
volved in apoptosis. In contrast to breast cancer, PR and bcl-2 expression in meningiomas is
negatively associated. Bcl-xl was positively associated with PR-B. Bax and bak protein levels
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were not associated with PR in meningiomas. This indicates that PR might be involved in
regulating the apoptotic balance in meningiomas.
Chapter 6 describes mutation analysis of the gene of another protein involved in the
regulation of cell death: p53. Overexpression of p53 caused by mutations of the p53 gene has
been reported to play a role in the etiology of nervous system and other neoplasms. In
meningiomas a relatively high percentage of p53 protein overexpression is described in lit-
erature indicating the presence of mutations in the p53 gene. Based on this thesis and re-
ports by others, however, we conclude that point mutations of the p53 gene are not likely to
be involved in the etiology of meningiomas.
The regulation of PR in other endocrine related tissues is under estrogen control. Chap-
ters 7 and 8 report the presence of ER-β splice variants in meningiomas. Some splice vari-
ants could fail to bind ligand and hence are not detectable with a LBA, however, could still
be capable of transcriptional activation. The experiments described in the present thesis
show that it is not very likely that these splice variants are involved in the regulation of PR in
meningiomas since PR negative meningiomas also express these variants.
Based on reliable LBA data from previous studies meningiomas are rich in PR whereas
ER is seldomly found and only in very low concentrations. ER mRNA analysis (chapter 7)
learnt that meningiomas contain ER wt mRNA. In addition, some authors reported IHC data
of ER expression in meningiomas. Chapter 8 describes the results from a sensitive
immunoblot analysis, which reveals that, in contrast to the previously existing thoughts,
meningiomas are ER-α positive. These minute ER-α levels alone, however, could not clarify
the expression of PR since ER-α was also found in PR negative meningiomas.
Chapter 9 is a review about the relevance of GH-IGF-axis in meningiomas. Several
members of the IGF-axis are present in meningiomas. The type 1 IGF-Receptor is present in
elevated levels in meningiomas. This is of special interest since this receptor is reported to
be involved in the regulation of members of the bcl-2 protein family. This justifies investiga-
tion of the use of antagonizing GH-IGF receptors as a possibility for adjuvant therapy.
In summary, we hypothesize that PR might be important for the regulation of proteins
involved in apoptosis. Both apoptotic proteins and PR are described as prognostic markers
for tumor grade, survival and recurrence in literature. Although minute quantities of ER are
present in meningiomas, exact regulation of PR in these tumors is not known and the in-
volvement of estrogens is considered to be not very likely. Meningiomas with high PR ex-
pression express relatively more PR-A and this might have consequences for the success of
an anti-tumor endocrine therapy.
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Progesteron is een steroïdhormoon onder andere betrokken bij de regulatie van de
zwangerschap. Daarnaast kan progesteron in een aantal tumorweefsels de proliferatie
remmen doordat het een anti-oestrogene werking heeft. Progesteron reguleert genen door
te binden aan een ligand afhankelijke transcriptiefactor, de progesteron receptor (PR). De
regulatie van PR aanmaak en de functie van PR in tumoren zijn biologisch en klinisch zeer
interessant, mede doordat het PR niveau de gevoeligheid van tumoren voor progestiva en
anti-progestiva bepaalt .
Meningeomen, een van de meest voorkomende tumoren van het centrale zenuwstelsel
(CNZ), blijken onder invloed te staan van progesteron. Het doel van het hier beschreven
onderzoek is het verkrijgen van een beter inzicht in de functie en regulatie van PR in
meningeomen.
Helaas is er op dit moment nog geen goed experimenteel celmodel voor meningeomen.
Dit komt doordat als monolaag gekweekte meningeoomcellen de PR expressie verliezen.
Dit, naast de hoge proliferatie van gekweekte meningeoomcellen, wijst op een
dedifferentiatie van deze cellen in vitro. Behalve een monolaag kweekmodel zijn er in
hoofdstuk 2 ook een ex vivo en een spheroid-kweekmodel getest. Meningeoomcellen waren,
echter, in geen van de kweekmodellen in staat om PR tot expressie te blijven brengen.
Er bestaan tenminste twee isovormen van de PR, PR-A en PR-B, die waarschijnlijk
verschillende biologische functies hebben. In hoofdstuk 3 hebben we aangetoond dat
meningeomen zowel PR-A, PR-B als een extra PR-78 eiwit bevatten. De ratio PR-A tot PR-B
was zeer variabel en hoger in meningeomen met een relatief hoge totaal PR expressie. Deze
variabiliteit kan klinisch en biologisch van belang zijn.
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Samenvatting in het Nederlands
Hoofstuk 4 en 5 illustreren dat PR niveau in meningeomen gerelateerd is aan dat van
eiwitten betrokken bij geprogrammeerde celdood (apoptose). In meningeomen waren de
PR en het anti-apoptotische bcl-2 negatief geassocieerd, in tegenstelling tot de positieve
associatie gevonden voor borstkanker. Bcl-xl was positief geassocieerd met alleen PR-B. De
expressie van andere pro-apoptotische eiwitten, bax en bak, bleken niet gerelateerd aan PR
expressie. Dit alles duidt erop dat de PR een rol zou kunnen spelen in de regulatie van de
apoptotische balans in meningeomen.
Een ander eiwit betrokken in de regulatie van apoptose is p53. P53 eiwit kan tot
overexpressie komen wanneer het gen gemuteerd. Deze mutaties zijn vaak betrokken bij de
ontwikkeling van tumoren. Echter, in hoofdstuk 6 is beschreven dat p53 mutaties niet
verantwoordelijk waren voor p53 eiwit overexpressie in meningeomen, en dus geen rol
blijken te spelen in het ontstaan van deze tumoren.
In andere hormoonafhankelijke tumoren staat de regulatie van PR vaak onder
oestrogene controle. In meningeomen is de ER (gebasseerd op een ligand bindings assay
(LBA)) niet of heel laag aanwezig. In hoofstuk 7 wordt beschreven dat er splicevarianten van
de ER-β zijn die geen ligand binden, maar nog wel in staat zouden kunnen zijn om
transcriptie te activeren. Southernblot analyse toonde echter aan dat noch de
splicevarianten van de ER-α noch die van de ER-β betrokken blijken te zijn bij de regulatie
van PR. PR negatieve meningeomen bevatten ook mRNA van deze splicevarianten.
ER mRNA analyse leerde ons ook dat meningeomen ER wildtype mRNA bevatten.
Hierbij komt dat door sommige onderzoekers in de literatuur gerapporteerd wordt dat ER
expressie in meningeomen aantoonbaar is met immunohistochemie. Hoofdstuk 8 laat zien
dat een gevoelige immunoblot techniek in staat was om ER-α eiwit aan te tonen in 22
onderzochte meningeomen. Dus, in tegenstelling tot onze eerste aanname, zijn
meningeomen ER en PR positief. Het is echter lang niet zeker dat deze lage hoeveelheden
biologisch aktief zijn. Het is onwaarschijnlijk dat zij verantwoordelijk zijn voor de activatie
van het PR gen, omdat PR negatieve meningeomen ook ER-α eiwit bevatten.
Hoofdstuk 9 is een review over de groeihormoon en IGF as in meningeomen. Veel van
de GH-IGF componenten komen tot expressie in meningeomen, maar meest opvallend is de
overexpressie van de type 1 IGF-receptor ten opzichte van het gezonde weefsel. Dit is
klinisch relevant omdat deze receptor direct betrokken lijkt te zijn bij de regulatie van
eiwitten van de Bcl-2 proto-oncogen familie. Het is interessant om de GH-IGF-as te
bestuderen omdat daaruit wellicht mogelijkheden voor een nieuwe adjuvante therapie
voort komen.
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Samengevat, de PR is in meningeomen mogelijk belangrijk is in de regulatie van de
eiwitten betrokken bij apoptose. Zowel PR als deze apoptotische eiwitten worden in de
literatuur beschreven als prognostische factoren voor recidivering en prognose.
Meningeomen zijn, in tegenstelling tot wat tot nu toe algemeen werd aangenomen, zowel ER
als PR positief. De biologische betekenis van ER-α in meningeomen is nog niet opgehelderd.
Meningeomen die veel PR tot expressie brengen, brengen relatief meer PR-A tot expressie.
Dit kan consequenties hebben voor het succes van antiprogestagene endocrine therapie
zoals die mogelijk gebruikt kan worden in de toekomst.
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